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57 ABSTRACT 
The present invention provides various novel covalently 
modified sapphyrin derivatives and conjugates; polymers 
including sapphyrin or derivatives thereof; and chromato 
graphic supports including sapphyrins and other expanded 
porphyrins and derivatives thereof. Disclosed are water 
soluble sapphyrins, including polyhydroxysapphyrins and 
sapphyrin-sugar derivatives; sapphyrin-metal chelating con 
jugates; sapphyrin nucleobase conjugates; oligosapphyrins 
and polysapphyrins, including sapphyrin dimers, trimers, 
oligomers and higher polymers; and polymer supported 
expanded porphyrin compositions, including advantageous 
rubyrin- and Sapphyrin-based chromatography columns and 
electrophoretic supports. Sapphyrin oligomers and polymers 
and polymer supported expanded porphyrins, such as, e.g., 
glass and silica expanded porphyrin constructs, are disclosed 
which include both repeating units of sapphyrin derivatives 
alone and which include other units, for example, 
nucleobases, sapphyrin-nucleobase conjugates and long 
chain alkyl groups. 
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METHOD OF CLEAVING DNA 
This application is a divisional application of application 
Ser. No. 08/424,288, filed Apr. 28, 1995 which is a 
continuation-in-part of U.S. patent application Ser. No. 
07/964,607, filed Oct. 21, 1992, U.S. Pat. No. 5.457,195. 
The entire texts of U.S. patent application Ser. No. 07/964, 
607, and U.S. patent application Ser. No. 08/015,208, filed 
Feb. 9, 1993 are specifically incorporated by reference 
herein without disclaimer. The government owns rights in 
the present invention pursuant to NIH grantAI28845 and AI 
33572. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to the field of macrocyclic 
expanded porphyrins and, more particularly, concerns novel 
sapphyrin derivatives, conjugates and polymers thereof and 
polymer-Supported expanded porphyrins. Sapphyrin mono 
mer derivatives of the invention include sapphyrin-sugar 
derivatives and other water soluble sapphyrins; sapphyrin 
metal chelating derivatives; and sapphyrin nucleobase con 
jugates. Also disclosed are oligosapphyrins and 
polysapphyrins, including sapphyrin nucleobase oligomers 
and polymers; and silica gel, glass, resin and other polymer 
Supported expanded porphyrins such as rubyrin- and 
Sapphyrin-containing chromatographic and electrophoretic 
Supports. 
2. Description of the Related Art 
Expanded porphyrins are large pyrrole-containing mac 
rocyclic analogues of the porphyrins (e.g. porphine, struc 
ture I, FIG. 1). A number of expanded porphyrin systems are 
now known. However, only afew fully conjugated examples 
have been reported that contain more than four pyrrolic 
subunits, namely the smaragdyrins, sapphyrins, 
pentaphyrins, hexaphyrins, and superphthalocyanines' 
(Sessler & Burrel, 1991). Sapphyrin, in its generalized 
substituent-free form, is represented by structure I(FIG. 1). 
Structure III (FIG. 1) provides a generalized representation 
of B-substituted sapphyrins. 
Sapphyrin, first discovered serendipitously by Wood 
ward is one of the more intriguing products to emerge from 
initial studies directed towards the synthesis of Vitamin 
Bia.” It is a 22 pi-electron pentapyrrolic macrocycle which 
exhibits an intense Soret-like band at about 450 nm (CHCI) 
along with weaker Q-type transitions in the 620 to 690 nm. 
region. These optical properties, along with the presence of 
a large central cavity which serves for metal binding, renders 
Sapphyrin useful for certain biomedical applications, includ 
ing photodynamic therapy (PDT) and magnetic resonance 
imaging enhancement (MRI). 
In addition to the above, certain expanded porphyrins, 
including especially those of the sapphyrin series, have been 
found to act as halide anion chelating agents in both solution 
and the solid state'. This finding, along with an appreciation, 
that the diprotonated form of 3,8,12,13,1722-hexaethyl-2, 
7,18,23-tetramethylsapphyrin acts as an efficient carrier for 
the through-dichloromethane-membrane transport of nucle 
otide monophosphates, such as e.g. guanosine-5' 
monophosphate, and related entities at acidic pH, led the 
inventors to consider that the basic sapphyrin structure and 
related compounds such as the rubyrins, if suitably modified, 
could be used to bind, recognize, and transport phosphory 
lated entities at or near neutral pH. The inventors also 
envisioned that this same approach could be used for the 





Unfortunately, all sapphyrins known at the time of this 
invention were known both to be essentially insoluble in 
water and also known to be ineffective as through membrane 
carriers for phosphate monoesters including those specifi 
cally that define the class of compounds known as nucle 
otides and nucleotide analogues. These two deficiencies 
limited the potential utility of sapphyrins for any applica 
tions associated with their use at or near neutral pH and, 
more generally, any conditions involving partial or complete , 
association with an aqueous environment. 
In addition, the sapphyrins known prior to the present 
invention were all of such simple character in terms of 
peripheral substituents, such that only hydrogen, alkyl and 
carboxylalkyl were known", that said systems, even if they 
were to demonstrate binding to nucleotides or nucleotides, 
would be expected to do so without any degree of specificity 








(“nucleobase") attached to the phosphate core. Thus, at the 
time of this invention, it was considered that the develop 
ment of a sapphyrin-derived species capable of binding, 
recognizing, and/or transporting a mononucleotide (or 
related entity) at or near neutral pH would represent a 
significant advance, especially if such system or systems 
could be made to achieve this binding, transport, or recog 
nition in a nucleobase specific manner. This would be 
particularly valuable if this binding and recognition could be 
used as the basis for improved chromatographic and elec 
trophoretic separations, such as in the analysis, detection and 
purification of oligonucleotides. 
In addition to the above, it was recognized that the 
synthesis of one or more water soluble sapphyrins would 
represent a considerable advantage, not only in terms of 
phosphate entity recognition and transport, but also because 
it would allow for a detailed study of the basic binding 
phenomena in aqueous media. In the case where said water 
soluble sapphyrins were neutral in character, this would also 
give an important advantage in applications involving chro 
matographic and/or electrophetic separations. 
A considerable number of ionic (e.g. phosphorylated) 
nucleotide analogues are known that exhibit antiviral activ 
ity in cell-free extracts and yet are inactive in vivo due to 
their inability to cross lipophilic cell membranes''. The 
anti-herpetic agent, acyclovir, is typical in that it enters the 
cell only in its uncharged nucleoside-like form. However, 
this compound is phosphorylated in the cytoplasm resulting 
in the active, ionic triphosphate species. In contrast, many 
other potential antivirals, including the anti-HIV agent, 
Xylo-G, are not phosphorylated intracellularly and are there 
fore largely or completely inactive. If, however, the active 
monophosphorylated forms of these putative drugs could be 
transported into cells, it would be possible to fight viral 
infections with a large battery of otherwise inactive mate 
rials. 
At present, no general set of nucleotide transport agents 
exists'. In early work, Tabushi was able to effect adenosine 
nucleotide transport using a lipophilic, diazabicyclooctane 
derived, quaternary amine system'. However, this same 
system failed to mediate the transport of guanosine 
5'-monophosphate (GMP) or other guanosine-derived nucle 
otides. Since then, considerable effort has been devoted to 
the generalized problem of nucleic acid base (“nucleobase”) 
recognition, and various binding systems have been 
reported. However, none are believed to have been applied 
to the problem of specific chromatographic and/or electro 
phoretic separations. 
Currently known nucleotide binding systems include vari 
ous acyclic, macrocyclic, and macrobicyclic polyaza 
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1Ok. systems''"; nucleotide-binding bis-intercalands'; 
guanidinium-based receptors''"; and various rationally 
designed H-bonding receptors''". These latter 
H-bonding receptors have been shown to be effective for the 
chelation of neutral nucleobase and/or nucleoside derived 
substrates but, without exception, have all proved unsatis 
factory for the important task of charged nucleotide recog 
nition. Thus, despite intensive efforts in this field, there is 
currently no synthetic system capable of effecting the 
recognition, or through-membrane transport, of phosphate 
bearing species such as anti-viral compounds. Furthermore, 
there are presently no rationally designed receptors which 
are "tunable” for the selective complexation of a given 
nucleobase-derived system. 
Not surprisingly, the transport of larger polyphosphory 
lated compounds across cellular membranes also poses 
significant problems. The difficulties in transporting oligo 
nucleotides across the plasma membrane and into mamma 
lian cells is one of the factors currently limiting the suc 
cessful application of antisense technology to human 
therapy. Further limitations may also result from the dynam 
ics of oligonucleotide recognition, binding and functional 
inhibition which occurs intracellularly, subsequent to any 
import that does occur. 
There is clearly, therefore, a major need for novel delivery 
systems to be developed. Compounds which would allow 
negatively-charged (anionic) structures, particularly 
phosphate-bearing compounds, including nucleotides and 
nucleotide derivatives such as anti-viral compounds and 
anti-sense oligonucleotides, to be transported across natu 
rally lipophilic cellular membranes would represent an 
important scientific and medical advance. 
It is also recognized that there is currently a considerable 
need for improved chemotherapeutic compounds which act 
upon DNA once inside a target cell to be designed. Since 
currently available chemotherapeutic agents have complex 
structures, or complicated modes of interaction with their 
targets that preclude systematic improvement, the develop 
ment of a novel class of DNA binding compounds would 
open up new avenues for the design of improved therapeu 
tics. In this regard, a class of compounds that can be 
modified in a number of different ways whilst maintaining 
their overall monomeric, or preferably polymeric, structure 
would be particularly advantageous. The same is true for 
compounds that can be activated by light, or other means, to 
produce singlet oxygen or hydroxyl radicals, once bound to 
DNA. 
There is also a significant need for improved nucleotide 
and nucleotide-binding compounds for use in connection 
with various laboratory techniques, both in clinical and 
research embodiments. For example, oligonucleotides are 
currently purified using polyacrylamide gel electrophoresis 
(PAGE) which is time-consuming, uses toxic materials, and 
is low-yielding.” Ion exchange columns can, on a limited 
basis, sometimes separate oligonucleotides containing 40 or 
fewer residues. However, this process is also generally 
unsuitable as, for example, severe conditions such as elution 
at pH 2.7, are often required.’ The availability of a new 
column material, or improved functionalized glass 
capillaries, for use in chromatographically or electrophoreti 
cally separating nucleotides and oligonucleotides would 
thus represent a significant breakthrough in this area. 
The foregoing and other considerations provided the 
present inventors with further impetus for the design and 
synthesis of the many different classes of improved 












polymer-supported expanded porphyrins embodied by the 
present invention. 
SUMMARY OF THE INVENTION 
The present invention addresses the above and several 
other shortcomings in the prior art through the synthesis of 
several novel monomeric and polymeric sapphyrin deriva 
tives and other compounds and compositions based gener 
ally upon the sapphyrin molecule. Novel polymer-supported 
expanded porphyrins are also provided, including 
sapphyrin- and rubyrin-containing chromatographic and 
electrophoretic supports. 
The invention therefore encompasses new sapphyrin 
derivatives and conjugates and polymers thereof. In a gen 
eral and overall sense, included within the novel compounds 
of the invention are covalently modified sapphyrin mono 
mers of the following general types: water soluble 
Sapphyrins, sapphyrin-metal chelating derivatives and sap 
phyrin nucleobase conjugates. The invention also provides 
Sapphyrin oligomers and polymers and polymer-supported 
expanded porphyrins including sapphyrin- and rubyrin 
functionalized materials, such as silica gel, Merrifield resins 
and glass, for use as chromatographic and electrophoretic 
supports and columns. The oligomers, polymers and 
polymer-supported compositions will typically comprise 
sapphyrin or sapphyrin derivatives alone, or sapphyrin in 
combination with other units such as nucleobases. Com 
plexes of sapphyrin-nucleobase polymers and polymer 
supported expanded porphyrins with oligonucleotides and 
methods of using such compositions are also encompassed 
by the invention. 
In general terms, sapphyrin derivatives of the present 
invention can be defined by the following general structure: 
R2 R1 R10 R9 I 
R R6 
wherein each of R'-R' is separately or collectively an H, 
alkyl, alkene, alkyne, halide, alkyl halide, hydroxyalkyl, 
glycol, polyglycol, thiol, alkyl thiol, aminoalkyl, 
carboxyalkyl, alkoxyalkyl, aryloxyalkyl, alkyloxycarbonyl, 
aryloxycarbonyl, aldehyde, ether, ketone, carboxylic acid, 
phosphate, phosphonate, sulfate, phosphate substituted 
alkyl, phosphonate substituted alkyl, or sulfate substituted 
alkyl, such that the total number of carbon atoms in each 
substituent R is less than or equal to 10. 
One of the novel aspects of the foregoing structure is the 
fact that in the context of the present invention, at least one 
R group substituent of the foregoing general structure will 
be of the general formula X-B, wherein X is any sapphyrin 
compound and B is a substituent that 1) confers water 
solubility, 2) is a metal chelating compound, 3) is a nucleo 
base compound, 4) is a polymer or oligomer of sapphyrin or 
one of the foregoing sapphyrin derivatives or 5) is a poly 
meric matrix or solid support. As will be made clear 
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hereinbelow, the term "polymeric matrix or solid support" 
includes common polymeric materials, such as 
polyacrylamide, polystyrene and the like; and other 
materials, such as silica gel, glass, Merrifield resins, agarose, 
clays and zeolites, that can be functionalized by those skilled 
in the art of chemical synthesis. 
The novel aspects of the invention may most readily be 
denoted through the use of the structure X-(CH2)-A- 
(CH2)-B, wherein Xis any sapphyrin macrocycle, and A 
is CH, O, S, NH or NR", wherein R' is alkyl, alkene, 
alkyne, halide, alkyl halide, hydroxyalkyl, glycol, 
polyglycol, thiol, alkyl thiol, substituted alkyl, phosphate, 
phosphonate, sulfate, phosphate substituted alkyl, phospho 
nate substituted alkyl, sulfate substituted alkyl, COO, 
CONH, CSNH, or CONR". 
The B substituent will generally include any alkene 
alkyne, halide, alkyl halide, hydroxyalkyl, glycol, 
polyglycol, thiol, alkyl thiol, substituted alkyl, phosphate, 
phosphonate, sulfate, phosphate substituted alkyl, phospho 
nate substituted alkyl, sulfate substituted alkyl, 
hydroxyalkyl, aryl, silyl, siloxy, aminoaryl, amino, ami 
doaryl silyloxy, Sugar, sugar derivative, polysaccharide, 
metal chelating group, nucleobase, modified nucleobase, 
oligonucleotide, sapphyrin, sapphyrin derivative, polymeric 
Sapphyrin, alkylating agent, steroid, steroid derivative, 
amino acid, peptide or polypeptide, polymeric matrix or 
solid support (e.g., polyacrylamide, polystyrene, silica gel, 
Merrifield resins, glass, clays, zeolites); and n and m will be 
integers of less than or equal to 10 or are zero. 
Certain particular embodiments of the invention relate to 
sapphyrin derivatives that are polyhydroxylated and there 
fore water-soluble. Water soluble sapphyrins are particularly 
desirable where one would like to exploit the various 
surprising properties of the sapphyrin macrocycle in con 
nection with human or animal applications. The nature of the 
polyhydroxylation is not particularly critical to achieving 
water solubility of the sapphyrin derivative, so long as at 
least three or four hydroxyl groups per sapphyrin macro 
cycle are incorporated into the structure. The inventors have 
found that the introduction of at least 3 hydroxyl groups per 
macrocycle will be sufficient to achieve some degree of 
water solubility. This aspect of the invention is also impor 
tant to the improved chromatographic and electrophoretic 
supports disclosed herein. 
One means for introducing hydroxyl groups into the 
sapphyrin macrocycle structure is simply through the addi 
tion of alkyl substituents to the basic sapphyrin macrocycle 
unit, wherein the added substituents include one or more 
hydroxyl groups within their structures. Thus, exemplary 
polyhydroxylated sapphyrins will be those that are modified 
to include structures such as hydroxymethyl, hydroxyethyl, 
hydroxypropyl, hydroxybutyl, dihydroxyalkyl, 
trihydroxyalkyl, or the like, at one or more R positions of the 
basic sapphyrin structure shown above. Exemplary 
polyhydroxylated, water soluble sapphyrins are set forth in 
FIG. 2, and are denoted as structures 1 and 3. 
An alternative means of achieving polyhydroxylation is 
through the addition of sugar moieties such as a saccharide, 
polysaccharide, saccharide derivative or aminosaccharide, 
to the Sapphyrin macrocycle structure. In such cases, it has 
been found that the addition of a single saccharide molecule 
to a sapphyrin macrocycle will achieve a degree of water 
solubility. These structures are referred to broadly herein 
simply as Sapphyrin-sugar compounds, conjugates or deriva 
tives. The nature of the sugar is not critical to the achieve 
ment of water solubility, and a non-exhaustive, exemplary 










forth in Table I. Of course, any sugar or modified sugar may 
be employed including sugars having additional phosphate, 
methyl or amino groups and the like. Moreover, the use of 
both D- and L-forms, as well as the o, and B forms is also 
contemplated. Particularly preferred are sugars such as 
glucose, galactose, galactosamine, glucosamine and man 
nose. Exemplary structures in this category are denoted as 
structures 4, 4a, 4b, 4c, 6, 6a and 6b of FIG. 2. 
In other aspects, the invention concerns sapphyrin deriva 
tives which incorporate a metal chelator or metal chelating 
moiety at the B position. It has been found that the addition 
of a chelator moiety confers exciting new properties to the 
sapphyrin macrocycle including, most notably, an ability to 
cleave DNA through an as yet unknown mechanism. This is 
particularly important because it allows one to prepare 
sapphyrin macrocycles that have the ability to both bind to, 
and cleave, DNA. Thus, not only will such molecules have 
clearin vitro uses, such as for DNA shearing or cleaving, but 
this also opens the door for in vivo uses. For example, it is 
quite possible that sapphyrin-chelator complexes will have 
the ability to bind to, and cleave, the DNA of blood-borne 
viruses. 
Additionally, it is possible that the metal chelating sap 
phyrin structures will be useful in disrupting enzymatic 
action, by competing for requisite metal cofactors or by 
cleaving proteins. It is posited that due to their strong 
attraction for charged phosphate groups, the sapphyrins of 
the present invention will be particularly useful in selec 
tively cleaving phosphorylated proteins, which are known to 
play a role in expression and activation of gene products 
including oncogene products. These structures may also be 
useful in an in vivo context through their introduction into 
cells, where they would be expected by the presentinventors 
to effect cleavage of intracellular DNA or RNA. It may even 
be possible to effect a base or sequence specific cleavage 
through modification of the sapphyrin macrocycle structure, 
such as by substituent modification. 
In particular embodiments relating to chelator conjugates, 
the sapphyrin-chelator derivative will include a metal chelat 
ing group such as 1,10-phenanthralene, EDTA, EGTA, 
DTPA, DOTA, crown ether, azacrown, catecholate or eth 
ylene diamine. An exemplary structure is set forth as struc 
ture 8 of FIG.3B, wherein the conjugated chelating group is 
EDTA. This particular molecule has been found to cleave 
DNA in a fashion that results in a "ladder” effect upon gel 
electrophoresis of the fragments that are generated. 
In further embodiments, the present invention relates to 
what are referred to as sapphyrin-nucleobase conjugates. As 
used herein, the term "sapphyrin-nucleobase conjugate” is 
intended to refer broadly to any conjugate formed by the 
covalent conjugation of any sapphyrin macrocycle to any 
nucleobase. The sapphyrin-nucleobase conjugates may also 
be attached to a polymeric matrix or solid support, such as 
silica gel, glass, Merrifield resins, polyacrylamide, 
polystyrene, Sepharose, agarose, clays, zeolites, and the like; 
to form a chromatography column or filter. 
As used herein, the term "nucleobase' is intended to refer 
broadly to any moiety that includes within its structure a 
purine or pyrimidine, a nucleic acid, nucleoside, nucleotide, 
or any derivative of any of these. Thus, the term nucleobase 
includes adenine, cytosine, guanine, thymidine, uridine, 
inosine, or the like, bases, nucleotides or nucleosides, as 
well as any base, nucleotide or nucleoside derivative based 
upon these or related structures. 
A particular example of useful nucleobases are the 
so-called antimetabolites, which are generally based upon 
the purine or pyrimidine structures. These compounds typi 
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cally exert their biological activity as antimetabolites 
through competing for enzyme sites and thereby inhibiting 
vital metabolic pathways. However, in the context of the 
present invention, the inventors are employing the term 
"antimetabolite nucleobase" quite broadly to refer to any 
purine or pyrimidine-based molecule that will effect an 
anticellular, antiviral, antitumor, antiproliferative or antien 
zymatic effect, regardless of the underlying mechanism. 
Exemplary structures are shown in Table 2, including pre 
ferred conjugates such as purine or pyrimidine antimetabo 
lites such as FU, AraC, AZT, dd, ddC, xylo-GMP, Ara 
AMP, PFA or LOMDP, and phosphorylated versions thereof. 
In still further embodiments, the nucleobase component 
of sapphyrin-nucleobase conjugates will include a protected 
nucleobase having attached substituents that protect the 
nucleobase frominappropriate or undesirable chemical reac 
tion. Examples include substituents such as 
9-fluorenylmethyl carbonyl, benzyloxycarbonyl, 
4-methoxyphenacyloxycarbonyl, t-butyl oxycarbonyl, 
1-adamantyloxycarbonyl, benzoyl, N-triphenylmethyl, 
N-di-(4-methoxyphenyl)phenylmethyl, and the like. 
It is contemplated that sapphyrin-nucleobase conjugates 
will have a wide variety of applications, ranging from their 
use as agents for selectively delivering an associated, bio 
logically active nucleobase to a particular body, or even 
subcellular, locale to their use in laboratory protocols con 
cerned with nucleotides or oligonucleotides. For example, in 
the case of antimetabolite nucleobases, it is contemplated 
that the sapphyrin-nucleobase conjugates will act to deliver 
the antimetabolite to subcellular sites through the DNA 
binding activity of the sapphyrin portion of the conjugate. 
Furthermore, and perhaps more importantly, it is recog 
nized that many, many nucleobase antimetabolites can not 
be readily employed in therapy due to the fact that their 
charged nature inhibits their uptake by target cells, or 
otherwise inhibits or suppresses their unencumbered move 
ment across biological membranes. Typically, this shortcom 
ing is due to the presence of charged structures such as 
phosphates, phosphonates, sulfates or sulfonates on the 
nucleobase which, due to their charged nature, prevents or 
inhibits their crossing of a biological membrane. It is pro 
posed that sapphyrins of the present inventions can be 
employed as transport agents for carrying such nucleobases 
across membranes, (whether the nucleobase is directly con 
jugated to the macrocycle or simply complexed with it). 
Generally speaking, in the context of sapphyrin 
nucleobase constructs designed for drug delivery it will 
usually be the case that one will employ only one 
nucleobase-containing substituent for each sapphyrin 
macrocycle, however this is in no way a limitation upon the 
invention. For example, sapphyrin-nucleobase conjugates of 
the present invention may have any number of nucleobases 
or nucleobase oligomers or polymers attached. 
The foregoing can be most readily appreciated through 
consideration of other embodiments and utilities that are 
contemplated by the inventors. For example, it is has been 
surprisingly discovered by the inventors that sapphyrin 
nucleobases which include a selected nucleotide nucleobase 
conjugate will serve to selectively bind, through hydrogen 
bonding interactions, the complementary nucleotide. Thus, a 
sapphyrin-nucleobase conjugate such as sapphyrin-adenine 
will selectively bind thymidine, presumably through a 
hydrogen bonding of the two nucleotides that is stabilized 
through the interaction of the charged phosphate groups of 
the hydrogen bonded nucleotide with the macrocycle struc 
ture. Such structures will likely have a wide variety of 
applications, such as intracellular carriers for nucleobases 
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that are hydrogen bonded rather than being covalently 
attached. Furthermore, as discussed in more detail below, it 
is contemplated that polymers of sapphyrin-nucleobase con 
jugates can be employed to carry hydrogen bonded oligo- or 
5 poly-nucleotides into target cells through complementarity 
with the sequence of bases “encoded" on the sapphyrin 
nucleobase polymer. 
The foregoing general structure could be exemplified by 
the formulas: 
" k-k-k-k-k-k-kee of 
N N N N N N N 
Y-Y-Y-Y-Y-Y-Y 




wherein X is the sapphyrin macrocycle, N is the conjugated 
o nucleobase structure, and Y is the hydrogen bonded poly- or oligonucleotide. 
Alternatively, it is contemplated that sapphyrins of the 
present invention may serve as a carrier for polymers of 
nucleobases, wherein the nucleobase polymers are attached 
covalently to the sapphyrin macrocycle, such as might be 
exemplified through the structural designation: 
wherein X is a single sapphyrin macrocycle, and N is a 
selected oligomeric or polymeric nucleotide or other 
30 nucleobase, and Y is a hydrogen bonded poly- or oligo 
nucleotide. 
Such structures would be useful in a number of contexts, 
including acting as a specific carrier for complementary 
nucleotides. The complementary nucleotides could be struc 
35 tures such as antisense molecules, including C-5 propyne 
containing antisense oligos, designed to inhibit the 
transcription, translation or both, of a given gene or con 
struct. Alternatively, they could be coding or "sense” strands 
of DNA which encode an entire gene, a functional protein 
40 domain, or any polypeptide, peptide, or fragment thereof. 
Such constructs may be used in in vitro molecular biological 
embodiments or in gene transfer protocols in which the 
DNA is intended to act as a template for the production of 
proteins or peptides such as normally-functional or 
45 therapeutically-important proteins and peptides. 
Chemically speaking, any number of nucleobase struc 
tures can be attached to the sapphyrin macrocycle. The 
ultimate number of such residues that are attached will, of 
course, depend upon the application. Where one intends to 
50 employ such a structure to carry complementary 
nucleotides, one may well desire to employ a structure 
having a polymer of at least 10 or so bases attached. 
However, for other applications, such as for intracellular 
delivery of the nucleobase or other charged compounds of 
55 non-polymeric size, it may be convenient to design and 
employ sapphyrin-nucleobase constructs employing from 
one to three nucleobases per single macrocycle. Moreover, 
the nature of the intended use will dictate the number of 
attachment points there are on the sapphyrin macrocycle for 
60 attaching nucleobase moieties. Thus, will it may typically be 
the case that a single attachment site will suffice for most 
applications, for certain particular applications those of skill 
may find it particularly advantageous to attach various 
nucleobases at various of the subcomponents of the macro 
65 cycle. 
Referring to structure III and the general formula pre 




nucleobase derivatives will be those in which n is an integer 
of less than or equal to 6 or zero, and mis an integer of less 
than or equal to 4 or zero. A number of the simpler 
sapphyrin-nucleobase conjugates contemplated by the 
inventors are setforthin FIGS. 4A-1 through 4A-6 and 4B-1 
through 4B-4, and serve as simple examples of the overall 
concept. Thus, for example, one may wish to refer to 
structures 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 of 
FIGS. 4A-1 through 4A-6 and FIGS. 4B-1 through 4B-4 as 
representatives of this class of novel sapphyrin derivatives. 
As mentioned above, a particular aspect of the present 
invention involves the realization that novel sapphyrin struc 
tures may be prepared through the construction of sapphyrin 
polymers or oligomers. As used herein, the terms "sapphyrin 
polymer” or "polysapphyrin” are intended to refer to any 
compound which includes at least two sapphyrin macro 
cycles joined covalently. The terms "oligomer" and "poly 
mer” are generally understood to be overlapping in terms of 
defining a given length. However, it will still be appreciated 
that a "sapphyrin oligomer" or "oligosapphyrin" refers to 
sapphyrin-containing structures having about 2 or 3, and 
more preferably, about 10, 15, 20 or 30 sapphyrin units/ 
molecule, up to an including about 40 or 50 units. On the 
other hand, "sapphyrin polymers' or "polysapphyrins' are 
sapphyrin-containing structures which generally have 
upwards of about 40 or 50 sapphyrin units, up to an 
including about 80, 100 or 150 sapphyrin units, or even up 
to about 200 sapphyrin units or even more. 
The sapphyrin oligomers and polymers of the invention 
also include sapphyrin dimers and trimers. Examples of such 
sapphyrin dimer and trimer structures include, but are not 
limited to, those represented by the dimer structures 21, 22 
and 23 of FIGS. 5B-1 through 5B-3 and the trimer structure 
24 of FIG. 5B-4. The various sapphyrin oligomers and 
polymers encompassed by the present invention are repre 
sented by, for example, structures 26 and Z7 of FIGS. 5C-3i 
and 5C-3i in which n, the number of individual sapphyrin 
derivative units, may be about 5, 10, 20, 30 or 40, for 
sapphyrin oligomers, and about 50, 75, 100, 150 or about 
200 or so for sapphyrin polymers. 
In still further embodiments, the present invention encom 
passes polymer-supported expanded porphyrin composi 
tions and methods of using such compositions. As used 
herein, "a polymer-supported expanded porphyrin' is an 
expanded porphyrin orderivative or conjugate thereof which 
has been covalently joined to a polymeric or solid support, 
"Polymeric or solid support matrices” include not only such 
common polymers as polyacrylamide and polystyrene, but 
also materials such as silica gel, Merrifield resins, glass, 
Sepharose, agarose, clays, zeolites, and the like, that can be 
functionalized to allow the formation of an expanded por 
phyrin bonded to a support matrix. Virtually any expanded 
porphyrin, including sapphyrins, rubytins aria even 
texaphyrins, may be joined to a polymeric or solid support 
matrix in accordance with this aspect of the invention. 
However, in preferred embodiments it is contemplated that 
one would use an expanded porphyrin capable of binding 
anions, and more preferably, one capable of phosphate 
chelation, as the porphyrin part of the polymer-supported 
expanded porphyrin. As such, the use of expanded porphy 
rins of the rubyrin and sapphyrin classes will generally be 
preferred. 
The synthesis of rubyrin and derivatives thereof is 
described in detail in U.S. patent application Ser. No. 
08/015,208, incorporated herein by reference. Polymer 
supported rubyrins prepared in accordance with the present 











derivative in accordance with Structure 28, 29 or 30 of 
FIGS.5D-1, wherein A and A may be nitrogen, oxygen or 
sulphur and one of the substituents R1-Rs or XI-X will be 
derivitized to form the (CH)-A-(CH2)-B structure, 
wherein B includes the polymeric support. The other of the 
substituents R-R and X-X in structures 28, 29 and 30 
may be separately and independently H, alkyl, aryl, amino, 
hydroxyl, alkoxy, carboxyl, carboxamide, ester, amide, 
sulfonato, hydroxy substituted alkyl, alkoxyl substituted 
alkyl, carboxyl substituted alkyl, amino substituted alkyl, 
sulfonato substituted alkyl, ester substituted alkyl, amide 
substituted alkyl, substituted aryl, substituted alkyl, substi 
tuted ester, substituted ether, substituted amide. 
In other preferred embodiments, the polymer-supported 
expanded porphyrin will be a polymer-supported sapphyrin 
comprising a sapphyrin unit, such as any of those disclosed 
herein, or a derivative, conjugate or polymer thereof. Exem 
plary polymer-supported sapphyrin structures are repre 
sented by structures 35, 32, 33, 34, 35, 36, 37 and 38 of 
FIGS. 5D-3 through 5D-10. However, given the synthetic 
methodology described herein, one of skill in the art will be 
able to prepare a wide range of sapphyrin-substituted poly 
meric supports, such as silica gel, glass and a variety of other 
supports, all of which will be understood to fall within the 
scope of the claimed invention. 
With reference to the general formula of the invention 
described above and represented in structure III, the 
polymer-supported sapphyrins may also be defined as a 
sapphyrin derivative wherein at least one of R'R' is of the 
formula (CH)-A-(CH2)-B, wherein B comprises the 
polymeric or solid support matrix. In preferred 
embodiments, the B substituent will also comprise an aryl, 
sily, siloxy, aminoary, amino, amidoaryl, or silyloxy group, 
which will be located between the polymeric or Solid 
support matrix and the expanded porphyrin and hence will 
act as a linking unit. In certain defined cases, the linkage 
between the expanded porphyrin and the polymeric or solid 
support matrix may be defined as matrix -(CH2)-(CH2) 
-SiR-O-B; (CH) - Si(R)O-B; (CH3)2 -SiCCH3) 
O-B. Exemplary polymer-supported expanded porphyrins 
are set forth in FIGS. 5D-1 through 5D-10 and include the 
rubyrin-supported structures of 28-30 in addition to the 
sapphyrin structures of 31-38. 
Many types of polymeric or solid support matrices are 
contemplated to be of use as supporting matrices in con 
nection with the present invention and as represented in any 
of structures 28-38. These include, for example, silica-based 
compounds such as silica gel and various forms of glass, 
including controlled pore glass; organic polymers such as 
Merrifield resins; and other compositions such as agarose, 
sepharose, polyacrylamide, polystyrene, clays, Zeolites, and 
the like. 
The polymeric or solid support matrix which forms the 
supporting part of the polymer-supported expanded porphy 
rin will generally be chosen according to the intended 
function and use of the resultant composition. For example, 
silica gel may be used to prepare bonded, sapphyrin 
substituted silica gels for formulation into columns for use 
in medium to high pressure applications, such as in analyti 
cal and preparative HPLC separation technology. 
Alternatively, for low pressure applications, organic 
polymer-based expanded porphyrins may be prepared, such 
as rubyrin- or sapphyrin-substituted Merrifield resins. Also, 
a glass support such as a glass capillary tube, may be 
employed to prepare a glass-supported expanded porphyrin 
for use, e.g., in analytical capillary electrophoresis (CE). 
The range of polymer-supported expanded porphyrins 
contemplated by the present inventors, and described herein, 
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extends to second and third generation compositions 
designed to separate negatively-charged, phosphorylated 
species based upon further specific binding modes, in addi 
tion to the phosphate recognition provided by the expanded 
porphyrin moiety. One particular example concerns 
polymer-supported expanded porphyrins which further com 
prise long chain alkyl groups, such as, those of the formula 
CH-(CH2)Si(CH), where n=1-20, such as, e.g., CH 
(CH), CH3(CH2) or CH3(CH2), and also groups such 
as CHCONH, phenyl, naphthyl, substituted naphthyl, and 
the like, to impart hydrophobic and TC-7C interaction sepa 
ration capacity to the modified solid support. A second 
example concerns the use of polymer-supported expanded 
porphyrin constructs which also comprise nucleobase struc 
tures and thus allow separation of nucleobase-containing 
compounds on the basis of specific base-pairing interactions. 
The further modified polymer-supported expanded por 
phyrins may be constructed by modifying either the 
appended expanded porphyrin moiety or the polymeric or 
solid support matrix itself. For example, in the case of 
expanded porphyrin-nucleobase columns, sapphyrin- or 
rubyrin-nucleobase conjugates may be used in the initial 
synthesis, or alternatively, the nucleobase units may be later 
appended onto available groups of the expanded porphyrin 
or onto available groups of the solid support itself. Where 
the addition of long chain alkyl groups is desired, it is 
contemplated that such groups will generally be introduced 
onto the surface of the polymeric or solid support matrix, 
although the invention is not limited to this mode of addi 
tion. 
As with the sapphyrin-nucleobase conjugates described 
above, the polymer-supported expanded porphyrin 
nucleobase constructs may contain a wide variety of nucleo 
base compounds. The choice of compound will be tailored 
to suit the intended function of the solid support, such as, to 
bind to a specific nucleobase-containing compound which 
one desires to purify, remove or otherwise separate from a 
mixture of compounds. The nucleobase-containing group, 
whether bonded to the expanded porphyrin or to the support 
matrix, may therefore comprise any purine or pyrimidine 
base including adenine, cytosine, quanine, thymidine, uri 
dine and inosine, or any analog or derivative thereof, includ 
ing antimetabolite nucleobases, nucleobase derivatives 
shown in Table 2, and even protected nucleobases. 
The expanded porphyrin-nucleobase solid support matri 
ces may also have appended nucleosides, nucleotides and 
oligonucleotides, for example, oligonucleotides comprising 
between two and about 10 nucleobase units. Such polymer 
supported sapphyrin nucleobase compounds may be based 
upon any of the structures 28 through 38 of FIGS. 5D-1 
through 5D-10. Constructs bearing a selected nucleotide or 
oligonucleotide may be formulated into columns, filters or 
other solid materials such as capillary tubes, and used to 
selectively bind compounds which include the complemen 
tary nucleotide or oligo or poly-nucleotides containing sub 
stantially complementary sequences. As used herein, a sub 
stantially complementary sequence is one which the 
nucleotides generally base pair with the complementary 
nucleotide and in which there are very few base pair 
mismatches. 
Accordingly, the present invention also provides methods 
for using the polymer-supported expanded porphyrins 
described above in separating a first molecule from a mix 
ture of at least two molecules. In the present sense, the term 
"molecule' is being used for simplicity to refer to both 
molecular and atomic structures and thus encompasses spe 











filters and the like, of the invention are contemplated to be 
of most use in separating negatively-charged or anionic 
species which include a phosphate, phosphonate, phosphate 
ester, arsenate, arsenate ester, sulfate, or sulfonate moiety 
within their structure. However, such constructs, and par 
ticularly the polymer-supported rubyrins and sapphryins, 
may also be used for separating other molecular or atomic 
anions, including halide orpseudohalide anions like azide or 
cyanide that contain a negatively-polarized portion within 
overall their structure, 
To separate a first molecule from a mixture of at least two 
molecules in accordance with the invention, one would 
generally first prepare a matrix support with an expanded 
porphyrin and then contact the matrix support with the 
mixture, thereby separating the first molecule. In more 
detail, this generally entails binding the mixture containing 
the molecules or species to be separated to a matrix- or 
polymer-supported expanded porphyrin, such as a column, 
capillary tube, filter or such like, and then subsequently 
removing, or eluting, the bound species in such as way as to 
result in the formation of distinct fractions containing mol 
ecules which have been separated from each other, 
The phrases “separated” and "purified” in this context are 
intended to mean separated away from, and purified relative 
to, the degree of purity of an individual molecule, atom or 
species in the original composition. Although the methods of 
the invention generally result in high resolution separation 
of, e.g., phosphorylated species such as nucleotides and 
oligonucleotides, there is no requirement that such high 
degrees of purity always be achieved and separation meth 
ods which result in less substantially separated species also 
have utility and are thus encompassed by the claimed 
invention. 
These methods for separating or purifying negatively 
charged species are generally encompassed by the terms 
"chromatographic or electrophoretic separation methods”. 
The chromatographic methods are those using columns, 
such as HPLC columns, whereas the electrophoretic sepa 
ration methods are exemplified by those using capillary 
tubes. Chromatographic and electrophoretic separation tech 
niques are well known in the art and any such method may 
be employed in connection with the invention simply by 
preparing a polymer-supported expanded porphyrin com 
prising an expanded porphyrin or derivative joined to a 
polymeric or solid support matrix, such as silica gel, Mer 
rifield resin, glass or any other suitable matrix, and using this 
as the column, filter or capillary tube central to the separa 
tion technique. 
In separating negatively-charged species in accordance 
with the invention, it is contemplated that one would gen 
erally first formulate the composition containing the 
negatively-charged species to be separated into a solution. 
One would then contact the polymer-supported expanded 
porphyrin with the solution under conditions effective to 
allow binding of the negatively-charged species to the solid 
support. This is straightforward and may be achieved simply 
by passing the solution over the solid material with or 
without the use of pressure or an electrostatic field. The 
negatively-charged species will, in the simplest case, bind 
specifically to the expanded porphyrin moiety. Where 
polymer-supported expanded porphyrins bearing other 
groups, such as long chain alkyl groups, nucleobases, or 
aromatic residues for TC-1t stacking interactions with 
nucleobases are used, other portions of the negatively 
charged compounds, such as hydrophobic portions or purine 
and pyrimidine nucleobase substituents, will also likely 
specifically bind to these additional functional groups or 
interact with the sapphyrin ring. 
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Suitable conditions effective to allow binding of the 
species to the solid support will be chosen based upon 
considerations such as the number and type of the particular 
species to be separated, the purity of the resultant compo 
sitions desired, the type of expanded porphyrin, other func 
tional groups appended to the expanded porphyrin or solid 
support matrix, and the like. At this stage, the solid support 
may be washed with the same or other buffers of chosen 
stringency and for varying periods of time to remove any 
non-specifically bound species from the solid support such 
separations in the case of chromatographic applications 
would be useful both for analysis and purification proce 
dures. In the case of capillary electrophoresis, however, they 
would be likely to be use only for analysis. 
The polymer-supported expanded porphyrin with the 
bound species should next be treated to remove the bound 
species which may then be collected in a more separate and 
purified form than when they were applied, for example, in 
distinct fractions. This process will generally be achieved by 
washing the solid support with a second solution effective to 
detach the bound negatively-charged species, i.e., a solution 
effective to disrupt the specific binding between the species 
and the expanded porphyrin or other functional groups of the 
Support. Such separations, in the case of chromatographic 
applications would be useful both for analysis and purifica 
tion procedures. In the case of capillary electrophoresis, 
however, they would be likely to be useful only for analysis. 
The second solution will be distinct from that first used 
and, again, will be chosen based upon the particular appli 
cation. It may, for example, have a different ionic strength, 
hydrophobicity or pH to the first solution and may contain 
different concentrations of salt or other chaotropic agents as 
desired. This removal process may be termed "elution” and 
the eluted material will generally be collected in relatively 
small fractions, such as in 1 to 2 mlfractions, and preferably 
in fractions of about 1 ml or smaller, so that the fractions 
contain one or more detached negatively-charged species 
which have been separated or purified away from the total 
number of species in the starting composition. Alternatively, 
for analysis applications, the fractions could be much 
Smaller, i.e. s.10 pil, and used only as a means of assessing 
by, e.g. optical absorbance, refractive index, or mass spectral 
fragmentation, the composition of a given fraction. From 
such an analysis one would then, in the usual way of the art 
obtain a profile of the purity and composition of the original 
solution. 
Any of the polymer-supported expanded porphyrin 
derivatives described above may be used as a separating 
apparatus in this regard. For example, those comprising a 
sapphyrin or rubyrin derivative and those including ode or 
more sapphyrin- or rubyrin-nucleobase conjugates may be 
employed, as may supports comprising long chain alkyl 
groups and oligonucleotides. The separating apparatus may 
use, for example, silica gel, Merrifield resins or glass as 
support matrices and may be prepared in virtually any solid 
form including columns, filters and tubes. Their use in 
analytical and preparative modes in both research and clini 
cal laboratories is envisioned. 
It is contemplated that these novel polymer-supported 
expanded porphyrins will be found to be particularly useful 
in separating compounds which have phosphate groups or 
phosphate esters within their structure. This includes sepa 
rating or purifying purine- and pyrimidine-containing 
compounds, including nucleotides oligonucleotides, gene 
fragments, nucleobase analogs and derivatives such as anti 
metabolite purines and pyrimidines, e.g., AZT phosphate, 












treatment of viral infections including HTV. The use of the 
methods and compositions of the invention in clinical analy 
ses to distinguish active phosphorylated nucleotide analogs 
from naturally occurring phosphorylated products, such as 
AMP or GMP, is a further particular utility envisioned by the 
inventors. 
Organophosphorus compounds, particularly pesticides, 
herbicides, fungicides and even chemical warfare agents 
may also be separated in the manner of the invention. For 
example, using polymer-supported expanded porphyrin con 
structs is envisioned to be of use in removing various such 
undesirable compounds from contaminated Solutions, e.g., 
in waste-removal and treatment regimens. 
As disclosed herein, nucleotide mono-, di- and tri 
phosphates may be advantageously separated from each 
other using polymer-supported Sapphyrins, as may mono 
nucleotides, di-nucleotides and various length 
oligonucleotides, such as oligo probes and primers. The 
separation of larger polynucleotides, up to and including 
gene fragments, genes, and antisense constructs is also 
encompassed by the present invention. The sequence 
specific purification of nucleotide-containing constructs is 
also envisioned, whereby specific oligo or polynucleotides, 
whether DNA or RNA species, may be obtained by employ 
ing second or third generation polymer-supported expanded 
porphyrins bearing appended oligos with specific sequences. 
This allows the separation of nucleotides and oligonucle 
otides not only on the basis of charge and length but also on 
the basis of nucleic acid type. 
In yet still further embodiments, the invention concerns 
compositions which are composed of a sapphyrin derivative 
in accordance with any one of the embodiments discussed 
above, including the polymer-supported versions, com 
plexed to a second compound, wherein the second com 
pound includes within its structure a negatively charged 
phosphate, phosphonate, sulfate, or sulfonate moiety. More 
particularly, the second compound will be one that will bind 
to the sapphyrin by means of its negative charge, afforded by 
a sulfate, sulfonate, an ester of sulfate or sulfonate, a 
phosphate, a phosphate mono or diester, a phosphonate or 
phosphonate ester moiety. 
In particular embodiments, the second compound will 
include a purine or pyrimidine, or an analog of either, within 
its structure. Exemplary structures include purine or pyri 
midine antimetabolites such as FU, AraC, AZT, dd, Xylo 
GMP, Ara-AMP, PFA or LOMDP. In other embodiments, the 
second compound of the composition will simply be DNA or 
RNA. 
In still further embodiments, the invention concerns a 
method for forming a complex between a sapphyrin deriva 
tive and a second compound which includes within its 
structure a negatively charged phosphate, phosphonate, sul 
fate or sulfonate moiety, wherein the method involves pre 
paring a sapphyrin derivative as described above, including 
the polymer-supported forms such as silica-, Merrifield 
resin-, glass- and organic polymer-supported expanded por 
phyrins; obtaining the second compound; and contacting the 
sapphyrin derivative with the second compound under con 
ditions effective to allow the formation of a complex 
between the sapphyrin derivative and the second compound. 
It will be appreciated by those of skill in the art that the 
invention is also generally applicable to the introduction of 
a sapphyrin molecule, alone or complexed with a second 
molecule, into a cell, including cells contained within an 
organism and cells maintained in vitro. This may be 
employed as a means, for example, of successfully intro 
ducing the second compound (typically a charged 
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compound) into the cell. An example might be introduction 
of a complex which includes an antimetabolic or antienzy 
matic compound such as an antiviral antimetabolic or anti 
enzymatic compound, which one desires to introduce into a 
virally infected target cell. Another example would be the 
introduction of an antimetabolic or antienzymatic antitumor 
or antiproliferative compound that is introduced into a 
targeted tumor or proliferating cell. A further example would 
be contacting a cell with a photoactivatable sapphyrin 
derivative. Of course, it is contemplated that the target cell 
may be located within an animal or human patient, in which 
case the complex will be formulated into a medicament and 
an effective amount of the medicament will then be admin 
istered to the patient. 
Generally speaking, it is contemplated by the inventors 
that useful medicaments and pharmaceutical compositions 
of the present invention will include the selected sapphyrin 
derivative (which preferably incorporates a water soluble 
sapphyrin macrocycle) in a convenient amount that is 
diluted in a physiologically acceptable buffer, such as phos 
phate buffered saline. The route of administration and ulti 
mate amount of material that is administered to the patient 
or animal under such circumstances will depend upon the 
intended application and will be apparent to those of skill in 
the art in light of the examples which follow. Preferred 
routes of administration will typically include parenteral or 
topical routes. 
In still further embodiments, the invention concerns a 
method of cleaving DNA comprising preparing a sapphyrin 
chelator derivative and contacting DNA with said sapphyrin 
under conditions effective to promote cleavage of the DNA. 
BRIEF DESCRIPTION OF THE DRAWTNGS 
The following drawings form part of the present specifi 
cation and are included to further demonstrate certain 
aspects of the presentinvention. The invention may be better 
understood by reference to one or more of these drawings in 
combination with the detailed description of specific 
embodiments presented herein. 
Throughout the figures and text of the present 
specification, where sapphyrins are concerned, roman 
numerals are employed to indicate a general Sapphyrin 
structure for which alternative substituents are possible, and 
arabic numbers are employed when referring to specific and 
exemplary sapphyrin compounds. However, two points 
should be noted. First, in regard to the expanded porphyrins 
of the rubyrin class, structures 28, 29 and 30 of FIG. 5D-1 
are general rubyrin structures for which alternative substitu 
ents are possible, as detailed in the specification and brief 
description of the drawings hereinbelow. Second, in the 
polymer- or matrix-supported expanded porphyrins of struc 
tures 28-38, in FIGS. 5D-1 through 5D-10, the polymer or 
matrix may always be any one of those described throughout 
the present application. 
FIG. 1. Porphyrins and expanded porphyrins (large 
pyrrole-containing macrocyclic porphyrin analogues). 
Structure I, porphine; structure II, sapphyrin. Compounds I 
and II are represented in their generalized substituent-free 
forms, and show the standard numbering scheme. Structure 
III will be used throughout as a basis to define the novel 
sapphyrin derivatives, and polymers thereof, of the present 
invention. 
In Structure III: R'-R' may be H, alkyl, alkene, alkyne, 
halide, alkyl halide, hydroxyalkyl, glycol, polyglycol, thiol, 
alkyl thiol, aminoalkyl, carboxyalkyl, alkoxyalkyl, 













ether, ketone, carboxylic acid, phosphate, phosphonate, 
sulfate, phosphate substituted alkyl, phosphonate substituted 
alkyl, or sulfate substituted alkyl; such that the total number 
of carbon atoms in each substituent, R, is less than or equal 
to 10. The novelty of these sapphyrin derivatives lies in the 
fact that at least one of the R (R-R') will be of the formula 
(CH)-A-(CH)-B; wherein Amay be CH, O, S, NH or NR", whereink" is alkyl, alkene, aikyne, halide, alkyl 
halide, hydroxyalkyl, glycol, polyglycol, thiol, alkyl thiol, 
substituted alkyl, phosphate, phosphonate, sulfate, phos 
phate substituted alkyl, phosphonate substituted alkyl, sul 
fate substituted alkyl, COO, CONH, CSNH, CONR'; and 
wherein B may be alkene, alkyne, halide, alkyl halide, 
hydroxyalkyl, glycol, polyglycol, thiol, alkyl thiol, substi 
tuted alkyl, phosphate, phosphonate, sulfate, phosphate sub 
stituted alkyl, phosphonate substituted alkyl, sulfate substi 
tuted alkyl, hydroxyalkyl, aryl, silyl, siloxy, aminoaryl, 
amino, amino arylsilyloxy, amidoaryl, silyloxy, sugar, Sugar 
derivative, polysaccharide, metal chelating group, 
nucleobase, modified nucleobase, oligonucleotide, 
sapphyrin, Sapphyrin derivative, polymeric sapphyrin, poly 
meric matrix, solid support, alkylating agent, steroid, steroid 
derivative, amino acid, peptide or polypeptide, and n and m 
are integers of less than or equal to 10 or zero. 
FIG. 2. Water-soluble sapphyrins. FIG. 2 represents 
examples of the two categories of water-soluble sapphyrins, 
namely, polyhydroxysapphyrins and sapphyrin-sugar 
derivatives. In that these structures are generally based upon 
structure III, it will be understood that R-R' may include 
any of the groups listed above, and that at least one of the 
R (R-R') will be of the formula (CH)-A-(CH), B; 
wherein, again, Amay include any of the groups listed above 
and B will provide the water-soluble polyhydroxy moiety 
(sugar or non-sugar). 
Specific examples of water-soluble polyhydroxysapphy 
rins include, but are not limited to, compounds such as 1 and 
3, which were synthesized from the starting compounds 2a 
and 2b. Specific examples of water-soluble sapphyrin-sugar 
derivatives include, but are not limited to, compounds such 
as 4a–4a and 6, which were synthesized from the starting 
compounds 2 and 5. Any sugar or sugar derivative, such as 
those listed in Table 1, may be coupled to sapphyrin to form 
a water-soluble sapphyrin-sugar derivative in accordance 
herewith. 
FIG. 3A. Sapphyrin-metal chelating group conjugates. 
Sapphyrin may be conjugated to a metal chelating moiety 
such as, for example, EDTA, EGTA, DTPA, DOTA, ethyl 
ene diamine, bipyridine, 1,10-phenanthralene, crown ether, 
aza crown, catechols, and the like. R'-R'may include any 
of the groups listed above, and at least one of these R groups 
will be of the formula (CH)-A-(CH2)-B; wherein A 
may include any of the groups listed above and B will be a 
metal chelating moiety, for example, one of those listed 
above, such as EDTA, ethylene diamine or 1, 10 
phenanthralene. 
FIG. 3B, Structure 8 is a specific example in which 
sapphyrin is conjugated to EDTA (the precursors for which 
compound are represented by structures 7a and 7b, also set 
forth in FIG. 3A). 
FIGS. 4A-1 through 4A-6, 4B-1 through 4B-4, and 4C 
show sapphyrin nucleobase derivatives. The sapphyrin 
nucleobase monomer derivatives of the present invention 
include both ditopic and tritopic sapphyrin receptors in 
which one or two nucleobases, respectively, are appended to 
the sapphyrin core. Again, R-R' may include any of the 
groups listed above, and at least one of these R groups will 
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be of the formula (CH)-A-(CH2)-B; wherein Amay 
include any of the groups listed above and B will be one or 
more nucleobases, nucleobase derivatives or protected 
nucleobases. Conjugation of a nucleobase to a sapphyrin 
derivative to form a mononucleobase sapphyrin conjugate 
may be via any of the R groups R'-R''. Conjugation of the 
two separate nucleobases to a sapphyrin derivative to form 
a dinucleobase sapphyrin conjugate may also be via any two 
of the R groups R-R'. However, it is contemplated that the 
creation of a symmetrical molecule, such as by substitution 
on R' and R', or RandR, will be generally be preferred. 
The sapphyrin nucleobase derivatives may include any of 
the naturally-occurring purine or pyrimidine nucleobases, 
namely, cytosine, guanine, thymidine, adenine or uridine. 
Alternatively, they may include modified versions of any of 
these, such as those listed in Table 2 and phosphorylated 
forms thereof; or chemically modified nucleobases such as 
"protected” bases including, for example, a protecting group 
on the amino group of the nucleobase, such as, for example, 
9-fluorenylmethylcarbonyl, benzyloxycarbonyl, 
4-methoxyphenacyloxycarbonyl, t-butyloxycarbonyl, 
1-adamantyloxycarbonyl, benzoyl, N-triphenylmethyl, 
N-di-(4-methoxyphenyl)phenylmethyl. FIG. 4 contains 
FIGS. 4A-1 through 4A-6, FIGS. 4B-1 through 4B-4 and 
FIG. 4C, a single diagram. 
FIGS. 4A-1 through 4A-6: Sapphyrin mononucleobase 
derivatives. Specific examples of sapphyrin mononucleo 
base derivatives include, but are not limited to, structures 
9-15; for example, the cytosine-containing compound, 10; 
and the guanine-containing compounds 12, 14 & 15. 
FIGS. 4B-1 through 4B-4: Sapphyrin dinucleobase 
derivatives. These sapphyrin derivatives may also include 
any of the naturally-occurring purine or pyrimidine nucleo 
bases in any combination (fifteen possible combinations), or 
any nucleobase derivatives or chemically modified 
nucleobases, such as those listed above. Specific examples 
of sapphyrin dinucleobase conjugates include, but are not 
limited to, structures 16-20; for example, compound 20, 
containing two cytosine groups; compound 18, containing 
two quanine groups; and compound 16, a heteronucleobase 
Sapphyrin conjugate. 
FIG. 4C: A possible structure for the proposed supramo 
lecular complex formed between conjugate 10 and monoba 
sic GMP 
FIGS.5A, 5B-1 thruogh 5B-4, 5C-1 through 5C-2,5C-3i 
through 5C-3ii, and 5D-1 through 5D-10 show sapphyrin 
oligomers and polymers and polymer-supported expanded 
porphyrins. FIG. 5 contains FIG.5A, the general structural 
guideline; FIGS. SB-1 through 5B-4, exemplary dimers and 
trimers; FIGS. SC-1 through5C-3, oligomers and polymers; 
and FIGS. 5D-1 through 5D-10, polymer- and matrix 
supported expanded porphyrins. 
FIG.5A: The sapphyrin molecules of the general structure 
III may be derivatized to include further sapphyrins or 
sapphyrin derivatives, oligosapphyrin derivatives, oligo 
nucleotides or polymeric matrices, thus creating sapphyrin 
oligomers and polymers. As with the other novel sapphyrins, 
R-R' may include any of the groups listed above, wherein 
at least one of these R groups will be of the formula 
(CH2)-A-(CH2), B, with. A being any of the groups 
listed above. In these cases, B will be a sapphyrin, sapphyrin 
derivative, oligosapphyrin, polysapphyrin, oligonucleotide 
or any polymer, polymeric matrix or solid support. Conju 
gation of further derivatives to form a sapphyrin oligomer or 
polymer may be via any of the R groups R'-R', with R', 











one point is also contemplated and may be via any two, or 
more, of the R groups R-R', such as RandR, RandR, 
or R and R. 
Structure IV of FIG. 5A represents the general structure 
for the oligomeric sapphyrins of this invention, and is an 
example of structure III, wherein a further sapphyrin deriva 
tive has been added. Structure IV includes R'-R', which 
may be any of the groups listed above, and also "C" which 
is a spacer group which may be H, O, S, NH, NR", wherein 
R' is alkyl, alkene, alkyne, halide, alkyl halide, 
hydroxyalkyl, glycol, polyglycol, thiol, alkylthiol, substi 
tuted alkyl, phosphate, phosphonate, sulfate, phosphate sub 
stituted alkyl, phosphonate substituted alkyl, sulfate substi 
tuted alkyl, COO, CONH, CSNH, CONR'; alkyl, alkene, 
polyene, alkyne, aryl, alkyl halide, hydroxyalkyl, glycol, 
polyglycol, sulfide, disulfide, alkyl thiol, aminoalkyl, 
carboxyalkyl, alkoxyalkyl, aryloxyalkyl, alkyloxycarbonyl, 
aryloxycarbonyl, aldehyde, dialkyl, ether, ketone, ester, 
phosphate, phosphonate, sulfate, phosphate substituted 
alkyl, phosphonate substituted alkyl, or sulfate substituted 
alkyl. 
FIGS. 5B-1 through 5B-3 includes specific examples of 
dimeric sapphyrin structures 21-23, and an exemplary tri 
meric sapphyrin structure, 24, FIG. 5B-4. 
FIGS. 5C-1 through 5C-3i: Structure V of FIG. 5C-1 
represents the general structure for the polymeric sapphyrins 
of the present invention. Structure V is a more specific 
polymeric example of both structures III and IV, wherein 
further sapphyrin derivatives or other moieties, such as 
oligonucleotides or sapphyrin-oligonucleotides, have been 
added. In structure V, n may be from 1-100, or even from 
1-200, R-R'' and A may be H, alkyl, alkene, alkyne, 
halide, alkyl halide, hydroxyalkyl, glycol, polyglycol, thiol, 
alkyl thiol, aminoalkyl, carboxyalkyl, alkoxyalkyl, 
aryloxyalkyl, alkyloxycarbonyl, aryloxycarbonyl, aldehyde, 
ether, ketone, carboxylic acid, phosphate, phosphonate, 
sulfate, phosphate substituted alkyl, phosphonate substituted 
alkyl, or sulfate substituted alkyl. 
Structure 25 of FIG. 5C-2 represents a sapphyrin deriva 
tive which was employed as a precursor in sapphyrin 
oligomer and sapphyrin polymer syntheses. Examples of 
sapphyrin polymers include, but are clearly not limited to, 
the sapphyrin structures 26A and 26B of FIG.5C-3i where 
X=NH and X-O, respectively, and structure 27 of FIG. 
5C-3i, where phosphate linkages are employed; in both of 
these structures, n may be up to and including about 200 
units or even more depending on the intended use of the 
polymer and the synthetic chemistry chosen. Structure 25 
represents a precursor sapphyrin derivative employed in 
oligomer synthesis. 
FIGS. 5D-1 through 5D-10: Polymer- and Matrix 
supported expanded porphyrins. The polymer- and matrix 
supported expanded porphyrins of the invention include 
both polymer-supported rubyrins and polymer-supported 
sapphyrins, as exemplified by Structures VI and VII, respec 
tively. The synthesis and use of rubyrin and various rubyrin 
derivatives is described in detail in U.S. patent application 
Ser. No. 08/015,208, which is specifically incorporated 
herein by reference. 
Structure VI represents the general structure for the class 
of polymer-supported expanded porphyrins which include 
rubyrin and rubyrin derivatives and conjugates. In structure 
VI, the rubyrin may be derivatized at any position to form 
a (CH2)-A-(CH2)-B structure, wherein Amay be any 
of the groups listed above and B will include a polymer, 
polymeric matrix or solid support. B may also include any 
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of the groups listed above for A, and preferably, will include 
an aryl, alkyl, silyl, siloxy, aminoaryl, amino, amidoaryl or 
silyloxy group. The polymer, or solid support, of this struc 
ture may also be one of a variety of polymers, polymeric 
matrices, glasses or solids, such as, for example, silica, 
agarose, polyacrylamide, controlled pore glass, silica gel, 
Merrifield resin, polystyrene, glass, clay, zeolites or 
Sepharose. 
In structure VI, the "rubyrin” attached to the polymer in 
Structure VI may be any of the rubyrins represented by 
structures 28, 29 or 30, as disclosed in U.S. Ser, No. 
08/015,208, incorporated herein by reference. In structures 
28, 29 and 30, A and A may be nitrogen, oxygen or 
sulphur. One of the substituents R-R or X-X will be 
derivitized to form the (CH)-A-(CH2)-B structure, 
wherein B includes the polymeric support. The other of the 
substituents R-R and X-X may be separately and inde 
pendently H, alkyl, aryl, amino, hydroxyl, alkoxy, carboxyl, 
carboxamide, ester, amide, sulfonato, hydroxy substituted 
alkyl, alkoxyl substituted alkyl, carboxyl substituted alkyl, 
amino substituted alkyl, sulfonato substituted alkyl, ester 
substituted alkyl, amide substituted alkyl, substituted aryl, 
substituted alkyl, substituted ester, substituted ether, substi 
tuted amide; or may be of the formula (CH)-A-(CH2) 
-B, as described above. Structure VII represents the 
general structure for the class of polymeric sapphyrins 
termed polymer suggited sapphyrins. In structure VII, any 
of the groups R'-R' may be derivatized to form a (CH) 
-A-(CH2)-B structure, wherein A may be any of the 
groups listed above and B will include a polymer, polymeric 
matrix or solid support. B may also include any of the groups 
listed above for A, and preferably, will include an aryl, alkyl, 
silyl, siloxy, aminoaryl or amino group. In structure VII and 
structures 31 through 38, the polymer, or solid support, of 
this structure may also be one of a variety of polymers, 
polymeric matrices, glasses or solids, such as, for example, 
silica, agarose, polyacrylamide, controlled pore glass, silica 
gel, Merrifield resin, polystyrene, clay, zeolite or sepharose, 
In structure VII, Z may be, for example, CH (CH) 
CH, (CH2)CH (CH), CH, phenyl, naphthyl, substi 
tuted naphthyl, a nucleobase, oligonucleotide, or other simi 
lar structures which will be known to those of skillin the art. 
In Structure VII, the other R groups of the sapphyrin 
molecule, particularly R may be, for example, H., COCH, 
CONHCCH)-nucleobase, an oligonucleotide or another 
expanded porphyrin such as a sapphyrin or sapphyrin 
derivative. 
Specific examples of polymer supported sapphyrins 
include, but are clearly not limited to, the sapphyrin struc 
tures 31, 32,33,34,35,36,37 and 38 of FIGS.5D-3 through 
5D-10. In structures 34, 36 and 37, Z may again be CH, 
(CH2)CH (CH2)CH (CH), CH, phenyl, naphthyl, 
substituted naphthyl, a nucleobase or oligonucleotide. In 
structure 37, Aris phenyl. In structure 38, T may be benzyl, 
benzoyl, naphthylmethyl, adamanty, or an alkyl chain with 
between 1 and about 18 Carbon atoms (CH2, where 
n=1-18); and X may be phenyl, naphthyl, p-nitrobenzoyl or 
an alkyl chain with between 1 and about 18 Carbon atoms 
(CH, where n=1-18). In structures 31 through 38, the 
polymer or matrix may be silica gel, Merrifield resin, glass, 
controlled pore glass, agarose, Sepharose, polyacrylamide, 
polystyrene, clay, Zeolite or other polymer or matrix that can 
be functionalized by one skilled in the art of chemical 
synthesis. 
FIG. 6. Structure 39. This molecule, a tetrahydroxy por 
phyrin derivative, was employed as a "control” molecule, or 
as a point of comparison, in the sapphyrin DNA binding 












FIGS. 7A-i and 7A-ii: HPLC separation of adenosine 
phosphates using the first sapphyrin-modified silica gel, 34, 
in which Z is CH. 20 pil of a mixture of adenosine, AMP. 
ADP, and ATP was loaded onto and eluted off the first 
sapphyrin-modified silica gel using an isochratic buffer of 
100 mM dibasic ammonium phosphate buffer at a pH of 7.0 
and a flow rate of 0.2 ml/min. The wavelength of 260 nm. 
was monitored and results were confirmed with retention 
times and UV-visible spectrum obtained from samples of 
individual compounds. Insert shows the same mixture run 
through a control column with no sapphyrin. 
FIG.7B: HPLC separation of adenosine phosphates using 
first sapphyrin-modified silica gel, 34, in which Zis CH-20 
ul of a mixture of adenosine, AMP, ADP, and ATP was 
loaded onto and eluted off the first sapphyrin-modified silica 
gel using an isochratic buffer of 500 mM dibasid ammonium 
phosphate buffer at a pH of 7.0 and a flow rate of 1.0 ml/min. 
The wavelength of 260 nm was monitored and results were 
confirmed with retention times and UV-visible spectrum 
obtained from samples of individual compounds. 
FIGS. 8A-i and 8A-ii: HPLC separation of commercially 
obtained adenosine-derived oligonucleotides using the first 
sapphyrin-modified silica gel, 34, in which Z is CH. 20 ul 
of a mixture of the 2-, 3-, 4-, 5- and 6-mer of polydeoxy 
adenylic acid was loaded onto and eluted off the column 
using an isochratic buffer of 100 mM dibasic ammonium 
phosphate at pH 7.0 and a flow of 0.35 ml/min. The 
wavelength of 260 nm was monitored and results were 
confirmed with retention times and UV-visible spectrum 
obtained from samples of individual compounds. The insert 
shows the same mixture run through a control column with 
no sapphyrin. 
FIG. 8B; HPLC separation of commercially obtained 
adenosine-derived oligonucleotides using the first 
sapphyrin-modified silica gel, 34, in which Z is CH. 20 ul 
of a mixture of the 2-, 3-, 4-, 5-, 6-, 7-, 8, and 9-mer of 
polydeoxyadenylic acid was loaded onto and eluted off the 
column using an isochractic buffer of 1.0M dibasic ammo 
nium phosphate at pH 7.0 and a flow of 1.5 ml/min. The 
wavelength of 260 nm was monitored and results were 
confirmed with retention times and UV-visible spectrum 
obtained from samples of individual compounds. 
DETALED DESCRIPTION OF THE 
PREFERRED EMBODMENTS 
Sapphyrins are large pyrrole-containing macrocyclic 
analogous to porphyrins (e.g. porphine, FIG. 1, structure I). 
The synthesis of various sapphyrins has been previously 
reported", see also U.S. Pat. No. 5,159,065, incorpo 
rated herein by reference. Structural information is available 
for a limited number of sapphyrin analogues, for example' 
6.11. The present invention concerns a variety of new 
Sapphyrin-based systems, in which the sapphyrin molecule 
has been derivatized in a number of novel ways. In 
particular, this invention encompasses, but is not limited to, 
four to five broad new groups of sapphyrin-based molecular 
structures. These may be generally defined as: (D water 
soluble Sapphyrins; (II) sapphyrin-metal chelating conju 
gates; (III) sapphyrin-nucleobase conjugates; (IV) oligo 
meric and polymeric sapphyrin derivatives; and (V), the 
polymer sub-group of polymer-supported sapphyrins which 
includes new chromatographic supports derived from 
expanded porphyrins and, particularly, sapphyrin-based 
chromatographic and electrophoretic supports. 
Individually and collectively these new sapphyrin species 
overcome known deficiencies associated with extant sap 
5,672.490 
21 
phyrins. This is because all sapphyrins known at the time of 
this invention were exclusively monomeric in nature and 
insoluble in aqueous media at or near neutral pH. Thus, the 
sapphyrins known prior to the present invention were inca 
pable of forming well-characterized, water soluble com 
plexes with phosphorylated entities, including DNA, RNA, 
nucleotides, nucleotide analogues, and simple phosphate 
and phosphorate monoesters, at or near neutral pH. 
In addition, all sapphyrins known at the time of this 
invention were recognized to be quite limited in terms of 
their substitution patterns, bearing either hydrogens, alkyl 
groups, or carboxylalkyl groups in the so-called B-positions. 
Thus, these systems could not and did not display any kind 
of binding selectivity as far as phosphate chelation was 
concerned; no specificity, for instance, for or against a 
particular nucleotide (i.e. guanosine-5'-monophosphate vs. 
cytosine 5-'-monophosphate) was observed in such cases 
where such binding was inferred. 
Furthermore, this same lack of substituent versatility 
meant that sapphyrin systems carrying potentially reactive 
side chains were completely unknown and this too was 
recognized as limiting the utility of those few sapphyrins 
known to be extant at the time of this invention. Thus, the 
inventors felt it worthwhile to prepare 1) water soluble 
Sapphyrins, 2) sapphyrins bearing specific recognition units 
Such as nucleobases, 3) sapphyrins bearing reactive sites, 
such as the metal chelating derivatives embodied in modi 
fied EDTA side chains, and 4) polymer supported sapphyrins 
and 5) oligomeric and polymeric sapphyrin systems, 
wherein the binding and recognition affects achieved in the 
monomeric sapphyrins might be expected to be greatly 
amplified. None of these could be prepared using the meth 
ods available in the prior art. 
Water soluble porphyrin and porphyrin-like derivatives, 
such as sapphyrins, are known to be of interestin biomedical 
applications including photodynamic therapy (PDT)". The 
present inventors also recognized their potential for use in 
DNA recognition and modification. They reasoned that 
water soluble sapphyrin-based compounds withoutionizable 
groups may be particularly advantageous for use in a num 
ber of ways, such as in PDT, cellular recognition and 
targeting, in the transport of biologically important 
molecules, as well as in the preparation of new solid 
supports for use in chromatographic or electrophoretic appli 
cations. 
Anionic phosphorylated entities are ubiquitousin biology. 
They play a critical role in a variety of fundamental pro 
cesses ranging from gene replication to energy transduc 
tion." In addition, certain phosphate-bearing nucleotide 
analogues, such as, e.g., 9-(B-D-xylofuranosyl)guanine-5'- 
monophosphate (Xylo-GMP), are known to display antiviral 
activity in vitro. However, Xylo-GMP, like a considerable 
number phosphorylated nucleotide analogues which exhibit 
antiviral activity in cell-free extracts, is inactive in vivo due 
to its inability to cross lipophilic cell membranes'. 
The anti-herpetic agent, acyclovir (9-(2-hydroxyethoxy) 
methyl-9H-guanine), is active in vivo. Acyclovir can enter 
the cell only in its uncharged nucleoside-like form. Once in 
the cytoplasm, it is phosphorylated, first by a viral-encoded 
enzyme, thymidine kinase, and then by relatively nonspe 
cific cellular enzymes to produce an active, ionic triphos 
phate nucleotide-like species. There it functions both as an 
inhibitor of the viral DNA polymerase and as a chain 
terminator for newly synthesized herpes simplex DNA. 
The biological limitations of many other potential anti 












are not phosphorylated once inside the cell and are therefore 
largely or completely inactive. If, however, the active mono 
phosphorylated forms of these putative drugs could be 
transported into cells, it would be possible to fight viral 
infections with a large battery of otherwise inactive mate 
rials. If such specific into-cell transport were to be achieved, 
it would therefore greatly augment the treatment of such 
debilitating diseases as, for example, AIDS, herpes, hepatitis 
and measles. Given the fact that AIDS is currently a major 
national health problem of frightening proportions, and that 
something so nominally benign as measles still claims over 
100,000 lives per year world-wide, treatment of these dis 
eases would be particularly timely and worthwhile. 
Not surprisingly, in recent years, increasing effort has 
been devoted to the problem of phosphate recognition and a 
number of phosphate-binding receptors are now known." In 
spite of this, there are currently no artificial entities capable 
of effecting the selective through-membrane transport of 
mononucleotides and oligomeric polynucleotides at neutral 
or near-neutral pH, i.e., at a biological pH. A major aim of 
the inventors' studies has been therefore to provide a means 
of transporting active mono- and polyphosphorylated forms 
of these and other agents into cells. This would allow a wide 
range of otherwise inactive compounds, such as antivirals, to 
be employed therapeutically, and would also create new 
possibilities for gene therapy. 
In preliminary work concerning nucleoside transport, th 
present inventors employed triisopropylsilyl (TIPS) substi 
tuted (phosphate-free) nucleosides'. It was found that effi 
cient and selective through-membrane transport of non 
charged nucleoside analogues could be achieved by using 
the complementary TIPS derivatives as carriers'. Not 
surprisingly, however, these same TIPS derivatives proved 
completely ineffective as transport agents for the analogous 
phosphate-containing nucleotide derivatives. Thus, whilst 
confirming the viability of a base-pairing approach to selec 
tive nucleotide recognition, this work served to highlight 
further the need for an organic soluble, neutralizing, phos 
phate binding group. 
The inventors reasoned that if sapphyrin-based systems 
were to be made effective as neutral-regime carriers, say, e.g. 
for GMP, it would require the construction of polytopic 
receptor systems in which a nucleobase recognition unit, in 
this case, a cytosine-like group, were "appended" directly 
onto the phosphate-chelating expanded porphyrin core. 
Naturally, they also contemplated the use of nucleobases 
recognition units other than cytosine for use in the specific 
binding and transport of the complementary nucleobases and 
nucleobase-containing compounds. 
To synthesize multitopic receptors, the inventors devel 
oped strategies to address the following objectives: (i) the 
independent development of molecular recognition strate 
gies for the complexation of two very different kinds of 
substrates (charged anionic and neutral nucleobase); (ii) 
their subsequent co-combination so as to provide receptors 
bearing both kinds of binding subunits; and (iii) various 
alternative methods of receptor oligomerization so as to 
provide oligomeric species bearing numerous combinations 
of multitopic receptors. 
Pursuing these strategies led to the development of the 
sapphyrin-based ditopic receptor systems of the present 
invention, capable of recognizing both the anionic phos 
phate and the neutral portions of the nucleotide derivatives, 
such as the purine or pyrimidine moieties. Molecules of this 
type are, indeed, capable of the binding and transport of 
nucleotides and their derivatives. This theme was extended 
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to the preparation of oligomeric, multitopic, receptors 
capable of recognizing multiple phosphate anions and 
nucleobase portions of nucleotide derivatives arranged in 
specific sequences. 
The ditopic receptor systems are ideal vehicles for the 
intracellular transport of nucleotides and their derivatives, 
including anti-viral agents. The multitopic receptors, 
likewise, are contemplated to be of use in binding to 
oligonucleotides and specific sections of DNA or RNA and 
in transporting such nucleic acid segments into cells. The 
phosphate and nucleic acid base ("nucleobase”) recognition, 
through-membrane transport and cell delivery properties of 
the present invention are thus applicable to the recognition 
and delivery of a large variety of monomeric and oligomeric 
species, including DNA, RNA and antisense constructs. In 
certain embodiments, one may wish to employ the novel 
constructs to transport oligonucleotides which contain C-5 
propyne analogues of uridine and cytidine into cells'. 
The sapphyrins and sapphyrin-containing compositions of 
the invention may be administered to an animal, including 
human subjects or patients, for a variety of reasons. For 
example, in order to deliver a specific compound to a cell, 
as may be used to introduce an anti-proliferative, anti-cancer 
or anti-viral agent or a sense or antisense oligonucleotide 
into a cell which would benefit from the actions of such a 
compound. Therefore, further compositions envisioned are 
those which comprise an effective amount of a sapphyrin, as 
disclosed herein, dissolved or dispersed in a pharmaceuti 
cally acceptable carrier or aqueous medium. 
The phrases "pharmaceutically or pharmacologically 
acceptable" refers to molecular entities and compositions 
that do not produce an adverse, allergic or other untoward 
reaction when administered to a human. As used herein, 
"pharmaceutically acceptable carrier" includes any and all 
solvents, dispersion media, coatings, antibacterial and anti 
fungal agents, isotonic and absorption delaying agents and 
the like. The use of such media and agents for pharmaceu 
tical active substances is well known in the art. Except 
insofar as any conventional media or agent is incompatible 
with the function of the sapphyrin, its use in the therapeutic 
compositions is contemplated. Supplementary active 
ingredients, e.g., other anti-viral agents, can also be incor 
porated into the compositions. 
In addition to the compounds formulated for parenteral 
administration, such as intravenous or intramuscular 
injection, other pharmaceutically acceptable forms include 
those for topical administration, such as sapphyrin 
containing compositions formulated into cremes, lotions and 
the like, and even time release capsules. The preparation of 
pharmaceutically-acceptable sapphyrin compositions will 
be known to those of skill in the art in light of the present 
disclosure. 
The inventors' surprising discovery that expanded 
porphyrins, such as rubyrin and sapphyrin, recognize and 
bind phosphates (see references 4a, 22 and U.S. Ser. No 
08/015,208, incorporated herein by reference), also lead the 
inventors to reason that such expanded porphyrins would be 
ideal for use in laboratory techniques to separate and purify 
nucleotides and oligonucleotides. This is a very important 
area to both scientists and clinicians as nucleotides, natural 
and synthetic oligonucleotides play critical roles in modern 
biotechnology. Oligonucleotides ("oligos') are used, for 
instance, as hybridization probes in blot analyses, primers 
for PCR amplification, and for site-specific mutagenesis. 
Furthermore, in areas that are under FDA jurisdiction, 












probes for the detection of genetic diseases and for proviral 
HIV, the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS). They are also being considered as 
potential chemotherapeutic agents, both directly, i.e., in gene 
therapy, and in an antisense fashion.' 
All the above applications for using oligos require oligo 
nucleotide materials of impeccable purity (often greater 
than>99.99%). Such purity, however, is not so easy to 
obtain using existing technology.” Presently, gene prod 
ucts and other oligonucleotide-type materials are purified 
using polyacrylamide gel electrophoresis (PAGE). This 
approach suffers from the drawbacks of being time 
consuming, requiring toxic materials, and is painfully 
manpower-sensitive and low-yielding.” 
Liquid chromatography, high performance liquid chroma 
tography (HPLC), and High Performance Affinity Chroma 
tography (HPAC)' using specialty silica gels are cur 
rently used to separate biological molecules. Indeed, silica 
gel phases with bonded groups, such as linear hydrocarbons, 
amino groups, cyano-groups, carboxylic amides and amino 
acids are all known.''” Unfortunately, few if any of these 
phases are efficacious for the efficient, high-yielding sepa 
ration of nucleotides and oligonucleotides. 
Those that work best for this purpose are ion exchange 
columns which, on a limited basis, can sometimes separate 
oligonucleotides containing 40 or fewer residues. However, 
this technique still suffer from several limitations, not least 
that it requires severe conditions, including elution at pH 
2.7, for routine operation. The use of high concentration 
buffers (greater than 1M), and gradients which often include 
formic acid or formamide, also limits the half lives of ion 
exchange columns. Furthermore, commercially available 
hydroxyapatite columns are limited for low pressure only 
(up to 719 psi). Reverse phase columns are designed for 
pressures up to 5000 psi. However, this separative technique 
is based on hydrophobic interaction and, because there is not 
a specific interaction for phosphorylated species, it is not 
surprising that effective separation is not generally achieved. 
Recently, Takemoto et al. reported a new type of station 
ary phase in which purine and pyrimidine bases were 
bonded to the silica gel. With this support, base-pairing 
interactions between the nucleic acid base pairs and the 
modified silica gel were expected to improve resolution in 
nucleic acid separation. Although such stationary phases 
were used to separate nucleic acid free-bases, purine 
alkaloids, nucleosides, and mono- and oligonucleotides, this 
approach unfortunately had least success with oligonucle 
otide separation, which is the most important area. Thus, 
there was still a critical need for improved solid supports that 
would effectively separate nucleotides and oligonucleotides. 
The inventors realized that for a solid support to be most 
useful, it must not only separate similar nucleotides and 
oligonucleotides from one another, it must do so rigorously 
and correctly based on chain length or size. Unfortunately, 
prior to the present invention, there were no suitable phos 
phate chelating agents which made this an achievable goal 
for use in either HPLC or electrophoretic separation sys 
tems. As described below, the inventors designed and con 
structed sapphyrin-based supports and used them to achieve 
the separation of nucleotides and oligonucleotides, thus 
overcoming many of the existing drawbacks described 
above. 
Afurther utility of such sapphyrin-substituted materials is 
their use as tools in the removal of phosphorylated environ 
mental contaminants from ground water, soil, foodstuffs, 
and the like. They may therefore be employed to analyze and 
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separate pesticides such as Dichlorovos, Phosphamidon, 
Diazanon, and Parathion, herbicides and fungicides, many 
of which contain organophosphorus compounds. Sapphyrin 
substituted gels and columns may even be employed in the 
rapid detection and analysis of organophosphorus chemical 
warfare agents, allowing them to be disposed of where 
necessary.' 
Another technical area in which significant improvements 
could be made is in oligonucleotide analysis. For example, 
automated gene sequencing is currently carried out using 
either radio- or fluorescent-labeled nucleic acid gel electro 
phoresis.” This technique is limited by the requirement for 
either slab or tubular polyacrylamide gels. An alternative 
approach, currently being considered on a research basis, is 
to use capillary electrophoresis.' Unfortunately, this is 
limited when it comes to achieving separations based purely 
on electrostatics and oligomer size. A technique which 
would allow for such separation would therefore represent a 
significant improvement in this area. 
As outlined above, the present invention therefore 
encompasses, but is not limited to, the following four or five 
groups of novel sapphyrin-based molecular structures: (I) 
water soluble sapphyrins; (II) sapphyrin-metal chelating 
conjugates; (III) sapphyrin-nucleobase conjugates; (TV) oli 
gomeric and polymeric sapphyrin derivatives, a sub-group 
of which can be independently termed group (V), the 
polymer-supported sapphyrins and chromatographic sup 
ports containing sapphyrin and other expanded porphyrins 
linked to polymers such as polyacrylamide, polystyrene, 
glass, clays, zeolites, silica gel or Merrifield resins. The 
water soluble sapphyrins include sapphyrin hydroxyalkyla 
mide and Sugar derivatives. The sapphyrin-nucleobase con 
jugates include an extensive group of structures in which 
nucleobase-like recognition units are appended directly into 
the phosphate-chelating sapphyrin core. The polymer group 
broadly comprises both group IV, the oligomers and poly 
mers of sapphyrin or sapphyrin derivatives and sapphyrin 
nucleotide oligomers and polymers with various linkages, 
and group V, the polymer supported expanded porphyrin 
constructS. 
In addition, it will be understood that the synthetic strat 
egies developed by the inventors, wherein a functionalized 
sapphyrin is appended to a moiety of desirable chemical 
function, can be used to prepare an extremely wide variety 
of sapphyrin-containing conjugates. Sapphyrins may thus be 
conjugated to, not only metal chelating agents, Sugars, 
nucleobases, and other sapphyrins, sapphyrin derivatives, or 
polysapphyrins, but also to a variety of other substances. 
These include, for example, phosphates, phosphonates, 
sulfates, sulfonates, amino acids, peptides, polypeptides, 
steroids, steroid derivatives, alkylating agents, and polymers 
glasses or solids, such as agarose and sepharose, 
polyacrylamide, controlled pore glass, silica gel, Merrifield 
resin, polystyrene, clays or zeolites. It is contemplated that 
one of skill in the art will be able to prepare sapphyrin 
conjugates including those listed above, without undue 
experimentation, given the extensive synthetic methodology 
disclosed throughout the present application 
I. WATER SOLUBLE SAPPHYRIN DERVATIVES 
Water soluble porphyrin and porphyrin-like derivatives, 
especially sapphyrin derivatives, are of potential interest in 
a variety of applications ranging from photodynamic therapy 
(PDT) to DNA recognition and modification to cellular 
recognition and transport. The present inventors considered 
that the development of water soluble sapphyrin-based com 
pounds without ionizable groups would likely be advanta 









In regard to PDT, water soluble sapphyrins may be used 
as photosensitization agents for the photodynamic inactiva 
tion of infectious agents having membranous envelopes. As 
such they may be employed in the photo-eradication of 
cell-free viruses from blood samples, such as, for example, 
the hepatitis viruses HBV and NANB, and especially HIV-1. 
In this process, sapphyrin localizes selectively at or near the 
morphologically characteristic viral envelope. Upon 
photoradiation, it catalyzes the formation of highly reactive 
singlet oxygen which, in turn, destroys the essential mem 
brane envelope, thus killing the virus and eliminating its 
infectivity, see U.S. Pat. No. 5,041,078, incorporated herein 
by reference. 
The search for compounds for use in in vivo cellular 
transport and uptake, where diffusion across a membrane is 
involved, led the inventors to synthesize and characterize a 
range of novel water soluble sapphyrin derivatives. Gener 
ally speaking, the water soluble sapphyrin derivatives of this 
invention will include at least four OH groups, such as can 
be supplied by a variety of different polyhydroxy groups, or 
a single sugar residue. This broad class of water soluble 
sapphyrins can be further divided into water soluble poly 
hydroxysapphyrins and water soluble sapphyrin sugar 
derivatives. These groups include a variety of distinct 
molecules, such as, for example, the compounds represented 
by structures 1 and 3–6 (FIG. 2), and substituted derivatives 
thereof. 
Naturally, those of skill in the art will understand that a 
wide range of water soluble sapphyrins are encompassed by 
the present invention. Both a variety of polyhydroxysap 
phyrins and sapphyrin sugar derivatives may be synthesized 
according to the methodology disclosed herein. For 
example, any one, or more, of the many sugar and modified 
sugar units depicted in Table 1 may be linked to a sapphyrin. 
core to create a water-soluble sapphyrin in accordance 
herewith. 
A. Water Soluble Polyhydroxysapphyrins 
These are water soluble sapphyrin derivatives based on 
two (poly)hydroxyalkylamido units attached to the macro 
cyclic periphery. Examples of compounds of this type 
include those represented by structures 1 and 3 (FIG. 2). 
Although, naturally, it will be understood that a wide variety 
of different, and yet analogous, substituted derivatives may 
be prepared in accordance herewith. Polyhydroxysapphyrins 
may be prepared from an activated form of a sapphyrin acid 
(acid chloride, mixed anhydride, O-acylurea derivative, 
N-acylimidazole) and polyhydroxyamines. 
B. Water Soluble Sapphyrin-Sugar Derivatives 
The second general group of water soluble sapphyrin 
derivatives are the sapphyrin-sugar derivatives, where any 
one of a number of various sugar subunits are connected to 
the macrocycle periphery. Specific examples of this type of 
compound are represented by structures 4 & 6 (FIG. 2). 
Again, in light of the present disclosure, those of skill in the 
art will be able to prepare a wide variety of distinct 
sapphyrin-sugar derivatives without undue experimentation. 
Examples of sugars and sugar-derivatives which be 
employed in accordance herewith are listed in Table 1. The 
sugars employed may be either D or L forms and may also 
be eithero, or Banomeric forms. The use of modified sugars 
is also envisioned, such as those including, for example, 
phosphate, methyl or amino groups. It is contemplated that 
preferred sugars for use in accordance herewith will include, 
for example, glucose, glucosamine, galactose, galac 




















For example, the efficiency of those compounds shown in 
Structures 4c and 6b for singlet oxygen generation has 
already been tested, when it was found to be 11% (in 
comparison with ZnTPPS). These water soluble sapphyrins 
4c and 6b thus have apparent utility as a potential cellular 
targeting agent. As is generally known, glycoconjugates 
have important roles in the control of cell division and 
intercellular association. Changes in the biochemical and 
organizational structures occur during malignant transfor 
mation'. Therefore it may be therapeutically advantageous 
to alter or inhibit the biosynthesis of these tumor cell surface 
constituents. This might result in tumor cell death caused by 
the inhibition of the biosynthesis of vital membrane com 
ponents. In this regard, D-glucosamine derivatives have 
been proven to be efficient inhibitors of tumor growth". 
It is envisioned that differential tumor toxicity and spe 
cific organ targeting can be achieved with different sugar 
sapphyrin derivatives. For instance, modified sugars such as 
e.g., Glc-NAc can be included within the image of substitu 
ents that can be appended to the sapphyrin core. All that 
would be needed is to start with an activated sapphyrin and 
2-acetamido-2-deoxy-3, 4,6-tri-O-acetyl-B-D- 
glucopyranosylamine. The synthesis and use of this and 
other related systems are thus considered to fall within the 
scope of the present invention. 
The synthesis of representative compounds 4 and 6 
involve compounds that are connected via glycoside bonds 
and obtained starting from dihydroxysapphyrin and C-D- 
acetobromoglucose, as precursors, and using silver triflate in 
dichloromethane to effect coupling. The second set of sys 





obtained starting from sapphyrin(bis)acid chloride and 1,3, . 
4,6-tetra-O-acetyl-2-amino-2-deoxy-O-D-glucopyranose 
(tetraacetyl-D-glucosamine). In both series, after removing 
the protecting groups from the sugar moieties, the desired 
water soluble sapphyrin derivatives may be obtained. 
It is contemplated that compounds such as those repre 
sented by structures 4 and 6 will have utility in both 
photophysical and biological embodiments. For example, it 
is envisioned that these new sapphyrins will have improved 
solubility and/or phosphate anion chelation properties, ren 
dering them of use in protocols such as anti-viral transport 
and RNA/DNA recognition and binding. 
II. SAPPHYRIN-CHELATING CONJUGATES 
The second general group of novel monomeric sapphyrin 
derivatives of the present invention are the sapphyrin-metal 
chelating derivatives. Suitable chelating groups contem 
plated for use in such conjugates include, but are not limited 
to, EDTA, EGTA, DTPA, DOTA, ethylene diamine, 






A specific example of this type of sapphyrin derivative is 
the sapphyrin-EDTA conjugate represented by structure 8 
(FIG. 3B). The inventors have demonstrated that, in the 
presence of Fe’ and dithiothreitol, this molecule, in micro 
molar concentrations, can cleave DNA. Sapphyrin-EDTA 
conjugates will therefore be useful in effecting affinity 
cleavage of double stranded DNA. It is particularly contem 
plated that they will be of use in cleaving double stranded 
DNA of a defined sequence, or more importantly, perhaps 
will cleave double stranded DNA with a particular structural 
motif. 
The sapphyrin-EDTA conjugate is believed to bind to 
DNA in a novel manner, based generally upon binding to the 
phosphate residues of the sugar-phosphate backbone. As 
such, it is contemplated that this sapphyrin conjugate will be 
capable of sensing conformational changes about the DNA 
back-bone. Sapphyrin-EDTA will thus be particularly useful 
as a structural probe of DNA, and the sapphyrin-metal 
chelating derivatives in general will be of use in a variety of 
photophysical embodiments. 
II. SAPPHYRENNUCLEOBASE DERIVATIVES 
The inventors initially found that organic-solubilized, 2', 
3', 5'-tris(triisopropylsilyl)substituted nucleosides would 
enhance the through-CHCl transport of the corresponding 
Watson-Crick complementary phosphate-free nucleoside in 
a standard 3-phase Aq -CH.Cl-Aq II liquid membrane 
cell.' They also reported that the deproteinated form of 
sapphyrin, a pentapyrrolic "expanded porphyrin",”“acts 
as an efficient but non-selective carrier for nucleotide mono 
phosphates at pH-4. Rubyrin", and a large excess of 
C-Tips (ca. 100-fold) was also found capable of effecting the 
selective through-transport of GMP at neutral pH (C-Tips is 
2',3',5'-tris(triisopropylsilyl)-cytosine). 
However, sapphyrin, which remains monoprotonated in 
the ca. 3.5spHs 10 regime' was itself found to be 
ineffective as a GMP carrier at pH 7, even in the presence of 
a large excess of C-Tips." Thus, it was thought that if 
sapphyrin-based systems were to be made effective as 
neutral-regime carriers, it would require the construction of 
sapphyrin systems in which nucleotide recognition units are 
“appended” directly onto the phosphate-chelating expanded 
porphyrin core. 
Precisely these types of sapphyrin derivatives have now 
been synthesized and form an important part of the present 
invention. These sapphyrin nucleobase cohjugates are mol 
ecules which have been derivatized by the addition of one or 
more nucleobase compounds, i.e., one or more purines, 
pyrimidines, or derivatives thereof. Sapphyrin derivatives 
with one nucleobase per sapphyrin molecule may be referred 
to as ditopic receptors, whereas those with 2 nucleobases per 
molecules are termed tritopic receptors. 
Sapphyrin mononucleobase derivatives may include any 
of the naturally-occurring purine or pyrimidine nucleobases, 
namely, cytosine, guanine, thymidine, adenine or uridine. 
Equally, they may include modified versions of any of these, 
such as the heterocyclic components of those nucleosided 
nucleotide analogues listed in Table 2 and phosphorylated 































Also included within the invention are the sapphyrin 
mononucleobase derivatives including chemically modified 
nucleobase such as "protected” bases. Protecting groups are 
used to protect reactive groups, such as amino and carboxyl 
groups, from inappropriate chemical reactions. Sapphyrin 
nucleobase conjugates with protected bases include, for 
example, conjugates wherein one or more base has a pro 
tecting group, such as 9-fluorenylmethylcarbonyl, 
benzyloxycarbonyl, 4-methoxyphenacyloxycarbonyl, 
t-butyloxycarbonyl, 1-adamantyloxycarbonyl, benzoyl, 
N-triphenylmethyl or N-di-(4-methoxyphenyl) 
phenylmethyl on the amino group of the nucleobase. 
As clearly detailed in the description of the figures, any of 
the groups R'-R' may be H, alkyl, alkene, alkyne, halide, 
alkyl halide, hydroxyalkyl, glycol, polyglycol, thiol, alkyl 
thiol, aminoalkyl, carboxyalkyl, alkoxyalkyl, aryloxyalkyl, 
alkyloxycarbonyl, aryloxycarbonyl, aldehyde, ether, ketone, 
carboxylic acid, phosphate, phosphonate, sulfate, phosphate 
substituted alkyl, phosphonate substituted alkyl, or sulfate 
substituted alkyl; with at least one of these R groups being: 
(CH2)-A-(CH2)-B, wherein Amay include any of the 
groups listed above and B will be one or more nucleobases, 
nucleobase derivatives or protected nucleobases. 
Conjugation of a nucleobase to a sapphyrin derivative to 
form a mononucleobase sapphyrin conjugate may be via any 
of the R groups R'-R''. Conjugation of the two separate 
nucleobases to a sapphyrin derivative to form a dinucleobase 
Sapphyrin conjugate may also be via any two of the R groups 
R-R''. However, it is contemplated that the creation of a 
symmetrical molecule, such as by substitution on RandR', 
or R and R, will be generally be preferred. 
Specific examples of sapphyrin mononucleobase deriva 
tives are represented by structures 9-15 (FIGS. 4A-1 
through 4A-6). These include, but are clearly not limited to, 
the cytosine-containing sapphyrin derivative represented by 
structure 10; and the guanine-containing sapphyrin com 
pounds 12, 14 & 15. The doubly substituted sapphyrin 
analogues, or tritopic sapphyrin receptors, of this invention 
may contain any combination of nucleobases. These sap 
phyrin derivatives may be homonucleobase conjugates, con 
taining two of the same bases, or heteronucleobase con 
structs containing two distinct nucleobases in any 
combination. Thus, for example, in the nomenclature used 
herein, a sapphyrin nucleobase derivative with a single 
cytosine residue is represented by structure 10; a sapphyrin 










sented by structure 18, and a sapphyrin nucleobase deriva 
tive with one guanine residue and one cytosine residue is 
represented by structure 16. 
These sapphyrin nucleobase monomers will act as selec 
tive carriers for the through-membrane transport of nucle 
otide monophosphates at biological, i.e. near-neutral pH. 
Thus, a sapphyrin nucleobase derivative bearing a cytosine 
residue will function in the binding and transport of GMP, 
and likewise, each nucleobase conjugates will be able to 
effect the transport of its complementary base, i.e., the base 
with which it naturally base-pairs. The nucleobase conju 
gates will be particularly useful for the transport of nucle 
otide derivatives, such as acyclovir monophosphate, Xylo 
GMP and Ara-AMP, phosphonate derivatives and simple 
species such as the pyrophosphate derivatives PFA and 
COMDP, each of which function as antiviral agents. 
For initial studies, ditopic and tritopic sapphyrin receptors 
bearing one and two cytosine molecules were first synthe 
sized. The ditopic receptor is represented by structure 10 
(FIG. 4A-2), and the tritopic receptor by structure 20 (FIG. 
4B-4). These sapphyrin nucleobase derivatives were pre 
pared by trifluoroacetic acid (TFA) induced detritylation of 
protected conjugates. The protected conjugates in question 
are those wherein the nucleobase derivative contains, 
instead of a single hydrogen, a C(CH) group. These, in 
turn, were prepared by coupling 1-(2-aminoethyl)-4- 
(triphenylmethyl)aminol-pyrimidin-2-one" with the appro 
priate sapphyrin mono- or diacid chlorides. 
The inventors have also prepared a variety of sapphyrin 
nucleobase conjugates by the condensation of sapphyrin 
mono and bis acids with conveniently modified nucleobases. 
Various spacers may be used for the connection, such as, for 
example, oligomethylene bridges with terminal amino, or 
hydroxy function, which allow formation of amide and ester 
bond for the connection of the sapphyrin and nucleobase 
units. This bridge may also be modified, e.g., by the reduc 
tion of the amide bond to give the amine function." Satis 
factory spectroscopic and analytic data have been obtained 
for all such new compounds. The present invention thus 
encompasses many possibilities for the connection of the 
same or different nucleobases to one sapphyrin macrocycle. 
Transport studies, using a standard'AqI-CHCl2-Aq II 
liquid membrane cell, were carried out using the sapphyrin 
cytosine conjugates represented by structures 10 and 20. It 
was found that both 10 and 20 were able to effect the 
selective through-membrane transport of GMP at, or near, 
neutral pH (Table 3). In all cases, compound 20 displayed a 
higher selectivity for GMP, by a factor of 8-100, relative to 
either AMP or CMP, than its congener 10. 
These results clearly demonstrate that the transport of a 
normally organic-insoluble species, namely guanosine-5'- 
monophosphate (GMP), can be effected by preparing and 
using an appropriate sapphyrin-nucleobase conjugate. A 
similarly designed sapphyrin receptor approach may be used 
to achieve the into-cell in vivo delivery of other nucleotides 
and nucleotide derivatives, such as, for example, Xylo-GMP 
and other antiviral nucleotide-based drugs. 
As described in detail below, any of the sapphyrin mono 
di- or oligo-nucleobase conjugated and derivatives, includ 
ing both naturally-occurring nucleobases and modified 
nucleobases, may also be linked to a solid support to form 
a polymer-supported sapphyrin composition. 
IV. OLGOMERIC AND POLYMERIC SAPPHYRIN 
DERVATIVES 
A further group of novel sapphyrin-based compounds 
embodied by the present inventionis the sapphyrin oligomer 
and polymer group. For convenience, this group can be 
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sub-divided into two further groups, one of sapphyrin-only 
oligomers and polymers or sapphyrin-conjugate and 
sapphyrin-nucleobase oligomers and polymers; and another 
of sapphyrin- and expanded porphyrin-based solid supports, 
including chromatographic supports and columns. 
The first group of sapphyrin oligomers and polymers 
include relatively low-number conjugates, such as dimers 
and trimers, and also larger oligomers or polymers. The 
oligomers will generally include between about 4 or 5 and 
about 30 or 40 residues, or even up to about 50 residues, 
whereas the polymers may generally comprise from about 
40 or 50 to about 100 or 150 residues, or even up to about 
200 sapphyrin units or even more where desired. 
The monomeric units employed in the synthesis of 
sapphyrin-sapphyrin conjugates may be known Sapphyrin 
molecules, such as those described in U.S. Pat. No. 5,159, 
065, incorporated herein by reference. Equally, any of the 
novel sapphyrin derivatives disclosed herein may be 
employed, in any combination, to create further novel sap 
phyrin dimers, trimers, oligomers or polymers. Encom 
passed within the terms oligomers or polymers are those 
sapphyrin conjugates synthesized by the controlled addition 
of particular monomeric units and those produced by more 
uncontrolled polymerization methods. 
Due to the unique mode of DNA interaction, sapphyrin. 
polymeric molecule will possess an unrivaled ability to act 
as a general DNA binding platform. This has the distinct 
advantage that it can be modified so as to adjust both target 
cell specificity and degree of interaction with the DNA. For 
sapphyrins and sapphyrin polymers, the basic site of inter 
action with the DNA involves the interior of the sapphyrin 
macrocycle, so that the exterior positions R-Ro can be 
substantially modified without significantly disrupting the 
DNA binding interaction. These exterior positions can be 
used to systematically adjust features such as solubility, 
membrane permeability and cell selectivity. Furthermore, 
groups designed to modulate interaction with DNA can be 
attached to the exterior of the sapphyrin polymers including 
alkylating functions (bromoacetamido groups, ethylene 
diamine, epoxides etc.) to provide covalent attachment to 
DNA or ene-diyne moieties to allow for double stranded 
cleavage. 
A further and important advantage of the sapphyrin sys 
temis that the simple DNA binding motif has been extended 
to several multimeric structures, in which multiple sapphy 
rins covalently linked together will be able to bind simul 
taneously and thus strengthen the entire interaction. This 
feature will allow a modular approach in which the appro 
priate number (2-10) of sapphyrin molecules is attached in 
a single molecule, perhaps with different sapphyrin units 
containing sapphyrin derivatives with different groups 
attached that control such important properties such as 
solubility, target cell specificity and DNA modification abil 
ity. 
A. Sapphyrin Oligomers 
Specific examples of sapphyrin oligomers include, but are 
not limited to, those compounds represented by the struc 
tures 21-24 of FIGS. 5B-1 through 5B-4. Sapphyrin oligo 
mers were been prepared by the condensation of sapphyrin 
mono and bis acids with amino groups as spacers units. As 
di- and tri-amino spacers, ethylenediamine, 1,3- 
diaminopropane, 1.3- and 14-phenylenediamine, diaminon 
aphtalenes and anthracenes, for example, have used in the 
synthetic approach. Sapphyrin trimers were built in one step 
reaction, in which 3 molar equivalents of Sapphyrin mono 
acid were combined with a trisamino component, e.g. tris 










For the coupling reaction, a variety of different methods 
have been used. These include, for example, acid chloride, 
O-acylurea, mixed anhydride and N-acylimidazole, which 
were found to be particularly successful. The synthetic 
methodology employed was essentially the same as that 
developed to prepare sapphyrin-nucleobase conjugates. It is 
important to emphasize that the synthesis of both the sap 
phyrin nucleobase conjugates and the sapphyrin oligomers 
and polymers may be readily performed using a standard 
automated oligonucleotide synthesizer. 
The present inventors have prepared mono- di- and tri 
sapphyrins and have proven them to be very efficient rec 
ognition species for nucleotides, monophospates, diphos 
phates and triphosphates. The formation of noncovalently 
bonded complexes between sapphyrin-like oligomers and a 
nucleotide allows the transport of nucleotide mono, di and 
triphosphates across cell membranes to occur at physiologi 
cal pH. This will likely be of direct use in the transport of 
antiviral triphosphates to mammalian cells, especially for 
the treatment of AIDS. 
As discussed above, any of the novel sapphyrins of the 
present invention may be employed, in any combination, in 
the synthesis of novel sapphyrin oligomers or polymers. The 
synthetic approach developed is equally suitable to the use 
of one or more novel sapphyrin derivatives as starting 
materials as it is to the use of known sapphyrins. 
Importantly, methods are disclosed herein for the generation 
of covalently bonded sapphyrin-nucleotide complexes. 
Importantly, the sapphyrin-sapphyrin nucleobase and 
sapphyrin-DNA linkage chemistry of the present invention 
is compatible with automated oligonucleotide synthesis, and 
phosphoramidate chemistry. 
The present invention encompasses two categories of 
sapphyrin polymers; these may be described generally as 
polymeric sapphyrins and polymer supported sapphyrins 
(see below, group V). The polymeric sapphyrins may be 
employed in a variety of different embodiments, for 
example, relating to oligonucleotide binding and transport, 
as will be discussed more fully below. The polymer sup 
ported sapphyrin group includes resin-synthesized sapphy 
rins. These sapphyrin polymers may ultimately be cleaved, 
resulting in the generation of a free polymer. However, 
following resin-bound synthesis, the polymers may be main 
tained covalently bound to the parent resin, thus opening 
further possibilities for their use. 
Sapphyrin polymers which are maintained bound to the 
parent resin may be advantageously employed as a "column 
material” for use in chromatography, for example, in the 
separation of nucleotides or in photoactivation. With regards 
to the latter, it is to be appreciated that polymer-supported 
sapphyrins could prove particularly advantageous for the in 
vitro inactivation of viruses and other blood borne patho 
gens: the fact that no sapphyrin would be left in the blood (or 
other substance) being purged would militate against any 
toxicity problems. 
B. Polymeric Sapphyrins 
One class of sapphyrin polymers contemplated by the 
present invention are those compounds resulting from the 
polymerization of monomeric units, by various types of 
processes other than those using a resin. For example, 
radical polymerization of olefin substituted sapphyrin may 
be employed to give a polyethylene type of polymer. 
Alternatively, polycondensation of sapphyrin bis acid with 
sapphyrin diamine could be used to give a polyamide type 
of polymer, or polycondensation of sapphyrin bis acid with 
sapphyrin bis alcohol may be employed resulting in a 
polyester type of polymer. In all of these cases, sapphyrin 
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based polymers may be prepared both with and without 
covalently bonded nucleobases. Examples of the latter are 
26A and 26B. 
V. POLYMER-SUPPORTED EXPANDED PORPHYRNS 
AND DERIVATIVES 
. The finding that certain expanded porphyrins bind to 
phosphate moieties led the inventors to propose that sap 
phyrins or rubyrins, when linked to a solid support, may be 
advantageously employed to purify complex mixtures of 
phosphorylated species. Such expanded-porphyrin solid 
supports were particularly envisioned to be suitable for use 
in the improved separation of nucleotides and oligonucle 
otides. This indeed proved to be the case and has given rise 
to the fifth broad group of novel expanded porphyrins of the 
present invention, namely polymer-supported rubyrin and 
sapphyrin constructs. The solid support or matrices of these 
constructs may be any of a variety of materials such as 
polyacrylamide, polystyrene, glass, clays, Zeolites, silica 
gel, Merrifield resins and other materials that can be func 
tionalized by those skilled in the art of chemical synthesis. 
In the following discussion, the polymer-supported 
expanded porphyrins will generally be exemplified by those 
containing sapphyrin, as set forth by general Structure VII. 
However, it will be understood that both the concepts and 
the synthetic methodology presented herein can be readily 
adapted for use with rubyrin and rubyrin derivatives, as in 
general Structures VI. The synthesis and use of rubytin, 
rubyrin derivatives and rubyrin conjugates is detailed in U.S. 
Ser. No. 08/015,208, incorporated herein by reference. 
A. Sapphyrin-Substituted Silica Gels and Merrifield Resins 
In certain embodiments, the polymer-supported expanded 
porphyrins of the present invention will be bonded, 
Sapphyrin-substituted glass capillaries or silica gels that will 
serve as specific, phosphate-chelating solid supports. These 
may be used in the chromatographic and electrophoretic 
separation of phosphorylated species, including nucleotides, 
oligonucleotides, and DNA or RNA molecules including 
gene fragments, and will be suitable for both analytical and 
preparative HPLC applications. 
These aspects of the invention therefore encompass a full 
range of sapphyrin-modified stationary phases in accordance 
with the generalized Structure VII set forth in FIG. 5D-2. 
When the bonded stationary phase (termed "polymer” in the 
figures) is silica gel, the resulting products will be used for 
medium to high pressure applications. For low pressure 
applications, organic polymer based sapphyrins, for 
example, modified Merrifield resins, will be prepared using 
the same basic strategy. In all cases the wide range of 
intrinsic variation, imparted via groups Z and the expanded 
porphyrin R groups such as R, will afford the opportunity 
to prepare stationary phases capable of separating a wide 
range of phosphorylated species. 
To date, a sapphyrin substituted Merrifield resin and a first 
generation sapphyrin-substituted silica gel which corre 
spond to structure 34 have already been prepared. In the 
sapphyrin-substituted silica gel 34, R=H and Z=CH. With 
this latter silica gel, a 4.6 mmx10.0 cm HPLC column was 
packed (by Alltech Inc). Then, in the initial series of studies, 
this column was used to separate various, adenosine-derived 
nucleotide mono-, di-, and triphosphates with significant 
success (FIGS. 7A-i, 7A-ii and 7B). 
The ability to separate nucleotide mono-, di-, and triph 
osphates from cell extracts has long been a challenging task. 
Most of the commercially available HPLC columns provide 
less than adequate separation of di- from triphosphates. 
However, such separations are instrumental in determining 












cell health in the study of many diseases. The successful 
results shown in FIGS. 7A-i, 7A-ii and 7B are therefore 
particularly important. 
ATP +0.5 ADP 
AMP-ADP+ ATP 
1. 
Adenylate Energy Charge = (1) 
A great advantage afforded by these aspects of the inven 
tion is that different numbers of sapphyrin molecules may be 
introduced per polymer unit simply by varying the molar 
ratio of sapphyrin derivative to the number of the groups 
bonded on polymer surface. The inventors therefore also 
propose to vary the micromolar concentration of sapphyrin 
used per gram of silica gel in order to control the retention 
times and to influence peak shape characteristics. Straight 
forward modifications such as these will thus allow such 
systems to be used in both analytical and preparative modes. 
In addition to the separation of nucleotides, as described 
above, the inventors have also achieved the separation of 
oligonucleotides using the same first-generation column, 34. 
They have been able to effectively separate a commercially 
obtained (Sigma Chemical Co.) mixture of adenosine 
derived 2-, 3-, 4-, 5-, 6-mers, 7-mers, 8-mers and 9-mers 
(FIGS. 8A-i, 8A-ii and 8B). These results are particularly 
remarkable as, not only was the separation of the 2-, 3-, 4-, 
5- 6-, 7-, 8- and 9-mers readily achieved, but that various 
impurities present in the commercially available mixture 
were also distinguished. Indeed, the presence of contami 
nants in this supposedly pure mixture was later confirmed at 
source (Sigma Chemical Co.). Furthermore, it was found by 
the inventors that separation at these 2- through 9-mers 
could be achieved in less than one hour. 
Thus, it is clear that these new chromatographic supports 
are suitable for use in analyzing and purifying a large 
number of critical products, including small molecule anti 
viral agents and oligonucleotides such as hybridization 
probes and primers. They already represent a marked 
advance over existing technology including PAGE, HPLC, 
HPAC, ion exchange columns and purina and pyrimidine 
base-bonded silica gels, and are expected to find many 
immediate applications in DNA-related biotechnology and 
medicine. 
Such expanded porphyrin polymeric supports are also 
contemplated for use in separating very large RNA or DNA 
molecules such as gene fragments and antisense constructs. 
In order to achieve separation of higher order 
oligonucleotides, the inventors envision that various elution 
related parameters, such as, e.g., flow rate, buffer strength, 
and sapphyrin-to-silica loading level, may be optimized so 
as to achieve the best possible separations. Second and/or 
third generation polymer-supported expanded porphyrins 
may also be prepared for use in connection with RNA or 
DNA separation and purification. 
B. Second and Third Generation Sapphyrin Solid Supports 
The preparation of improved, i.e., second and third 
generation, expanded porphyrin solid supports is also con 
templated. Such new systems will be designed to separate 
phosphorylated compounds based upon other specific bind 
ing modes in addition to the phosphate recognition provided 
by the expanded porphyrin moiety. For example, hydropho 
bic interaction separation is contemplated, and can be pro 
vided by modifying the length of alkyl chains employed. 
Recognition mediated by Watson-Crick hydrogen bonding 
interactions is also contemplated. This may be achieved by 
using expanded porphyrin-nucleobase conjugates, by 
appending nucleobases onto the solid support itself, or by 
using a combination of both methods. Introduction of aro 
matic ring (phenyl, substituted phenyl) or amino or silanol 
groups gives the possibility for TI-7C stacking interactions. 
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The second generation stage of this new synthetic devel 
opment may be considered to be the stage of long chain alkyl 
addition. Long chain alkyl groups will thus be introduced 
onto the surface of the sapphyrin-substituted silica-gel. This 
will result in columns that will combine the properties of 
both reverse phase separation and sapphyrin-based phos 
phate chelation and ion exchange. Further, in light of the 
existing theories of HPLC, the inventors contemplate 
using appropriate synthetic modifications to optimize the 
retention characteristics of the columns so that they separate 
selectively any desired length of oligonucleotide and/or gene 
fragment. 
The yet superior third-generation systems contemplated 
by the inventors are those in which the stationary phases will 
combine the best features of three different known modes of 
separation: hydrogen bonding, electrostatics, and reverse 
phase hydrophobicity. This will be achieved by using vari 
ous different substituents on both the expanded porphyrin 
molecules and on the stationary phase materialitself (e.g., Z. 
and R' groups). 
For example, in certain embodiments, the Z or R groups 
may be varied so as to introduce a nucleobase or nucleobase 
analog. Such nucleobase-bearing systems' are expected 
to act in conjunction with the combined sapphyrin electro 
static and reverse phase hydrophobic interactions described 
above. Thus, by this triple combination, it is expected that 
the resultant solid phase will be able to separate nucleotides 
and oligonucleotides not only on the basis of charge and 
length but also on the basis of nucleic acid type. Such 
phases, of course, would prove to be of tremendous value in 
applications involving the analysis and purification of gene 
fragments since these are often of similar size but of very 
different chemical (i.e., nucleic acid) composition. 
These same third generation phases would also be of 
tremendous benefit in the separation and analysis of AZT 
phosphate, dideoxycytidine phosphate, and other prodrugs 
used in the asymptomatic treatment of HIV and other viral 
infections. Here, in particular, it would be of significant 
value to have access to an analytical method that would 
allow one to distinguish the active phosphorylated nucle 
otide analogs from naturally occurring phosphorylated 
products, such as AMP or GMP, since this would allow for 
facile, on-line clinical analysis. 
C. Sapphyrin Substituted Capillary Electrophoresis 
In still further embodiments, the inventors also contem 
plate using polymer-supported expanded porphyrins in con 
nection with capillary electrophoresis (CE). In CE, unlike 
HPLC, no solid silica or Merrifield resin support is used. 
Rather, differential adherence to the glass surface of a 
capillary is used to effect separation.' Thus, in this 
embodiment, sapphyrin-modified glass capillary surfaces 
will be prepared and used for improved CE resolution. In 
these embodiments, the polymer in any of the structures 31 
to 38 will be an untreated glass capillary rather than silica 
gel. Since glass is chemically similar to silica gel (both are 
silicate-derived), the preparation of a range of modified glass 
surfaces, as represented by structures 31 to 38 can be 
straightforwardly achieved in light of the present disclosure. 
Such sapphyrin-glass constructs may be used to separate 
natural and synthetic nucleotides and oligonucleotides. 
Here, as above, the best combination of Z and R groups 
needed to effect any given type of separation will be 
determined. The information gained using silica gels will be 
applied in these considerations and supplemented by further 
straightforward studies. It is expected that this will lead to a 
significantly improved new CE system. To highlight the 











out a Sanger sequencing of per322 using fluorescently 
labeled dideoxy nucleotides (Applied Biosystems Inc.). 
Since an entire range of fragment sizes is produced here, this 
will allow the superiority of the new sapphyrin-based 
approach to be quickly demonstrated. 
The following examples are included to demonstrate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 
disclosed in the examples which follow represent techniques 
discovered by the inventor to function well in the practice of 
the invention, and thus can be considered to constitute 
preferred modes for its practice. However, those of skill in 
the art should, in light of the present disclosure, appreciate 
that many changes can be made in the specific embodiments 
which are disclosed and still obtain a like or similar result 
without departing from the spirit and scope of the invention. 
For example, other macrocyclic, positively-charged entities 
can be envisioned as binding to phosphate-containing spe 
cies such as nucleotides, oligonucleotides and DNA by 
means of the same or similar oriented electrostatic interac 
tions described herein. 
EXAMPLE 1. 
SYNTHESIS OF POLYHYDROXYSAPPHYRNS 
A. Preparation of 3,12,13.22-tetraethyl-8,17-bis(tris 
(hydroxymethyl)methylaminol-carbonylethyl-2,7,18,23 
tetramethylsapphryin, structure 3. 
Sapphyrin bis acid structure 2a (66 mg, 0.1 mmol) was 
dissolved in dry tetrahydrofuran (20 ml) and 1,1'- 
carbonyldimidazole (33 mg, 0.2 mmol) was added and 
solution was stirred at room temperature for 1 hour. A 
solution of tris(hydroxymethyl)aminomethane (24.2 mg, 0.2 
mmol) in 3 ml of water was added. The reaction mixture was 
stirred for 12 hours then imidazole was filtered off, the 
solvent was evaporated in vacuo and the product crystallized 
from mixture methanol-dichloromethane (1:10), the yield of 
product 3 was 73 mg (81.5%). 
FAB MS mile (rel. intensity) 896 (100, MI), 897 (60, 
MH"). HRMS: Calcd. CHN,Os 895.52072. Found 
895.52099. UV/VIS (HO): A 412,622,673. 




(544 mg, 2.0 mmol) and 2,5-bis (5-carboxyl-3- 
hydroxypropyl-4-methypyrrol-2-ylmethyl)-3,4- 
diethylpyrrole (1.02g, 2.0 mmol) were dissolved in absolute 
ethanol (2L) under heating. The reaction mixture was 
allowed to cool to room temperature and p-toluenesulfonic 
acid monohydrate (1.5 g) was added. The air was vigorously 
bubbled through reaction mixture for 4 days. The ethanol 
was then removed on rotorary evaporator and product was 
isolated by column chromatography on silica gel with 
dichloromethane with 1-5% of methanol. Bis hydrochloride 
salt was prepared by washing of dichloromethane solution of 
sapphyrin with 1N HCl and gave a yield of product of 1.151 
g (78.0%). 
H NMR for 5. 2HCl: (300 MHz, CDC) 8: -4.93 
(2H.S.NH), -4.63 (1H,s.NH), -4.30 (2H.s.NH), 2.07 (6H.t, 
CHCH), 2.76 (4H, pentet, CHCHCH-OH), 4.03 (6H,s, 
CH), 4.06 (4H,t,CHCHCH-OH), 4.20 (6H.S.CH), 4.59 
(4H,q,CHCH), 4.68 (4H, q.CHCH), 4.77 (4H,t, 
CHCHCH-OH), 11.59 (2H.s, meso-H), 11.66 (2H,smeso 
H); "C NMR (80 MHz, CDCI) 8: 13.15, 16.19, 17.84, 
19.14, 21.85, 21.94, 25.04, 36.94, 62.25, 91.17, 97.53, 
127.30, 128.38, 128.77, 131.77, 133.65, 134.46, 138.63, 
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140.54, 142.26, 143.88; Vis (MeOh) (loge), 443 (5.36), 
573 (3.26), 618 (3.81), 669 (3.83). HRMS FAB calcd for 
CHNO2Cl2.H2O: C,67.19; H.7.65; N,933; C1,9.44. 
Found: C,67.25; H.7.61; N,9.41; C1,9.35. 
C. Preparation of 3,12,13.22-Tetraethyl-8,17-bis(di 
(hydroxyethyl)aminocarbonylethyl)-2,7,18,23 
tetramethylsapphyrin, structure 1. 
3,12,13,22-Tetraethyl-8,17-bis (carboxyethyl)-2,7,18,23 
tetramethylsapphyrin 2a (69 mg, 0.1 mmol) was dissolved/ 
suspended in dry dichloromethane (30 ml) and 0.5 ml 
oxalylchloride and 1 drop of DMF was added under argon. 
The reaction mixture was stirred at room temperature for 3 
hours, then evaporated to dryness. Sapphyrin bis acid chlo 
ride was dissolved in dry dichloromethane (20 ml) and 
slowly added under argon to the solution of diethanolamine 
(52.5 mg, 0.5 mmol) in dry dichloromethane (30 ml), (or 
tetrahydrofrane, 30 ml) which also contained 5 mg of 
4-dimethylaminopyridine and 0.2 ml pyridine. Reaction 
mixture was stirred at room temperature for 24 hours and 
then evaporated to dryness, 30 ml of 1M NaOH added, 
stirred for 10 min, precipitated product was filtered off, 
washed with cold water (30 ml), dried, crystallization from 
ethanol-hexane (1:3). Free base sapphyrin is not soluble in 
water; conversion to freely water soluble hydrochloric acid 
salt was made by adding 3 ml of 5% HCl and evaporation. 
Crystallization from ethanol-hexane (1:3) gave 75 mg 
(80.12%) of product 1 as bis chloride salt. 
"H NMR1 (300 MHz, CDC1) 0:-5.13 (2H.S.NH).-4.95 
(1Hs.NH), -4.78 (2H.s.NH), 2.00 (6H,t,CHCH), 3.26 
(8H,m,NCH), 4.18 (6H.S.CH), 4.47 (4H.qCHCH), 5.02 
(4H,t,CHCHCON), 11.58 (2H, smeso-H), 11.61 (2H, s, 
meso-H). 
"H NMR 1 free base (300 MHz, CDC1, with 10% 
CDOD) d: 1.98 (6H, t, CHCH), 2.11 (6H, t, CHCH), 
3.13 (4H, t, CONCHCH), 3.42 (4H, t, CHCHCON). 
3.59 (8H, t, CHCH-OH), 3.91 (6Hs,CH), 4.09 (6H,s, 
CH), 4.39 (4H.qCHCH), 4.57 (4H.s,CHCH), 4.94 (4H, 
t,CH2CH2CON), 11.16 (2H,s, methine, 11.18 (2H,s, 
methine). 
°C NMR (75 MHz, CDC1, with 10% CDOD) 0:12:46, 
15.59, 16.02, 16.51, 17.76, 1846, 20.52, 20.56, 23.23, 
35.50, 36.39, 37.02, 51.63, 59.63, 60.67, 60.74, 75.66, 
90.27, 90.50, 90.91, 97.94, 127.17, 130.88, 135.74, 136.07, 
137.14, 137.53, 142.55, 142.69, 172.98. FAB MS mile (rel. 
intensity) 862 (98, MHH), 863 (78, MH+), 861 (56, 
M+). 
HRMS Calcd for CHNO: 862.520676. Obds 
862.523102 UVIVIS (HO, pH 7.0): 400.5 (5.01), 
623.0 (3.75), 672.0 (3.62). Anal. Calcd for 
CoHNO3.H2O: C,68.23; H.7.83; N, 11.17. Found: 
C,68.11; H.7.85; N.11.04. Calcd for CHNO2HCl: 
C,64.23; H,7.44; N, 10.49; C1,7.58. Found: C,64.12; H.7.61; 
N,10.52; C17.38. 




tetramethylporphyrin (5 mmol) was converted to bis(p- 
nitrophenyl ester). Bis(p-nitrophenyl ester) of porphyrin 
diacid (106mg, 0.1356mmol) was added under argon to dry 
pyridine (150 ml) at 55° C., followed by diethanolamine 
(104 mg, 1 mmol). The reaction mixture was stirred for 4 
days at 55°C. under argon in the dark. The pyridine was then 
removed in vaccuo, 25 ml of 0.1NNaOH was added, stirred 
for 15 min, the product filtered off, washed with cold water 
(5 ml) and dried. The porphyrin is freely soluble in acidic 











5% HCl (10 ml, 5%) was added and evaporated to dryness, 
crystallization from water (pH adjusted to 8, compound 
precipitate from solution). Porphyrin 5.2HCl is freely 
soluble in water. Product for elemental analysis was 
obtained by precipitation from water after adding solution of 
NaHCO, washing (water) and dryed. 
H NMR (300 MHz, CDC1, with 3% TFA): 8–3.99 
(4H,bs,NH), 1.72 (6H, t,CHCH), 4.04 (4H,q,CHCH), 
5.53 (4H.s..CHCON), 10.62 (2H,smethine), 10.81 (2H.s, 
methine). 
CNMR (80 MHz, CDC1,TFA): 811.37, 11.98, 1648, 
1986, 31.58, 51.73, 59.37, 59.89, 98.10, 99.48, 112.26, 
135.84, 138.11, 140.11, 141.04, 141.84, 142.23, 143.71, 
158.65, 159.17, 171.62. FAB HRMS Calcd for CHNO 
714.410484, obsd 714.411287; Calcd for CHNO 
713.402659, obsd 713.400834. UV-Vis (HO, pH 1): Ahd 
max 400.0 Anal. Calcd for CH3NO2H2O: C,63.98; 
H.7.79; N, 11.19. Found: C,64.07; H,7.84; N, 11.22. 
EXAMPLE 2 
SYNTHESIS OF SAPPHYRIN DIGLYCOSEDES 
Sapphyrin mono and diglycosides were prepared by the 
glycosylation of sapphyrin alcohols with O-D- 
acetobromoglucose and ol-D-acetobromogalactose with a 
silver catalyst. The most advantageous catalyst was found to 
be silver triflate, although silver tetrafluoroborate and silver 
carbonate also gave very good results. With polyalcohols it 
is possible to determine the conversion to glycosides by the 
molar ratio alcohol-halogenose/silver catalyst. The inventors 
were able to introduce 1 or 2 sugar units as a function of the 
molar ratio of hydroxy groups/halogenose/silver catalyst. 
A. Preparation of 8,17-di(tetraacetate-o, B-D- 
glucopyranoxypropyl)-3,12,13,22-tetraethyl-2,7,18,23 
tetramethylsapphyrin, structure 4A. 
3,12,13.22-Tetraethyl-2,7,18,23-tetramethyl-8,17-di 
(hydroxypropyl) sapphyrin structure 5 (132 mg, 0.2 mmol) 
was dried with silver trifiate (0.2569 g, 1 mmol) and barium 
carbonate (0.5 g) for 2 hours at 20° C./1.32 mm Hg in 
apparatus equipped with septum. The apparatus was flushed 
with argon (2x) and dry dichloromethane (50 ml) was added 
through the septum. After dissolution, the mixture was 
cooled to -45 C. and solution of O-D- 
glucopyranosylbromide tetraacetate (0.411 g 1 mmol) in 
dichloromethane (20 ml) was gradually added through sep 
tum under stirring. The reaction mixture was stirred at -45° 
C. for 1 hour, then allowed to warm to room temperature 
with exclusion if light and stirred for 8 hours. The reaction 
mixture was diluted with 50 ml of dichloromethane, filtered 
with celite, the filtrate was washed with saturated solution of 
sodium hydrogencarbonate and water, dried over sodium 
sulfate and solvent was evaporated. Pure product was 
obtained by column chromatography on silica gel with 
dichloromethane with 4% of methanol as a eluent. The yield 
of product 4a was 250 mg (94.7%). 
"H NMR spectrum (300 MHz, CDCl) 8-6.21-6.07, 
-5.81, -5.75, 2.03, 2.05, 2.11, 2.13, 2.16, 2.28, 2.31, 3.09, 
4.11, 4.17, 4.24, 4.33, 4.51, 4.53, 4.72, 4.74, 5.29, 11.59, 
11.66. FABMS, mile (rel. intensity): 1321 (90, (ME), 1322 
(56. (MHI), 1320 (45, MI). HRMS Calcd. for 
CoHNOo. 1319.6100. Found 1320.617916 (MHI). 
The same experimental procedure was used for the prepa 
ration of tetraacetylgalactose and tetraacetylmannose sub 
stituted sapphyrins. In these cases, the sugar unit was varied 
using the same protecting group. 
B. Preparation of 8,17-di(tetrabenzoate-o, B-D- 
glucopyranoxypropyl)-3,12,13.22-tetraethyl-2,7,18,23 
tetramethylsapphyrin, structure 4.B. 
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The same procedure as for tetraacetylderivative with 
o-D-glucopyranosylbromide tetrabenzoate (0.660 g. 1 
mmol) gave product 4b in 97.6% yield. 
FABMSm/e (rel. intensity): 1817 (95, MHI), 1818 (67, 
(MEI), 1816 (62, MI). HRMS Calcd. for CHNO 
1815.7346. Found 1816.743117 (MHI). 
C. Preparation of 8,17-di(O.B-D-glucopyranoxypropyl)-3, 
12,13.22-tetraethyl-2,7,18,23-tetramethylsapphyrin, struc 
ture 4c. 
The product was prepared from protected derivatives 
(acetyl, benzoyl) by splitting of protecting group in metha 
nol with a catalytic amount of sodium methoxide, or potas 
sium hydroxide, or potassium cyanide. Pure product was 
obtained by crystallization, or reverse phase chromatogra 
phy (C-modified silicagel) with methanol as a eluent. The 
yield of product 4c was 67%. 
FAB. MS m/e (rel. intensity): 986 (70, MI), 987 (56, 
(MHI). HRMS Calcd. for CHNO985.54108. Found 
985.5417. Elemental analysis: calc. 65.77% C, 7.67% H, 
7.10% N; found 65.65% C, 7.69%H, 7.04%N. UV/VIS 
(H2O): A 416,597.5, 642,712; (MeOH): W. 445. 
EXAMPLE 3 
SYNTHESIS OF SAPPHYRIN BIS 
(GLYCOSAMIDES) 
Sapphyrin bis(glycosamides) were prepared by conden 
sation of an activated form of the above-described sapphyrin 
acid (acid chloride, mixed anhydride, O-acylurea, 
N-acylimidazole derivative) with free, or O-acetylated gly 
coamines (2-amino-2-deoxy-glucopyranose, 
mannopyranose, galactopyranose). 




Sapphyrin bis acid structure 2a (69 mg, 0.1 mmol) was 
converted to bis acid chloride as previously described. Bis 
acid chloride was dissolved in dry dichloromethane under 
argon and slowly added to the solution of 13,4,6-tetra-O- 
acetyl-2-amino-2-desoxy-O-D-glucopyranose (0.1736, 0.5 
mmol) in dichloromethane, which also contained 10 mg of 
4-dimethylaminopyridine and 0.5 ml of dry pyridine atroom 
temperature. The reaction mixture was stirred for 14 hours, . 
then washed with water, the organic layer was evaporated 
and the product obtained by column chromatography on 
silica gel with dichloromethane containing 2-10% methanol 
as an eluent. The yield of product 6a was 114.6 mg (85.0%). 
"H NMR spectrum (300 MHz, CDC1): 8=-4.91, -4.59, 
1.94, 2.06, 2.12, 2.27, 3.41, 3.689, 3.84, 3.91, 3.93, 4.05, 
4.12, 4.22, 4.54, 4.63, 4.72, 5.04, 5.19, 5.22, 11.59, 11.69. 
FAB. MS, m/e (rel. intensity):1347 (96, MI), 1348 (84, 
MHI). HRMS: Calcd. CHNO 1347.61428. Found 
1347. 61624. 
B. Preparation of 3,12,13.22-Tetraethyl-8,17-bis(2-amino 
2-deoxy-o,6-D-glucopyranose)-carbonylethyl)-2,7,18,23 
tetramethylsapphyrin, structure 6b. 
The above-described acetylated sapphyrin derivative 6a 
(13.4 mg, 0.01 mmol) was dissolved in methanol (10 ml) 
and a solution of 3 mg KOH in methanol was added. The 
reaction mixture was stirred for 4 hours and then the pH 
adjusted to 6 by adding hydrochloric acid. After evaporating 
to dryness, the product was crystallized from methanol 
dichloromethane (1:1), or obtained by reverse phase chro 
matography with methanol as eluent. The yield of product 
6b was 10.38 mg (88.0%). 
FABMS, m/e (rel. intensity): 1012 (76, MHI), 1011 (54, 












Deacetylation could also be achieved under basic condi 
tions by using, e.g., NH in methanol, sodium methoxide in 
methanol, DABCO in methanol, or KCN in methanol, each 
with good yields. 
EXAMPLE 4 
SYNTHESIS OF SAPPHYRIN-EDTA 
CONJUGATE (STRUCTURE 8) 
One example of the sapphyrin-metal chelating conjugates 
of the present invention is sapphyrin-EDTA. To a solution of 
diethylenetriamine (22.0 ml, 210 mmol) in 200 ml of dry 
dichloromethane at 0° C., was added triphenylmethyl 
choride (1.8 g. 6.5 mmol) and the solution was warmed to 
room temperature with stirring overnight. The organic layer 
was washed 1MNaOH (200 mlx3), dried with NaSO, and 
the solvent was removed by rotary evaporation. Purification 
on silica gel using methanol/dichloromethane yielded 2.1 g 
(94%) of a viscous oil that gave a positive test using 
ninhydrin. 
"H NMR 8(CDC) 2.27 (2H, t, (CNCHCH), 2.55 
(2H, t, (b.CNHCHCH), 2.70 (4H, m, RNHCHCH-NH), 
7.23-7.65 (15H,m, aromatic-H's), 'CNMRö(CDCl)415, 
43.1, 49.9, 42.1, 70.7. 126.1, 127.7, 128.4, 146.1; MS FAB, 
MHI:m/z 346; HRMS, MH:346.2278 (calcd for 
CHN:346.2283). 
Tert-butyl bromoacetate (1.3 ml, 8.5 mmol), tritylated 
diethylenetriamine (4, 0.89 g, 2.6 mmol), KCO (1.18 g, 
8.5 mmol), and CsCO (1.69 g, 5.2 mmol) in 15 ml of 
acetonitrile were stirred at 0° C. overnight. The inorganic 
salts were removed by vacuum filtration, and the solvent was 
removed by rotary evaporation. Purification on silica gel 
using dichloromethanehexanes yielded 1.2 g (68%) of a 
light yellow oil: 
"H NMRö(CDC) 1.41 (9H, s, (b,cNRCHCOC(CH) 
a), 1.44 (18H, s, N(CH2COC(CH))) 2.21 (2H, t, 
(bCNRCH), 2.62 (2H, t, (CNRCHCH), 2.72 (4H, m, 
NRCHCHNR), 3.11 (2H, s, CHCHNRCHCOat 
buty1), 3.36 (4H, s, N(CH2COat-butyl)2), 7.17–7.51 (15H, 
m, aromatic H's); ' CNMR: 8(CDC) 27.9, 28.1, 41.1, 
52.6, 52.8, 54.5, 55.0, 55.6, 56.1, 70.6, 80.8, 126.1, 127.7, 
128.7, 146.3, 170.6, 170.9 (one quaternary carbon missing); 
MS FAB, MEI688.5; HRMS, MH:688.4323 (calcd for 
CHNO:688.4326). 
The tritylated amine (120 mg, 0.2 mmol) and palladium 
black (150mg) were stirred in 5.0 ml of methanol for 16 
hours under an atmosphere of hydrogen gas. The palladium 
metal was removed by vacuum filtration and the solvent 
removed by rotary evaporation. Purification on silica gel 
using methanol/chloroform yielded 50mg (64%) of a yellow 
oil: 
"H NMR: 8(CDC) 142 (27H, s, COC(CH)), 2.14 
(2H, b, NH), 2.69 (4H, m, H2NCHCH), 2.77 (4H, m, 
RHNCHCHNR), 3.27 (2H, s, CHCHNRCHCOat 
butyl), 3.42 (4H, s, N(CHCO,t-butyl); 'CNMR 8(CDCl) 
28.1, 39.9, 52.3, 52.8, 56.1, 57.1, 80.8, 80.9, 170.6, 171.1; 
MS FAB, MH:m/z 446; HRMS, MHI:446.3242 (calcd 
for C2HNO3:446.3230). 
To the sapphyrin mono-carboxylic acid structure 7a (37 
mg, 50 pmol) in 20 ml of dry dichloromethane was added 
one drop of dimethylformamide followed by the cautious 
dropwise addition of 2.5 ml (5.0 mmol) of a 2.0M solution 
of oxalyl chloride in dichloromethane. The resulting solu 
tion was stirred at room temperature for 4 hours and the 
solvent was removed under vacuum. The resulting solids 
were redissolved in 20 ml of dry dichloromethane and 0.1 ml 
5,672.490 
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of dry pyridine and the amine (68 mg, 150 mol) in 20 ml 
of dry dichloromethane was added dropwise over 1 hour. 
The reaction was allowed to stir overnight and the solvent 
was removed under vacuum. Purification on silica gel using 
methanolfdichloromethaneyielded 32 mg of structure 8 as a 
blue solid (57%). The macrocycle can be further purified by 
recrystallization from dichloromethane/pentane: 
"H NMR: 8(CDC) -5.03 (2H, m, NH), -4.57 (1H, s, 
NH), -4.38 (2H, s, NH), 1.32 (18H, s, COC(CH)), 1.38 
(9H, s, COC(CH)), 3.29 (2H, s, RNCHCO), 3.42 (4H, 
s, N(CHCO)), 3.49 (4H, m, NCHCHN), 4.12 (6H, s, 
CH), 423 (6H, s, CH), 428 (3H, s, CH), 4.53 (4H, q, 
CHCH), 4.70 (4H, q, CHCH), 5.09 (2H, t, 
CHCHCONH), 7.58 (1H, b, CONH), 11.62 (s, 1H, meso 
H), 11.70 (s, 2H, meso-H), 11.80 (s, 1H, meso-H); MSFAB, 
M: 1057; HRMS, M: 1056.6790 (calcd for CHNO: 
1056.6776). 
EXAMPLE 5 
SYNTHESIS OF SAPPHYRIN DERVATIVES 
7a;7b, FOR USE AS PRECURSORS 
The synthesis of the precursor 3,8,1722-Tetraethyl-12 
(carboxyethyl)-2,7,13,18,23-pentamethyl-sapphyrin, struc 
ture 7a, is a two part procedure requiring the preparation of 
the ester 3,8,1722-tetraethyl-12-(methoxycarbonylethyl)-2, 
7,13,18,23-pentamethylsapphyrin, structure 7b and subse 
quent hydrolysis to the sapphyrin acid of general structure 
7a. Ester 7b was prepared in accord with the general 
optimized procedure for the production of substituted 
sapphyrins', incorporated herein by reference. 4,4'-diethyl 
5.5'-diformyl-3,3'-dimethyl-2,2'-bipyrrole (272 mg, 1.0 
mmol) and 2,5-bis(5-carboxyl-3-ethyl-4-methyl-pyrrol-2- 
ylmethyl)-3-methoxycarbonylethyl-4-methylpyrrole (523 
mg, 1.0 mmol) were condensed to give this desired sapphy 
rin product in 75.4% yield (0.490 g). 
"HNMR (300 MHz, CDC1): 8=-478 (1H, s, NH),-476 
(1H, s, NH), -4.32 (1H, s, NH), -4.13 (2H, s, NH), 
2.35-2.43 (12H, m, CHCH), 3.85 (2H, t, 
CHCHCOCH), 3.99 (3H, s, CH), 4.29 (6H, s, CH), 
4.38 (3H, s, CH), 4.44 (3H, s, CH), 4.67-474 (8H, m, 
CHCH), 5.22 (2H, t, CHCHCOCH), 11.82 (1H, s, 
meso-H), 11.85 (1H, s, meso-H), 11.88 (2H, s, meso-H). "C 
NMR (75 MHz, CDC1): 8-12.7, 13.1, 15.9, 17.8, 17.9, 
21.0, 23.0, 37.1, 52.1, 91.5, 92.0, 98.3, 98.4, 126.9, 127.0, 
129.5, 129.6, 130.2, 132.7, 132.8, 134.7, 135.3, 135.5, 
136.6, 136.7, 137.7, 139.1, 1415, 141.7, 1733. HRMS: 
Calcd. for CHNO: 643.3886. Found 643.3887. 
The second part of the procedure involves the synthesis of 
sapphyrin acid 7a which was prepared as follows: a ca. 1:1 
v.v. mixture of trifluoroacetic acid and conc. hydrochloric 
acid (10 ml for 100 mg of starting sapphyrin 7b) was used 
to hydrolyze the ester. The reaction was run at 50° C. for 2 
days after which time the desired sapphyrin acid product 
was obtained as its bis HCl adduct. After drying in vacuo, 
this protonated product was purified by column chromatog 
raphy on silica gel (methanol 5% in dichloromethane, 
eluent). The yield was ca. 95%. 
"H NMR (300 MHz, CDC1): 8e-5.84 (2H, bs, NH), 
-5.35 (3H, bs, NH), 2.20 (12H, t, CHCH), 3.23 (2H, t, 
CHCHCO2H), 4.03 (3H, s, CH), 4.15 (6H, s, CH4), 4.23 
(3H, s, CH), 441 (3H, s, CH), 4.65 (4H, q, CHCH), 4.74 
(4H, q, CHCH), 4.79 (2H, m, CHCHCO2H), 11.42 (2H, 
s, meso-H), 11.55 (1H, s, meso-H), 11.58 (1H, s, meso-H). 
CNMR (75 MHz, CDC1): 812.7, 12.9, 14.3, 15.9, 17.7, 







1209, 125.4, 125.4, 127.3, 129.1, 1292, 130.0, 132.7, 
132.8, 134.8, 1349, 135.2, 135.4, 135.6, 135.7, 136.1, 
136.8, 136.9, 137.0, 137.7, 139.31, 1414, 1418, 141.8, 
1744. FAB MS, mile (rel intensity): 631 (48, MHV), 630 
(100, MH)), 629 (52, M); HRMS: Calcd. for 
CHNO: 629,3730. Found 630.3798 (EMH"); for 
CHNO (MHI": Calcd. 630,3808. 
EXAMPLE 6 
SYNTHESIS OF SAPPHYRN 
MONONUCLEOBASE DERIVATIVES 




Method A: The sapphyrin acid 7a, as prepared above (63 
mg, 0.1 mmol), was dissolved in 10 ml of dry dichlo 
romethane under argon. Oxalyl chloride (0.2 ml) was added 
followed by 0.03 ml of DMF. The reaction mixture was 
stirred at room temperature for 3 hours under argon and then 
evaporated to dryness in vacuo. The sapphyrin acid chloride 
so obtained was then redissolved in dry dichloromethane (20 
m) and added slowly under argon and at room temperature 
to a solution of 59.4 mg (0.15 mmol) of 1-(2-aminoethyl)- 
4- (triphenylmethyl)-aminol-pyrimidin-2-one" containing 
5mg of 4-dimethylaminopyridine and 0.4 ml of dry pyridine 
in 20 ml of dry dichloromethane. After the addition was 
complete (ca. 1 hour), the reaction mixture was stirred 
overnight. The reaction mixture was then washed in succes 
sion with first dilute hydrochloric acid (3%, 20 ml), then 
water (20 ml) followed by saturated sodium bicarbonate (20 






phase was then dried over sodium sulfate and the solvent 
removed in vacuo. The desired product 9 was isolated by 
column chromatography on silica gel using methanol, 2-5% 
in dichloromethane, as the eluent. The yield obtained this 
way was 91.0 mg (ca. 90%). 
Method B. The sapphyrin acid 7a, described above (31.5 
mg, 0.05 mmol), was dissolved in dry dichloromethane (20 
ml). The resulting solution was then cooled to 0° C. and 
dicyclohexylcarbodiimide (41.27 mg, 0.2 mmol) and 
1-hydroxybenzotriazole (5 mg) were added. The resulting 
solution was then stirred in an ice bath for 30 min. and the 
amino-functionalized cytosine, 1-(2-aminoethyl)-4- 
(triphenylmethyl)aminolpyrimidin-2-one (29.7 mg, 0.075 
mmol) was then added followed by 0.1 ml of dry pyridine. 
The reaction mixture was then stirred, first for 0.5 hours at 
0° C. and then for 48 hours at room temperature. Acetic acid 
(0.2 ml) was then added and the solution stirred a further 1 
hour at room temperature. Dicyclohexylurea was then fil 
tered off and the reaction worked up as per method A. The 
yield of 9 obtained using this method was 42 mg (83.3%). 
"H NMR (300 MHz, CDC1): 8=-5.43 (2H, bs, NH), 
–4.67 (2H, bs, NH), 2.21 (12H, t, CHCH), 2.73 (2H, t, 
CONHCHCH), 3.11 (2H, t, CHCHCONH), 4.07 (9H, s, 
CH), 4.18 (3H, s, CH), 4.30 (3H, s, CH), 4.50 (4H, m, 
CHCH), 4.60 (4H, m, CHCH), 4.67 (2H, m, 
CONHCHCH), 4.90 (2H, m, CHCHCONH), 6.20 (1H, 
d, CH), 6.80, (1H, bs, NH), 7.06 7.26 (15H, m, Tr), 7.54 
(1H, s, CONH), 7.73 (1H, d, CH), 11.55 (2H, s, meso-H), 
11.56 (2H, s, meso-H). FAB MS, m/e (rel. intensity): 1008 
(25, MHT), 1007 (58, M), 1006 (22, M-H), 765 (22, 
M-Tr"). HRMS: Calcd. for CHNO (M): 1007.5574. 





SYNTHESIS OF SAPPHYRIN 
MONONUCLEOBASE STRUCTURES 
3, 8, 17,22-Tetraethyl-12-2-1-(4-amino-2- . 
oxopyrimidinyl)ethyl-aminocarbonylethyl)-2,7,13,18,23 
pentamethylsapphyrin, structure 10. 
Compound 9 (50.4 mg., 0.05 mmol) was dissolved in 
trifluoroacetic acid (5 ml) and the solution was heated at 
reflux for 1 hour. After allowing the solution to cool, the 
solvent was removed in vacuo. The residue was then redis 
solved in dichloromethane, filtered, and taken to dryness on 
a rotary evaporator. The crude product so obtained was 
purified by recrystallization from a dichloromethane-hexane 
(1:3, v.v.) mixture, or by column chromatography on silica 
gel using dichloromethane-methanol 9:1 v.v. as the eluent. 
Such purifications afforded compound 10 as its bis trifluo 
roacetic salt in ca. 75% yield (28.5 mg). Prior to use in 
transport studies, this trifluoroacetate salt was dissolved in 
dichloromethane and washed with either a 1M solution of 
NaOH in HO or with a saturated aqueous solution of 
sodium bicarbonate. 1H NMR (300 MHz, CDC1): 8-6.66 
(1H, s, NH), -6.57 (1H, s, NH), -6.50 (1H, s, NH), -6.45 
(1H, s, NH), -5.79 (1H, s, NH), 2.17 (12H, m, CHCH), 
2.37 (2H, t, CONHCHCH), 3.08 (2H, t, CHCHCONH), 
3.35 (2H, t, CONHCHCH), 4.11 (6H, s, CH), 4.20 (3H, 
s, CH4), 4.23 (3H, s, CH), 4.25 (3H, s, CH), 4.54 (4H, q, 
CHCH), 4.68 (4H, q, CHCH), 5.12 (2H, t, 
CHCHCONH), 5.50 (1H, d, J-72, CH), 6.26 (2H, s, 
NH), 6.84 (1H, d, J-72, CH), 7.47 (1H, s, CONH), 11.52 
(1H, s, meso-H), 11.65 (1H, s, meso-H), 11.69 (1H, s meso 
H), 11.70 (1H, s, meso-H). 'CNMR (125 MHz, CDCl): 
8-12.52, 12.67, 12.86, 15.47, 15.83, 17.33, 17.51, 17.55, 
17.57, 20.57, 20.68, 20.75, 22.55, 36.99, 37.74, 48.46, 
91.50, 91.81, 91.87, 98.08, 98.22, 121.47, 126.37, 127.08. 
127.82, 129.08, 129.92, 130.15, 130.20, 132.95, 132.98, 
135.02, 135.25, 135.35, 135.61, 137.41, 138.51, 138.59, 
140.49, 142.03, 142.10, 142.48, 147.08, 158.57, 173.65. 
FAB MS, mile (rel. intensity): 768 (65, MHI), 767 (78, 
MH)), 766 (100, M), 766 (45, M-H). HRMS: Calcd. 
for CHNO (M):765.4478. Found 766.4535 (MHI); 
for CHNO (MHI): calcd, 766.4556. 
B. Preparation of 3,8,17.22-tetraethyl-12-2-7-(2- 
benzamide-6-oxopurinyl)ethyl)-aminocarbonylethyl)-2,7, 
13,1823-pentamethylsapphyrin, structure 11. 
Sapphyrin monoacid 7a (63 mg, 0.1 mmol) was dissolved 
in dry tetrahydrofurane (30 ml) and cooled to 0°C., dicy 
clohexylcarbodiimide (103.2 mg 0.5) was added with 10 
mg of hydroxybenzotriazole and solution was kept at 0°C. 
for 30 minutes. 7-(2-Aminoethyl)-2-benzamidopurin-6-one 
was added with stirring. Reaction mixture was kept at 0°C. 
for 1 hour, then allowed to room temperature, and stirred for 
48 hours. Acetic acid (0.1 ml) was added and stirred 1 hour, 
dicyclohexylurea was filtered off, solvent evaporated in 
vacuo. Redissolved in dichloromethane with 5% methanol, 
washed with diluted hydrochloric acid (10 ml, 3%), satu 
rated solution of sodium hydrogencarbonate (10 ml) and 
with water (10 ml). Organic phase was dried over sodium 
sulfate and evaporated to dryness. Product 11 was purified 
by column chromatography on silica gel with 2-5% metha 
nol. The yield was 81 mg (89.0%). 
FABMS, m/e (rel. intensity): 911 (96, MH'), 910 (86, 
MI). HRMS: Calcd. for CHNO 910.48739. Found 
910.48806. 
C. Preparation of 3,817,22-tetraethyl-12-2-7-(2-amino-6- 
oxopurinyl)ethylamino-carbonylethyl-2,7,13,18,23 











This was prepared by splitting of benzoyl protecting 
group from derivative 11 described above using NH in 
methanol at room temperature for 24 hours in 85% yield. 
FAB. MS, m/e (rel. intensity: 806(96, MI), 807 (68, 




2,7,18,23-tetramethylsapphyrin, structure 13. 
3,12,13.22-Tetraethyl-8-(carboxymethyl)-17 
(methoxycarbonylethyl)-2,7,18,23-tetramethyisapphyrin 2c 
(23.5 mg, 0.033 mmol) was dissolved in dry dichlo 
romethane (20ml), solution was cooled by ice, dicyclohexy 
lcarbodiimide (51.2 mg, 0.2 mmol) was added together with 
5 mg of hydroxybenzotriazol, reaction mixture was kept at 
0° C. for 30 minutes and then 7-(2-aminoethyl)-2- 
benzamidopurin-6-one (30 mg, 0.1 mmol) was added. The 
solution was kept cooled for 1 hour, then allowed to warm 
to room temperature and stirred for 30 hours. Acetic acid 
(0.1 ml) was added and stirred for 1 hour, dicyclohexylurea 
was filtered off, organic phase washed with water (10 ml), 
product was purified by crystallization from 
dichloromethane-hexane (1:1), final purification was made 
by column chromatography on silica gel with dichlo 
romethane with 10% methanol and 0.3% of trifluoroacetic 
acid as a eluent. The yield of product 1328 mg (79.5%). 
"H NMR spectrum (300 MHz, CDC1): 8–5.50 (1H, s, 
NH), -5.31 (1H, s, NH), -5.04 (1H, s, NH), -4.97 (1H, s, 
NH), -4.95 (1H, s, NH), 2.05 (6H, t, CHCH), 2.20 (6H, t, 
CHCH), 2.91 (2H, t, CHCH-NH), 3.46 (2H, t, 
CHCHN), 3.51 (3H, s, COCH), 3.63 (2H, t, 
CHCH-CO), 4.08 (6H, s, CH,), 4.23 (6H, s, CH), 4.50 
(2H, t, CHCH-NH), 4.52 (4H, q, CHCH), 4.67 (4H, q, 
CHCH)4.96 (2H, t, CHCHCONH), 7.40 (2H, m, BzH), 
7.58 (1H, m, BzH), 7.65 (2H,m, BzH), 7.98 (1H, brs, CH), 
8.01 (1H, s, CONH), 11.62 (2H, s, meso-H), 11.63 (2H, s, 
meso-H). 
'C NMR (125 MHz, CDC1, with 20% CDOD): 
8=12.68, 12.82, 16.52, 16.61, 17.76, 17.86, 18.47, 18.57, 
20.56, 20.61, 20.65, 20.76, 22.76, 23.50, 29.58, 36.97, 
51.98, 91.71, 96.25, 126.88, 127.41,127.46, 128.27, 129.44, 
129.59, 129.85, 129.96, 132.23, 133.96, 134.45, 138.12, 
139.23, 143.45, 144.79, 145.10, 173.23, 173.35, 173.45. 
FAB. MS mile rel. intensity): 982 (95, M-HI), 983 (87, 
MI). HRMS: Calcd. for CHNO 982.51087. Found 
982.50919. 
E. Preparation 3, 12, 13,22-Tetraethyl-8- 
(methoxycarbonylethyl)-17-2-17-(2-amino-6-oxopurinyl) 
ethyl-amino carbonyl ethyl-2, 7, 18,23 
tetramethylsapphyrin, structure 14. 
This compound was prepared in 88% yield from the 
benzoyl derivative 13 previously described using a saturated 
solution of NH in methanol at room temperature for 30 
hours. 
FAB. MS, mile (re. intensity): 879 (98, MI), 880 (68, 
(MHI). HRMS: Calcd. for CHNO 879.49291. Found 
879.080. 
F. Preparation of 3,12,13.22-Tetraethyl-8-(carboxymethyl)- 
17-2-7-(2-amino - 6-oxop urinyl)ethyl 
aminocarbonylethyl-2,7,18,23-tetramethylsapphyrin, 
structure 15. 
This compound was prepared in 75% yield from the 
benzoyl derivative 13 by hydrolysis with KOH solution in 
methanol at room temperature for 48 hours. This is a very 
convenient building block for construction of sapphyrin 
conjugates with different nucleobases. 
FAB. MS, mile (re. intensity): 866 (68, MI), 867 (56, 
ME, 865 (54, M-H). HRMS: Calcd. for CHNO 




SYNTHESIS OF SAPPHYRIN DINUCLEOBASE 
STRUCTURES 
A. Preparation of 3,12,13.22-Tetraethyl-8-2-1-(2-oxo 
4-triphenylmethyl)aminolpyrimidylethyl 
aminocarbonylethyl-17-2-7(2-amino-6-oxopurinyl) 
ethyl-amino carbonyl ethyl-2, 7, 18, 23 
tetramethylsapphyrin, structure 16. 
This compound was prepared in 69% yield from sapphy 
rin 15 as described above by condensation (carbodimide 
method) with 1-(2-aminoethyl-4(triphenylmethyl)aminol 
pyrimidin-2-one. 
FAB MS. m/e (rel. intensity): 1244 (78, MI), 1245 (65, 
(MHI). HRMS: Calcd. for CHNO 1243.659547. 
Found 1243.65940. 
B. Preparation of 3,12,13.22-Tetraethyl-8,17-bis(2-7-(2- 
benzamido-6-oxopurinyl)ethyl)-aminocarbonylethyl-2.7, 
18,23-tetramethylsapphyrin, structure 17. 
Sapphyrin bis acid 2a (34.5 mg, 0.05 mmol) was con 
verted to its corresponding bis acid chloride as previously 
described herein. A solution of this acid chloride in dry 
dichloromethane (20 ml) was then slowly added to a solu 
tion of 7-(2-aminoethyl)-2-benzamidopurin-6-one (60 mg. 
0.2 mmol), which contained 0.3 ml of dry pyridine and 10 
mg of 4-dimethylaminopyridine. The reaction mixture was 
stirred at room temperature for 36 hours. Dichloromethane 
methanol (5:1) 20 ml was added and the resulting solution 
then washed first with diluted hydrochloric acid (10 ml, 3%), 
then with saturated solution of sodium hydrogencarbonate 
(10 ml) and then finally with water (10 ml). The organic 
phase was dried over sodium sulfate and evaporated to 
dryness. The product 17 was crystallized from methanol 
dichloromethane (1:15). The yield was 55 mg (88.0%). 
'C NMR spectrum (125 MHz, CDC1, with 25% 
CDOD): 8=13.90, 15.63, 17.63, 1841, 20.72, 20.83, 22.20, 
22.81, 23.26, 33.99, 46.32, 46.36, 63.07, 92.00, 98.80, 
110.10, 111.59, 123.02, 127.16, 127.73, 27.89, 128.34, 
128.65, 128.95, 129.97, 131.09, 133.21, 133.41, 138.57, 
138.91, 142.66, 144.00, 148.28, 151.44, 168.59, 168.89, 
172.91, 173.30. FAB MS, mile (rel. intensity): 1249 (88, 
MI), 1250 (56, MH), 1251 (45, M+2H). HRMS: 
Calcd. for CoH7NO. 1251.62667. Found 1251.62427. 
MH". 
C. Preparation of 3,12,13.22-tetraethyl-8, 17-bis(2-7-(2- 
amino-6-oxopurinyl)ethyl)-amino-carbonylethyl-2,7,18, 
23-tetramethylsapphyrin, structure 18. 
This compound was prepared in 78% yield from the 
above-described bis benzoyl derivative 17 by stirring with 
NH in methanol at room temperature for 30 hours. 
FAMMS, m/e (rel. intensity): 1041 (95, MI), 1040 (78, 
M-H"), 1042 (56, MH). HRMS: Calcd. for 
C5H7NO. 1041.55787. Found 1041.55619. 
D. 3,12,13.22-tetraethyl-8, 17-bis(2-1-2-oxo-4 




7,18,23-tetramethyl-sapphyrin 2b and 3,12,13.22-tetraethyl 
8,17-bis(carboxyethyl)-2,7,18,23-tetramethylsapphyrin 2a 
were prepared as described by Sessler et al. (1990; reference 
4a), incorporated herein by reference. This latter diacid 2a 
(34.5 mg, 0.05 mmol) was then suspended in dry dichlo 
romethane (20 ml), and, under argon, treated with oxalyl 
chloride (0.3 ml) and DMF (0.03 ml). The reaction mixture 
was stirred at room temperature for 3 hours and then taken 











ride was redissolved in dry dichloromethane (15 ml) and 
added slowly to a solution of 1-(2-aminoethyl-4- 
(triphenylmethyl)amino-pyrimidin-2-one (51.48 mg, 0.13 
mmol) in dry dichloromethane (20 ml) containing 
4-dimethylaminopyridine (5 mg) and dry pyridine (0.3 ml). 
The reaction mixture was stirred under argon at room 
temperature for 12 additional hours, then washed with first 
dilute hydrochloric acid (3%,30ml), then water followed by 
saturated aqueous sodium bicarbonate, and then, finally, 
with water once again. After drying over anhydrous sodium 
sulfate, the product was isolated by column chromatography 
on silica gel using dichloromethane-methanol (1->10%, 
gradient) as the eluent. The yield of compound 19 obtained 
in this manner was 65.0 mg (89.9%). 
1H NMR (300 MHz, CDC1): 3-5.25 (2H, s, NH), -5.05 
(2H, s, NH), 2.13 (12H, t, CHCH), 2.93 (4H, m, 
CONHCHCH), 3.23 (4H, m, CHCHCONH), 3.83 (4H, 
t, CONHCHCH), 4.00 (6H, s, CH), 4.15 (3H, s, CH), 
4.25 (3H, s, CH), 4.57 (4H, q, CHCH), 4.75 (4H, q 
CHCH), 4.99 (4H, m, CHCHCONH),550 (2H, d, CH), 
6.73 (2H, s, NH), 7.01-729(30H,m, Tr), 7.28 (2H, d, CH), 
7.67 (2H, s, CONH), 11.43 (4H, bs, meso-H). FABMS mile 
(rel intensity): 1446 (58, M), 1447 (38, MH"). HRMS 
Calcd for CHNO: 1445.7645. Found 1445.7658. 
E. 3,12,13.22-Tetraethyl-8,17-bis(2-1-(4-amino-2- 
oxopyrimidinyl)-ethyl-aminocarbonylethyl-2,7,13,18,23 
pentamethylsapphyrin, structure 20. 
The bis(trityl) sapphyrin-cytosine derivative 19 (72.3 mg, 
0.05 mmol) was dissolved in trifluoroacetic acid (5 ml) and 
heated to reflux for 0.5 hour. After cooling, the trifluoro 
acetic acid was removed by evaporation and the product 
purified (as its trifluoracetate salt) by column chromatogra 
phy on silica gel using methanol (15% by volume) in 
dichloromethane as the eluent. Alternatively, this salt could 
be purified by recrystallization from dichloromethane 
hexane-methanol (1:1:0.1 v.v.v.) to give 38.0 mg (79.0%) of 
deprotected product 20, (CFCOH). Prior to use in trans 
port studies, this trifluoroacetate salt was dissolved in 
dichloromethane and washed with either a 1M solution of 
NaOH in HO or with a saturated aqueous solution of 
sodium bicarbonate. 
"HNMR (300MHz, CDC1): 8=-5.91 (1H, s, NM), -5.70 
(2H, s, NH), -5.47 (2H, s, NH), 2.08 (6H, m, CHCH), 2.13 
(6H, m, CHCH), 2.71 (4H, t, CONHCHCH), 3.08 (4H, 
t, CHCHCONH), 3.50 (4H, t, CONHCHCH), 4.07 (3H, 
s, CH), 4.13 (3H, s, CH), 4.20 (3H, s, CH), 4.23(3H, s, 
CH), 4.51 (4H, q, CHCH), 4.68 (4H, q, CHCH), 5.29 
(4H, m, CHCHCONH), 5.69 (2H, d, J=7.20, CH), 635 
(4H, bs, NH), 6.89 (2H, d, J=720, CH), 7.50 (2H, S, 
CONH), 11.52 (1H, s, meso-H), 11.57 (1H, s, meso-H), 
11.61 (1H, s, meso-H), 11.63 (1H, s, meso-M). 'CNMR 
(125 2 MHz, CDC with 10% CDOD): S=12.88, 12.90, 
12.98, 16.03, 17.55, 17.63, 17.70, 18.23, 18.29, 18.37, 
1843, 20.23, 20.55, 20.75, 20.89, 20.91, 20.96, 22.58, 
29.59, 35.58, 37.69, 37.84, 37.91, 48.80, 48.98, 49.15, 
49.32, 49.48, 49.66, 49.83, 97.79, 97.91, 97.94, 97.97, 
122.99, 128.27, 129.62, 129.74, 129.84, 129.86, 129.91, 
129.95, 130.06, 130.10, 130.15, 130.24, 130.32, 135.38, 
135.43, 138.93, 139.53, 143.23, 144.23, 144.59, 172.66. 
FABMSm?e (rel intensity): 962 (45, M),962 (38, MH). 





PREPARATION OF OLGOMERIC 
SAPPHYRNS 
A. Preparation of sapphyrin dimers 
Sapphyrin monoacid. 7a (126 mg, 0.2 mmol) was con 
verted to acid chloride as previously described hereinabove. 
A solution of acid chloride in dry dichloromethane (20 ml) 
was slowly added to the solution of 0.1 mmol aromatic 
bis(amino) compound in dry dichloromethane (20 ml), 
which contained 5 mg 4-dimethylaminopyridine and 0.3 ml 
of dry pyridine. The reaction mixture was stirred 48 hours at 
room temperature, then washed with water, organic phase 
was dried with magnesium sulfate and evaporated. The 
product was isolated by column chromatography on silica 
gel in dichloromethane with 2-10% of methanol as a eluent. 
Reaction with 1,8-diaminonapthalene (0.1 mmol, 15.8 mg) 
gave 80 mg (57.89%) of product 21. 
FABMS me (rel. intensity) 1382 (67, MHI), 1381 (56, 
MI). HRMS Calcd. for CoHooN2O: 1380.80916. 
Found 1380.8093. 
Reaction with m-phenylenediamine (0.1 mmol, 10.8 mg) 
gave 69 mg (51.80%) of product 22. 
FAB. MSm/e (rel. intensity) 1333 (78, MH), 1332 (65, 
(MI). HRMS Calcd. for CHNO: 1330.79352. Found 
1330.79349. 
Reaction with aliphatic diamino compounds was carried 
with DCC as a coupling reagent, Sapphyrin acid. 7a (126 mg, 
0.2 mmol) was dissolved in dry dichloromethane under 
argon and cooled by ice. Dicyclohexylcarbodiimide (0.5 g) 
was added with 5 mg of hydroxybenzotriazole. The reaction 
mixture was stirred at 0° C. for 30 minutes and then 
1,3-diaminopropane (7.4 mg, 0.1 mmol) was added. The 
reaction mixture was stirred 30 minutes at 0° C. and 48 
hours at room temperature. Acetic acid (0.2 ml) was added, 
stirred 1 hour, dicyclohexylurea was filtered off, and the 
product was isolated by column chromatography on silica 
gel with dichloromethane contains 5-10% of methanol. The 
yield of compound 23 was 96 mg (73.97%). 
Preparation of sapphyrin trimers 
The inventors used the same coupling procedures as 
described above for the sapphyrin dinners. Thus sapphyrin 
monoacid 7a (189 mg, 0.3 mmol) was coupled (DCC 
method, 0.75 g) with tris(2-aminoethyl)amine (14.6 mg, 0.1 
mmol) giving 160 mg (80.73%) of compound 24. 
FAB MSm/e (rel. intensity) 1983 (36, MEI), 1982 (32, 
(MI). HRMS Calcd. for CHNO: 1980.240296. 
Found 1980.2402.89. 
EXAMPLE 10 
PREPARATION OF SAPPHYRTN POLYMERS 
(CLASSI) 
This class of sapphyrin polymers may be termed Class I 
of the broad group of sapphyrin polymers, or may be 
referred to as group IV of these wide-ranging sapphyrin 
inventions. For the preparation of this class of polymers, 
sapphyrins with ethylene units could be used, as prepared by 
the elimination of acetoxy derivative, as well as sapphyrin 
bis acid, sapphyrin diamino and dihydroxyderivatives. Sap 
phyrins bearing covalently attached nucleobases could also 
be used for the polymerization reactions. 
Radical polymerization may be catalyzed by 
dibenzoylperoxide, or bisazaisobutyronitril in inert solvent 





tetramethylsapphyrin 2a (1 mmol) and 1,1'- 
carbonyldiimidazole (1.1 mmol) were mixed in diphe 
nylether for 1 hour, then 3,12,1322-tetraethyl-8,17 
diaminoethyl-2.7.1823-tetramethylsapphyrin 25 (1 mmol) 
was added and reaction heated at 190°-250° C. for 2 hours. 
After cooling dichloromethane was added, polymeric sap 
phyrin structure 26A (where X=NH) was filtered off, washed 
with water (50 ml) and methanol (50 ml). 
Polymeric sapphyrin was obtained also with using 










reaction could be also carried out without solvent. 
The same procedure was used for the sapphyrin dialcohol 
as a starting compound for the reaction with sapphyrin. 
diacid structure 26B (where X=O). 
To synthesize structure 27, it is contemplated that one 
would employ standard phosphoramidate chemistry, as will 
be known to those of skill in the art in light of the present 
disclosure. 
EXAMPLE 11 
SYNTHESIS OF POLYMER SUPPORTED 
SAPPHYRINS (CLASS II) 
This class of sapphyrin polymers may be termed Class II 
of the broad sapphyrin polymer group, and is also referred 
to as group V of the overall sapphyrin invention. 
The new chromatographic bonded phases that are the 
subject of these aspects of the present invention were 
prepared in two steps. In the first, a phosphate thioether 
recognition unit was connected (via amide, ether, thioether, 
or NH bonds) with silica gel. This was followed, as a second 
step, by protection of residual silanol groups on the silica gel 
surface using variety of silylating reagents (from C to C). 
The density of coverage for the covalently bonded recogni 
tion groups on the silica gel was controlled by the amount of 
expanded porphyrin, or guanidinium derivatives (in mmol) 
that was attached to 1 g of the starting silica gel. Elemental 
analysis data, namely comparison of the %C and %N in the 
starting material and the product, provided a measure of the 
ratio of phosphate receptor (in M) to 1 g of silica gel. Solid 
state 'PNMR spectra also provided a unique tool for the 
detailed study of the mechanism of phosphate binding. 
A. 3,8,17,22-Tetraethyl-12-(propylamidoethyl)-2,7,13,18, 
23-pentamethylsapphyrin-silica gel, structure 34 where 
Z=CH 
3,8,17,22-Tetraethyl-12-carboxyethyl)-2,7,13,18,23 
pentamethylsapphyrin (0.63 g, 1 mmol) was dissolved under 
nitrogen in 100 ml of dry dichloromethane and 1 ml of 
oxalylchloride was added, followed by 0.05 ml of dry 
N,N-dimethylformamide. The reaction mixture was then 
stirred at room temperature for 2 hours, and subsequently 
evaporated to dryness. Sapphyrin acid chloride was redis 
solved in dry dichloromethane (50 ml) and slowly (2 hours, 
dropping funnel) added to suspension of 5 g of 
3-aminopropyl functionalized silica-gel (from Aldrich, 9% 
functionalized, dried for 24 hours at high vacuum) in 100 ml 
of dichloromethane, which contained 1 ml of dry pyridine 
and 10 mg of 4-dimethylaminopyridine. After addition was 
complete, the reaction mixture was stirred for two days. The 
product was then filtered off, washed with dichloromethane 
(300 ml), dichloromethane-methanol (5:1; 200 ml), metha 
nol (200 ml), water (300 ml), methanol (300 ml), dichlo 
romethane (300 ml) and hexane (300 ml). The produce was 
then dried at high vacuum giving 5.35 g of the sapphyrin 
bonded silica gel. 
Elemental analysis: starting 3-aminopropyl 
functionalized silica gel: 4.85% C, 1.48% H, 1.62% N. 
5,672.490 
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Product: 6.28% C, 1.73% H, 1.99% N. IR: Solid state 'C 
NMR: Shift 3.5 ppm (up field) was observed for AMP 
(standard AMP on aminopropylsilica gel). 
As a coupling reagent, 1,1'-carbonyldiimidazol, active ester 
(generated by reaction 1,1'-carbonyldiimidazol and 
1-hydroxybenzotriazole), carbodiimide derivatives e.g. 
1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide were also 
used. 
B. 3,8,17,22-Tetraethyl-12-(amidioethyl)-2,7,13,18,23 
pentamethyl-silica gel, structure 34 where Z=CH 
Sapphyrin acid (63 mg, 0.1 mmol) was dissolved in dry 
tetrahydrofuran (100 ml) and cooled to 0°C. Then 0.2 g of 
1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide was 
added along with 10 mg of 1-hydroxybenzotriazol. The 
reaction mixture was then stirred at 0° C. for 45 minutes. 
After this 3 g of dried 3-aminopropyl-functionalized silica 
gel was added and the resulting mixture kept at 0°C. for 1 
hour and 24 hours at room temperature. After that, another 
0.1 g of carbodiimide was added and the whole stirred for 
another 2 days. The product was then filtered off and washed 
as described above. The yield of sapphyrin-bonded silica gel 
is 3.05 g. 
C. 3,8,17.22-Tetraethyl-12-(amidoethyl)-2,7,13,18,23 
pentamethyl-silica gel, structure 34 where Z=CH 
This represents another synthetic method for preparing 
the silica gel version of structure 34 where Z=CH. This 
would be conducted as described in previous, except that 
0.25 g of 1,1'-carbonylidiimidazol would be used as the 
coupling agent at room temperature. 
D. Preparation of partially sapphyrin-functionalized 
3-aminopropyl silica gel, structure 35 
This sorbent was prepared for the second and third 
generation of columns, with the intention to leave a certain 
number of amino groups free (unbound to sapphyrin) for the 
binding of another type of recognition unit-second 
generation-hydrogen-bond recognition unit for nucleo 
bases; the third generation-aromatic residue for introduc 
tion ?t-TE stacking interaction with pyrimidine or purine 
ring of nucleotides. 
1 g of 3-Aminopropyl silica gel (from Sigma, 1.0 mmol N 
per gram) was suspended in dry dichloromethane (25 ml) 
with 0.5 ml of dry pyridine. 3,8,1722-tetraethyl-12 
(carboxyethyl)-2,7,13,1823-pentamethylsapphyrin (0.567 
g, 0.9 mmol) was converted to acid chloride as described 
before and slowly added to the3-aminopropyl silica gel. The 
reaction mixture was stirred at room temperature for 3 days, 
then product was filtered off, washed with dichloromethane 
(30ml), methanol (50 ml), water (100 ml), methanol (50 ml) 
and dichloromethane (50 ml). The product was dried (giving 
1.49 g; 95% yield) and used for further derivatization-10% 
of amino groups were left unbound for coupling with 




For the separation of highly polar phosphorylated species 
on both analytical and preparative scale, the surface of silica 
gel must be modified by a silylation procedure. This proce 
dure basically converts most, if not all, the free silanol 
groups (-Si-OH) to -Si-O-Z type residues, where Z is 
an alkyl chain, or aryl substitution (ARCO-, ARCO ). 
Sillylation reagents which have been employed are those of 
type ZSiCl, ZSiCl, and Z(CH4)2SiCl, where Z is an alkyl 













For the silylation of the bonded silica gels in this inven 
tion we have used the following procedure: Introduction of 
the C, C, C2, and C groups by reaction of mono and 
trichlorosilanes with suspended bonded silica gel in an 
organic solvent (dry dichloromethane, dichloroethane, 
benzene, toluene, xylene, or pyridine and 2.6-lutidine was 
used directly as a solvent) either directly or in the presence 
of organic bases such as pyridine or 2.6-lutidine, in a 
temperature range of 25° C-150° C. for the preparative 
HPLC phases, the corresponding triflates were used for 
silylation. 
A. Dimethylsilyl functionalized sapphyrin silica gel, struc 
ture 34 where Z=CH 
The bonded sapphyrin-silica gel prepared as described 
above in Example 11, section A, (1g) was suspended in 50 
ml of dry dichloromethane, 1 ml of trimethylchlorosilane 
was then added, followed by 0.5 ml of dry pyridine. The 
suspension was then stirred for 2 hours atroom temperature. 
The product was then filtered off, washed with dichlo 
romethane (200 ml), methanol (100 ml), methanol-water 1:1 
(200 ml), methanol (100 ml), dichloromethane (100 ml) and 
hexane (200 ml) and dried in vacuo. The yield was 1.1 g of 
product. 
Elemental analysis: 8.55% C, 1.92% H, 1.82% N. . 
EXAMPLE 13 
SYNTHESIS OF SAPPHYRIN SUBSTITUTED 
MERRIFELD RESIN 
A sapphyrin substituted Merrifield resin was prepared 
using the same basic strategy as described above. This is 
intended for use in low pressure applications. 
A. 3,8,1722-Tetraethyl-12-(aminocarbonyl)-2,7,13,18,23 
pentamethylsapphyrin structure derivative, structure 31. 
(0.63 g, 1 mmol) of 7a was converted to acid chloride as 
described hereinabove, oxalylchloride with DMF catalyst. A 
solution of this sapphyrin acid chloride in dry dichlo 
romethane was then slowly added to a suspension of the 
benzhydrylamine hydrochloride polymer bound (BHAresin, 
o-aminodiphenylmethane hydrochloride polymer bound; 
polystyrene crosslinked with 2% divinylbenzene, 
o-aminobenzylated hydrochloride-0.7 mmol amine/g 
resin; 100-200 mesh), 1 g in 100ml of dry dichloromethane, 
with 2 ml of dry pyridine. The reaction mixture was stirred 
at room temperature for 3 days. The polymeric material was 
filtered off, washed 5 times with dichloromethane (5x30ml), 
5 times with water (5x20 ml), 5 times with methanol (5X20 
ml) and with dichloromethane (20 ml). The polymeric 
products were deep green in color as a result of the 
covalently attached sapphyrins, elemental analysis (a most 
important determination of bonded sapphyrin is an increase 
in nitrogen content as compared to the starting polymeric 
material) showed, that 85% of amino groups are attached to 
Sapphyrin, structure 31. 
B. Preparation of 3,8,17.22-Tetraethyl-12-1aminocarbonyl) 
-2,7,13,18,23-pentamethyl sapphyrin derivative, Structure 
32 
The sapphyrin acid 7a (63 mg 0.1 mmol), described 
hereinabove, was converted to its corresponding acid chlo 
ride. A solution of this acid chloride in dry dichloromethane 
was then added, under argon, to a suspension of 
aminomethyl-polystyrene (benzylamine polymer bound; 
copolymer of styrene and divinylbenzene, aminomethy 
lated; 1.1 mmol amine/g resin) 500 mg in 50 ml of dry 
dichloromethane, with 0.5 ml of dry pyridine. The reaction 
mixture was stirred at room temperature for 7 days, and the 
resin was filtered off and washed as previously described. 
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Elemental analysis was used to determine the quantity 
(loading level) of the attached sapphyrin. It was found that 
ca. 15% of the amino groups of the polymeric support were 
attached to sapphyrin, 32. 
The same reaction starting with 200 mg of the above 
specified aminomethyl-polystyrene gave 42% saturation in 
terms of amino groups bound to sapphyrin. 
C. Preparation of 3,12,13.22-tetraethyl-8, 17-bis 
(aminocarbonyl)-2,7,18,23-tetramethyl sapphyrin 
derivative, Structure 33 
The same type of procedure was used for sapphyrin bis 
acid. For the connection of the sapphyrin mono acid with 
covalently bonded nucleobase, the amino functionalized 
polymer used as the solid support and either 1,1'- 
carbonyldiimidazole or 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide were used as the acid activating agents as 
appropriate. 
Sapphyrin bis amino derivative 25 (0.1 mmol) was dis 
solved in dry dimethylformamide and added to chlorom 
ethylated styrene-divinylbenzene resin (0.8 mmol Ci/g 
resin), 250 mg, together with 500 mg potassium carbonate. 
The reaction mixture wag stirred and heated at 110° C. for 
24 hours. After cooling to room temperature a solid material 
was filtered off, washed with water (250 ml), methanol (100 
ml), and dichloromethane (100 ml). After drying, elemental 
analysis showed (as determined by a decrease in C1 content 
and an increase in N content) that 21% of the chloromethyl 
groups were transformed to sapphyrin-aminomethyl groups. 
EXAMPLE 14 
COLUMN PACKING AND SEPARATION OF 
PHOSPHORYLATED SPECIES 
Columns using the new bonded sapphyrin materials are 
stable in aqueous buffers from pH 2.5 to pH 9.0 and stable 
to normal organic solvents. Furthermore, the packings are 
mechanically rigid due to their silica gel backbone. Indeed, 
the chemical and mechanical stability of such new columns 
makes them suitable for use over long periods of time 
without loss of resolution. Moreover, columns made from 
the presently described supports do not compress at high 
pressure and flow rates. The use of surface modified spheri 
cal silica gels results in products for use in medium to high 
pressure applications. For low pressure applications, organic 
polymer based sapphyrins, for example, modified Merrifield 
resins, may be used. 
The effectiveness of separation using these new stationary 
phases is far superior to those currently used. Also, the 
lifetimes of the columns are long because only very mild 
elution conditions are required: low concentration of buffer 
at neutral pH. Usually isocratic (i.e., non gradient) condi 
tions are sufficient for the separation even for very compli 
cated mixtures. This makes the analysis of a series very fast 
and there is no need for column equilibrium after each 
analysis. These advantageous features allow for the rapid 
and efficient separation of different phosphorylated species, 
such as nucleotides, mono-, di- and triphosphates, 
oligonucleotides, DNA and RNA fragments, phosphosugars, 
phosphoproteins and organophosphorus compounds, using 
the sapphyrin-based solid supports of this invention. 
In one example, a column containing first generation C34 
Sapphyrin-substituted silica gel was prepared using a stan 
dard column packing procedure, as described in the litera 
ture (see, e.g., reference 23b, pp. 207-210). In this context, 
the columns are slurry-packed in methanol or acetone, 
followed by a wash with water and an HPLC pump which 











A. Separation of mono-, di-, and tri-phosphorylated nucle 
otides 
Using the first generation of the sapphyrin-substituted 
silica gel, structure 34, the inventors were able to success 
fully separate adenosine and its mono-, di-, and tri 
phosphorylated nucleotide forms. 
The results of the HPLC separation of adenosine, mono-, 
di-, and tri-phosphates using the first sapphyrin-modified 
silica gel are shown in FIGS. 7A-i and 7A-ii. Commercially 
obtained adenosine, AMP, ADP, and ATP were prepared by 
dissolving in 5 mM tris (hydroxymethyl) aminomethane 
buffer at pH 7.0.20 pil of an adenosine, AMP. ADP, and ATP 
mixture was loaded onto and eluted off the sapphyrin 
modified silica gel using an isochratic buffer of 100 mM 
dibasic ammonium phosphate buffer at a pH of 7.0 and a 
flow rate of 0.2 ml/min. The wavelength of 260 nm was 
monitored and results were confirmed with retention times 
and UV-visible spectrum obtained from samples of indi 
vidual compounds. 
The insert in FIG. 7A-i shows the same mixture run 
through a control column with no sapphyrin. It is clear that 
there is a striking difference between the sharp peaks using 
the new sapphyrin-based technology and the unresolved 
broad band obtained with a more conventional column. 
The HPLC separation of adenosine, mono-, di-, and 
tri-phosphates using the first sapphyrin-modified silica gel, 
structure 34 is also shown in FIG. 7B. In this case, the 
applied mixture was eluted off the sapphyrin-modified silica 
gel using an isochratic buffer of 500 mM dibasic ammonium 
phosphate buffer at a pH of 7.0 and aflow rate of 1.0 ml/min. . 
Clear separation is still achieved. The wavelength of 260 nm. 
was monitored and results were confirmed with retention 
times and UV-visible spectrum obtained from samples of 
individual compounds, 
B. Separation of 2-, 3-, 4-, 5-, 6-, 7-, 8-, and 9-mers 
oligonucleotides 
Using the first generation Sapphyrin of substituted silica 
gels, structure 34, the inventors were able to successfully 
separate 2-, 3-, 4-, 5-, 6-, 7-, 8- and 9-mer oligonucleotides. 
Results of the HPLC separation of commercially obtained 
adenosine-derived oligonucleotides using the first 
sapphyrin-modified silica gel are shown in FIGS. 8A-i-and 
8A-ii. Samples of 2-, 3-, 4- and 5-mers of polydeoxyade 
nylic acid were prepared by dissolving in 5 mM of tris 
(hydroxymethyl) aminomethane at pH 7.0. 20 pil of this 
mixture was loaded onto and eluted off the column using an 
isochratic buffer of 100 mM dibasic ammonium phosphate 
at pH 7.0 and a flow of 0.35 ml/min. The wavelength of 260 
nm was monitored and results were confirmed with retention 
times and UV-visible spectrum obtained from samples of 
individual compounds. 
The results obtained with this new sapphyrin-based meth 
odology are very impressive. Note the marked difference 
between the sharp, distinct peaks shown in this figure with 
the broad, unresolved peak of the insert which represents the 
same mixture run through a control column with no sap 
phyrin. Furthermore, in addition to separating out the oli 
gonucleotides in this supposedly pure mixture, higher and 
lower order impurities were also observed. 
Results of the HPLC separation of longer commercially 
obtained adenosine-derived oligonucleotides using the first 
sapphyrin-modified silica gel, structure 34 are shown in FIG. 
8B. A sample of a mixture of 2-, 3-, 4-, 5-, 6-, 7-, 8- and 
9-mers of polydeoxyadenylic acid was loaded onto and 
eluted off the column using 100 mM dibasic ammonium 
phosphate at pH 7.0 and a flow of 0.35 ml/min. The 
wavelength of 260 nm was monitored and results were 
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confirmed with retention times and UV-visible spectrum 
obtained from samples of individual compounds. 
These results are also striking, and effective separation of 
all species was achieved. Clearly, all of these results are 
remarkable, particularly as various impurities not known to 
be present in the commercially available mixture were 
identified, the presence of which was later confirmed at 
Source (Sigma Chemical Co.). 
EXAMPLE 15 
SECOND GENERATION SAPPHYRIN SOLD 
SUPPORTS 
The preparation of improved, second generation sapphy 
rin solid supports may be achieved in many ways. For 
example, in one stage of the synthetic development, long 
chain alkyls may be introduced onto the surface of the 
Sapphyrin-substituted silica-gel. This will result in second 
generation columns that will combine the properties of both 
reverse phase separation and sapphyrin-based phosphate 
chelation and ion exchange. 
A. Octadecylsilyl functionalized supply in silica gel, struc 
ture 34 where Z=octyl group CH7 
The bonded silica gel prepared as described above in 
Example 11, sections A and B, (1 g) was suspended in dry 
toluene (50 ml). Octadecyltrichlorosilane was then added 
(0.5 ml) followed by dry pyridine (0.3 ml). The resulting 
reaction mixture was then heated at 100° C. for 6 hours and 
cooled. The product was then filtered off and washed as 
described above in Example 11, sections A and B. The yield 
was 1.095 g of product. 
B. Dimethyloctadecylsolyl functionalized sapphyrin silica 
gel, structure 34 where Z=octadecyl group CH 
The bonded silica gel prepared as described above in 
Example 11, sections A and B, (1g) was suspended in 50 ml 
of dry 1,2-dichloroethane. 0.5 gram of chlorodimethylocta 
decylsilane was then added followed by 0.3 ml of 2,6- 
lutidine. The resulting reaction mixture was subsequently 
heated to reflux for 8 hours. It was then cooled and the 
product filtered off, washed and dried. The yield was 1.086 
g of product. 
C. Dimethyldodecylmethyl functionalized supply in silica 
gel, structure 34 where Z-C2H 
The same procedure as described above in Example 15, 
section. A was also carried out using chlorodimethyldode 
cylsilane as silylation agent. 
D. Dimethyloctylsilyl functionalized sapphyrin silica gel, 
structure 34 where Z-CH 
The same procedure as described above in Example 15, 
Section B, was also carried out using chlorodimethyloctysi 
lane as sillylation agent. 
E. Octyl functionalized supply in silica gel, structure 36 
where Z-CH and R=CIOH 
The same procedure as described above in Example 15, 
section A, was also carried out using octyltrichlorosilane as 
a silylation agent. followed by hydrolysis in water (10 pull, 2 
hours, 40° C.). 
F. Dodicyl functionalized supply in silica gel, structure 36 
where Z=CHs and R=Cl 
The same procedure as described above in Example 15, 
section B, was also carried out using dodecyltrichlorosilane 
as a silylation agent. 
G. Dimethyloctadeyl functionalized supply in silica gel, 
structure 36 where Z=CH and R=Cl 
The same procedure as described above in Example 15, 
section B, was also carried out using dimethyloctadecylsi 













THIRD GENERATION SAPPHYRN SOLD 
SUPPORTS 
Even further improved, third generation, sapphyrin solid 
supports may also be prepared. For example, third 
generation systems may be prepared in which various dif 
ferent substituents on both the expanded porphyrin mol 
ecules and on the stationary phase material itself (e.g., Z and 
R groups) are chosen to impart the desired groups and 
properties to the resultant material. 
In one case, nucleobase-bearing systems may be gener 
ated which are expected to be able to separate nucleotides 
and oligonucleotides not only on the basis of charge and 
length but also on the basis of nucleic acid type. Introduction 
of aryl substituents give the possibility for improved sepa 
ration based on phosphate cheletion and T-T stacking. Any 
substituent for multiple type separation introduced by 
acylation, akylmethylation on free amino groups and/or by 
silylation with pheyl (substituted phenyl), silyl reagents or 




Nucleobase substituted sapphyrins were attached to silica 
gel in accordance with general procedure as described above 
in Example 11, section A. More particularly, 3,12,13.22 
tetraethyl-8-(carboxyethyl)-17-2-1-(4-amino-2 
oxopyrimidinyl)-ethylaminocarbonylethyl-2,7,13,18,23 
pentamethylsapphyrin (30 mg) was activated by 1.1'- 
carbonylidiimidazol (2 eq.) in 30 ml of dry THF, room 
temperature with stirring for 2 hours before being allowed to 
react with 1 g of 3-aminopropyl-functionalized silica gel for 
3 days at room temperature. As usual, in this case the 
product was recovered by filtration. 
B. Mixed Sapphyrin-Orotic acid silica gel (ratio 10:1 
Sapphyrin-orotic acid) 
Orotic acid (0.1 mmol, 0.174 g) were suspended in 5 ml 
of water. The pH of the resulting solution was then adjusted 
to pM 7.5 by adding PIPES buffer. The solution was then 
cooled to 0° C. and 1-(3-dimethylaminopropyl)-3- 
ethylcarbodiimide (1 mmol, 0.174 g) was added. After 1 
hour 0.5 g of silica gel (prepared as described was added. 
The reaction mixture was then stirred for 48 hours at room 
temperature and the product filtered off, washed (as 
described above in Example 11, section A, and dried. The 
yield was 1.18 g. 
C. Preparation of phenyl substituted sapphyrin silica gel, 
structure 37 where Ar=phenyl 
Solution of benzoylchloride (0.3 g) in 25 ml of dry 
dichloromethane was slowly added under nitrogen to the 
suspension of partially functionalized sapphyrin silica gel, 
see Example 11, section E, (1 g) with 0.5 ml of dry pyridine. 
The reaction mixture was stirred at room temperature for 2 
days, then product was filtered off and washed as described 
in Example 11, section A. Yield 1.09 g. 
D. Preparation of 4-nitrophenyl substituted sapphyrin silica 
gel, structure 37 where Ar=4-nitrophenyl 
The same procedure as described above in Example 16, 
section C, was also carried out using 4-nitrobenzoylchloride 
as a acylation agent. 
E. Preparation of naphtyl substituted sapphyrin silica gel, 
structure 37 where Ar=naphthyl 
The same procedure as described above in Example 16, 
section C, was also carried out using naphtoic acid chloride 
as a acylation agent. 
F. Preparation of 4-nitrobenzyl substituted sapphyrin silica 
gel, structure 37 where Ar=4-nitrobenzyl 
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Solution of 4-nitrobenzylbromide (0.3 g) in 25 ml of dry 
dioxane was slowly added to suspension of 1 g of partially 
substituted sapphyrin silica gel, see Example 11, section D, 
(1 g) in dioxane (50 ml) with 1 g of potassium carbonated 
reflux. Reflux was continued for 3 hours, then allowed to 
cool to room temperature, solid material was filtered off, 
washed with water (250 ml), then methanol (100 ml) and 
dichloromethane (50 ml); dried, yield 1.09 g. The similar 
procedure was used for modification of sapphyrin silica gel 
as in Example 11, section A, using 4-nitrobenzylchloride for 10 remains monoprotonated in the ca. 3.5SpHs 10 regime, 
reaction with silanol groups on silica gel surface. The similar 
procedure (with pyridine as a base and 4-nitrobenzoyl 
chloride as a reagent) was used for the introduction of acyl 
on silanol groups. 
EXAMPLE 1.7 
SAPPHYRN SUBSTITUTED GLASS 
CAPLLARES FOR ELECTROPHORESS 
Polymer-supported expanded porphyrins may be prepared 
in which the polymer is a glass capillary, intended for use in 
capillary electrophoresis (CE). 
As glass is chemically similar to silica gel (both are 






SELECTIVE NUCLEOTIDE TRANSPORT BY 
SAPPHYRN-NUCLEOBASE CONJUGATES 
As discussed above, the sapphyrin molecule itself, which 
5,18 
is ineffective as a GMP carrier at pH 7, even in the presence 
of a large excess of C-Tips." Therefore, sapphyrin systems 
in which nucleotide recognition units were appended 
directly onto the phosphate-chelating core, were 
synthesized, as described in the preceding examples. 
Transport studies were carried out, using a standard'Aq 
I-CH2Cl2-Aq II liquid membrane cell, using the sapphyrin 
cytosine conjugates represented by structures 10 and 20. 
Both 10 and 20 were found to be able to effect the selective 
through-membrane transport of GMP at, or near, neutral pH 
(Table 3). 
TABLE 3 
Initial Nucleotide Transport Rates (kr) for Carriers 10 and 20. 
Carrier Aq. I kr CMP kr GMP 
kokc (pH) Aq, I (10 mol/cm-h) kr AMP koka 
10 6.15 HO 0.12 12.0 157 7.6 100 
10 7.05 HO 0.0005 0.011 0.001 11 22 
10 6.70 10 mMNaOH. O.30 12.3 2.82 4.4 41 
10 T.05 10 mMNaOH 0.16 7.08 0.74 9.6 44 
20 6.15 HO 0.16 101 0.73 1.4 6.3 
20 7.05 10 mMNaOH 0.049 1.15 0.36 3.2 24 
none 6.15 HO <10 <10 <10 did 
sap 70 10 mMNaOH <10 <10 O,004 
0.1 mM in dichloromethane 
The source phase, AgI, contained a 1:1:1 ratio of AMP, CMP, and GMP at a 10 mM conc. 
(in each). The initial pH was adjusted by the careful addition of NaOH. 
Transport experiments were performed in a manner similar to those reported in refs. 14 and 
5. Walues reported are the average of three independent measurements; estimated error <5%. 
Not determined. 
Control experiment using 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethyisapphyrin (0.1 
mM) as the putative carrier, 
may be achieved generally as described herein. Different 
combinations of Zand R groups may also be employed. 
A. Preparation of sapphyrin modified 3-amidosubstituted 
glass 
1 g of Aminopropyl glass (firma Sigma, 75 A average 
pore size, 200-400 mesh, 250 mol primary amine per g of 
glass) was suspended in dry dichloromethane and 0.5ml was 
added. A solution of 3,8,17,22-tetraethyl-12 
(chlorocarbonylethyl)-2,7,13,18,23-pentamethylsapphyrin 
(63 mg, 0.1 mmol) in 20 ml of dry dichloromethane was 
slowly added under argon and reaction mixture stirred at 
room temperature for 3 days. The product was filtered off, 
washed with dichloromethane (50 ml), methanol (50 ml), 
water (50 ml), methanol (20 ml) and dichloromethane (20 
ml). Yield 1.05 g. 
B. Preparation of sapphyrin modified arylamine glass 
The same procedure as described above in Example 17, 
section A was also carried out using arylamine substituted 
glass (from Sigma). 
C. Sillylation of sapphyrin modified glass 
The same procedures as described above in Example 2, 




As can be seen from Table 3, both 10 and 20 are able to 
effect the selective through-membrane transport of GMP at, 
or near, neutral pH. Using the standard' detection system, 
a quantitative analysis of uridine 5'-monophosphate (LIMP) 
in Aq II could not be made. In qualitative control 
experiments, it was confirmed, however, that carrier 20 
caused no apparent increase in the rate of through 
membrane UMP transport at pH 6.7. 
Interestingly, in all cases, receptor 20 displays a higher 
selectivity for GMP (by a factor of 8-100 relative to either 
AMP or CMP), than its congener 10. Further, better through 
transport efficiency is always observed when the receiving 
phase (Aq D is kept highly basic. Finally, a significant drop 
offin efficiency, for both 10 and 20, is observed as the initial 
pH of Aq I is increased from 6.15 to 7.05. 
The above results are considered consistent with a model 
wherein complexation between the monoprotonated form of 
the receptor and the monobasic (ROPOH) form of GMP 
takes place at the Aq -CH2Cl interface to produce a 
neutral, organic-soluble, Supramolecular complex such as 
that depicted in FIG. 4C. This modelis in accord with X-ray 
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diffraction data in which the 2:1 complex formed between 
monobasic phenyl phosphate and diprotonated sapphyrin. 
was analyzed in the solid state. One phenyl phosphate is 
bound on the “top” face of the macrocycle to each of three 
pyrroles, while the other phosphate is bound to two pyrroles 
on the “bottom' side. 
This model, and the structure presented in FIG. 4C, 
provides a simple rationale for the experimental findings: 
First, decreased selectivity would be expected upon the 
introduction of "extra" cytosine chelating subunits, since 
this would result in an increase in number of possible 
hydrogen bonding interactions and an incumbent loss in 
required substrate specificity. Second, higher through 
transport rates would be observed in those cases where the 
receiving phase is kept basic since sapphyrin deproteination 
and facilitated product release at the CHCl-Aq II interface 
would necessarily be favored. Finally, a decrease in through 
transport rate is predicted since a lower concentration of the 
putative substrate, monobasic GMP (the ROPOHIT form) 
in Aq I, would be expected as the second phosphate-centered 
ionization constant of GMP (pKa=ca. 6.7') is first 
approached and then surpassed (charge neutralization as a 
requirement for efficient carrier mediated transport is known 
as Fick's First Law). 
That some transport occurs even at pH 7.05 is thus 
considered a reflection of the fact that, under the conditions 
of the experiment, binding of monobasic GMP is enhanced 
relative to that of the dibasic (IROPO') form and that this 
binding enhancement, in turn, serves to augment the effec 
tive concentration of this monoanionic (and hence readily 
neutralizable) species in the organic membrane phase. 
EXAMPLE 19 
SAPPHYRTN-DNAINTERACTIONS 
The present inventors have discovered that sapphyrin 
binds to double- and single-stranded DNA and RNA, and 
furthermore, that it does so in a novel and unexpected 
26. 
A. Sapphyrin Binds to DNA 
The first evidence for sapphyrin DNA binding came from 
the observation that an excess of sapphyrin, which is green 
in solution, can rapidly and specifically precipitate green 
DNA fibers. The inventors propose that this binding and 
precipitation is due to the chelation of the polyanionic 
sugar-phosphate backbone of DNA. This leads to charge 
neutralization and through the resulting hydrophobic effects, 
the DNA falls out of solution. Such precipitation effects have 
not been reported for other DNA binding compounds which 
are known to either intercalate or groove bind with DNA. 
Further evidence that sapphyrin binds to DNA was pro 
vided by CD spectroscopy, a technique that can detect 
chirality. Sapphyrin is an achiral macrocycle that shows no 
significant CD spectra by itself in solution. However, in the 
presence of DNA, a sapphyrin CD spectrum was induced. 
This is consistent with relatively rigid binding to DNA, a 
chiral macromolecule, which places sapphyrin in a chiral 
environment and yields the observed induced CD effect, 
In addition, UV-Visible spectroscopy provides still further 
evidence that sapphyrin binds DNA. Upon addition of a 
large excess of DNA, changes in the visible absorption 
spectrum occur. The Soret-like transition that occurs at 410 
nm is red-shifted by approximately 12 nm. This is taken as 
evidence that DNA is interacting directly with the sapphyrin 
macrocycle. 
Finally, the inventors have determined that sapphyrin 











Sapphyrin alone shows only minimal fluorescence in aque 
ous buffered solution, but has been shown to either dimerize 
or aggregate in polar solvents resulting in a quenching of the 
sapphyrin fluorescence. The fluorescence enhancement 
effect discovered by the inventors is thus considered to be 
the result of binding to DNA which breaks up the dimers 
aggregates and creates "monomeric' sapphyrins bound to 
DNA. Using this fluorescence enhancement as measurement 
of binding, the lower limit of the apparent binding constant 
has been estimated to be approximately 10 M'. 
B. Sapphyrin-DNA Binding is not Intercalation or Groove 
Binding 
Unwinding of double helical DNA has traditionally been 
accepted as a signature of DNA intercalators. Based on the 
apparent binding constant obtained using fluorescence 
spectroscopy, the inventors conducted topoisomerase-based 
unwinding studies using concentrations of sapphyrin where 
the sapphyrin macrocycle was significantly bound to the 
DNA. In such studies, no sapphyrin-mediated DNA unwind 
ing was detected, leading to the conclusion that sapphyrin 
cannot be intercalating. 
Preliminary results have indicated that nearly identical 
visible absorption changes can be observed when sapphyrin 
is titrated with either double-stranded DNA or single 
stranded DNA. As single-stranded DNA contains no higher 
order structure, such as a major or minor groove, and the 
interaction appears to be spectroscopically identical between 
the two types of DNA, this data demonstrates that sapphyrin 
cannot be groove binding. 
C. Sapphyrin Binds to the Phosphate Backbone of DNA 
Recent X-ray crystallographic evidence has shown that 
the sapphyrin macrocycle can bind both monobasic phos 
phoric acid and monobasic phenylphosphate. The inventors 
conducted a study aimed to link this solid state evidence to 
the interaction between sapphyrin and DNA which occurs in 
solution. They found that, in solution, spectroscopic simi 
larities exist between sapphyrin in the presence of DNA and 
sapphyrin in the presence of diethyl phosphate. The latter is 
a simple phosphate that compares with the phosphates used 
in the X-ray crystallographic studies. 
UV-visible spectral shifts comparable to those obtained 
with DNA can be observed when sapphyrin is titrated with 
diethyl phosphate. With diethyl phosphate, the Soret-like 
transition is red-shifted by approximately 9 mm. In addition, 
fluorescence enhancement in the presence of diethyl phos 
phate can be observed as in the case with DNA. The only 
structural similarity between this simple phosphate and the 
DNA is the phosphate anion and, when taken in conjunction 
with the X-ray crystallographic data, these spectroscopic 
techniques provide evidence for the novel mode of DNA 
binding proposed by the present inventors. 
D. Porphyrins and Sapphyrins Interact Differently with 
DNA 
To demonstrate that sapphyrins interact differently with 
DNA than their nearest relatives, porphyrins, the inventors 
synthesized a porphyrin 39 which was functionalized in a 
similar manner as the sapphyrin 1. Spectroscopically, these 
two molecules act very differently in the presence of DNA. 
Neither an induced CD effect nor any significant shifts in the 
visible absorption spectrum are observed with the function 
alized porphyrin in the presence of DNA. In contrast to the 
fluorescence enhancement of sapphyrin, the porphyrin 
shows a decrease influorescence intensity in the presence of 
DNA. 
The novel findings described in this example form the 
basis for even further uses of sapphyrin and sapphyrin 
derivatives as tools in the research or clinical laboratory. A 
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particularly important application contemplated by the 
present inventors is to use sapphyrin, or derivatives or 
polymers thereof, in recovering DNA samples, for example, 
after electrophoresis. This may be applied as a general 
technique, or adapted for more specific DNA recognition 
and recovery by employing functionally derivatized 
Sapphyrins, such as specific sapphyrin-nucleobase or 
-oligonucleobase conjugates. It is particularly contemplated 
that silica-supported sapphyrin may be employed in a “DNA 
catch" method to recover DNA samples from agarose gels. 
EXAMPLE 2.0 
SAPPHYRIN, DERIVATIVES AND 
CONJUGATES AS THERAPEUTICAGENTS 
The discoveries embodied by the present invention may 
be advantageously exploited in further scientific research, 
and importantly, in the development of new methods and 
compositions for treating various human diseases including 
cancer. Sapphyrins and their derivatives are envisioned to be 
of use in a wide variety of clinical embodiments, including 
the binding, delivery and cellular transport of nucleotide 
derivatives, such as antiviral agents. The sapphyrin-sugar 
derivatives have the added potential of more specific cellular 
targeting according to sugar recognition by specific recep 
tors. Sapphyrins and modified sapphyrins also have potential 
for use directly as chemotherapeutics. 
Sapphyrin may also be used as a delivery agent for the 
intracellular targeting of any drug that has a phosphate 
group. Of course, given the synthetic methodology disclosed 
herein, it is contemplated that the sapphyrin may be deriva 
tized by the introduction of further groups to the periphery 
of the macrocycle, which groups would add the specificity 
and/or selectivity of the sapphyrin-drug interaction. 
Sapphyrin-drug interactions of this sort may be based upon 
either noncovalent interactions, or alternatively, may 
employ a covalent bond that is cleaved on exposure to the 
intracellular environment 
In particular embodiments, oligomers or polymers of 
sapphyrin or sapphyrin-nucleobase conjugates are envi 
sioned to be of use in antisense technology. Such polymers 
will be of use both in the delivery and transport of oligo 
nucleotides ("oligos'), and in enhancing their effectiveness 
once inside the target cell. The enhancing effect is based 
upon the newly discovered properties of sapphyrin in bind 
ing to the phosphate portions of nucleic acids. This property 
will increase the affinity of the antisense construct for its 
target, and reduce diffusion which generally limits the 
effectiveness of an antisense molecule. This dual transport 
and binding role of sapphyrin-oligonucleotide conjugates in 
anti-sense treatments is particularly advantageous in that no 
other method or combination of methods available have a 
DNA (or RNA) affinity component. 
The newly-discovered interaction between sapphyrin and 
DNA, in which sapphyrin acts as a chelate for the phosphate 
backbone of DNA, is particularly important. The binding 
constant of unmodified sapphyrin for DNA has been deter 
mined to be on the order of 10 M', and evidence shows 
that the mode of DNA binding is not intercalation or groove 
binding. The inventors will extend these findings and create, 
using all the available experimental evidence, computer 
models of the sapphyrin-DNA interaction. These models 
will allow the design and engineering of covalently linked 
multimeric sapphyrin molecules with increased affinity and 
specificity. 
These second generation multimeric sapphyrin-based 













interfere with biological processes such as transcription and 
translation. It is contemplated that this will ultimately lead 
to the development of sapphyrin-based therapeutic agents 
for use in treating a variety of human diseases, including 
CCC. 
Sapphyrin molecules themselves are also contemplated 
for use directly as chemotherapeutic agents. Currently avail 
able chemotherapeutics generally have complex structures, 
or complicated modes of interaction with their targets, that 
preclude systematic improvement. The development of a 
novel class of DNA binding compounds, namely the sap 
phyrins of the present invention, therefore creates important 
new opportunities for the development and use of novel 
therapeutic agents. 
Due to the unique mode of sapphyrin-DNA interaction, 
the sapphyrin molecule possesses an unrivaled ability to act 
as a general DNA binding platform. Binding can also be 
modified so as to adjust both target cell specificity and 
degree of interaction with the DNA. For sapphyrins, 
importantly, the basic site of interaction with the DNA 
involves the interior of the sapphyrin macrocycle, so that the 
exterior positions R-Ro can be substantially modified 
without significantly disrupting the DNA binding interac 
tion. These exterior positions can be used to systematically 
adjust features such as solubility, membrane permeability 
and cell selectivity. Furthermore, groups designed to modu 
late interaction with DNA can be attached to the exterior of 
the sapphyrins including alkylating functions 
(bromoacetamido groups, ethylene diamine, epoxides etc.) 
to provide covalent attachment to DNA or ene-diyne moi 
eties to allow for double stranded DNA cleavage. 
Another advantage of the sapphyrin system is that the 
DNA binding motif can be extended to multimeric 
structures, including the several described in the present 
application, in which multiple sapphyrins covalently linked 
together can bind to DNA simultaneously and thus 
strengthen the entire interaction. This feature will allow a 
modular approach in which the appropriate number (2-10) 
of Sapphyrin molecules is attached in a single molecule, 
perhaps with different sapphyrin units containing sapphyrin 
derivatives with different groups attached that control such 
important properties such as solubility, target cell specificity 
and DNA modification ability. 
All of the compositions and methods disclosed and 
claimed herein can be made and executed without undue 
experimentation in light of the present disclosure. While the 
compositions and methods of this invention have been 
described in terms of preferred embodiments, it will be 
apparent to those of skill in the art that variations may be 
applied to the composition, methods and in the steps or in the 
sequence of steps of the method described herein without 
departing from the concept, spirit and scope of the invention. 
More specifically, it will be apparent that certain agents 
which are both chemically and physiologically related may 
be substituted for the agents described herein while the same 
or similar results would be achieved. For example, other 
macrocyclic, positively-charged entities can be envisioned 
as binding to phosphate-containing species such as 
nucleotides, oligonucleotides and DNA by means of the 
same or similar oriented electrostatic interactions described 
herein. All such similar substitutes and modifications appar 
ent to those skilled in the art are deemed to be within the 
spirit, scope and concept of the invention as defined by the 
appended claims. 
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We claim: 
1. A method of cleaving DNA, which method comprises 












conditions effective to promote cleavage of the DNA, 
wherein the sapphyrin-EDTA conjugate has the structure: 
R R6 
wherein, 
each of R'-R' is independently H, alkyl, alkene, alkyne, 
halide, alkyl halide, hydroxyalkyl, glycol, polyglycol, 
thiol, alkyl thiol, aminoalkyl, carboxyalkyl, 
aikoxyalkyl, aryloxyalkyl, alkyloxycarbonyl, 
aryloxycarbonyl, aidehyde, ether, ketone, carboxylic 
acid, phosphate, phosphonate, sulfate, phosphate sub 
stituted alkyl, phosphonate substituted alkyl, or sulfate 
64 
substituted alkyl, such that the total number of carbon 
atoms in each substituent R is less than or equal to 10; 
and 
wherein, at least one of R'-R' is of the formula (CH2) 
5 A-(CH)-EDTA where 
A is CH, O, S, NH or NR', 
R" is alkyl, alkene, alkyne, halide, alkyl halide, 
hydroxyalkyl, glycol, polyglycol, thiol, alkyl thiol, 
substituted alkyl, phosphate, phosphonate, Sulfate, 
10 phosphate substituted alkyl, phosphonate substituted 
alkyl, sulfate substituted alkyl, COO, CONH, CSNH, 
CONR'', and 
each of n and m is independently an integer of less than 
15 or equal to 10 or zero. 
2. A method of cleaving DNA, which method comprises 
contacting DNA with a sapphyrin-EDTA conjugate under 
conditions effective to promote cleavage of the DNA. 
3. The method of claim 1, wherein the sapphyrin-EDTA 
conjugate is Structure 8 of FIG. 3B. 
4. The method of claim 1, wherein one of R'-R' is 
(CH2)A-(CH2)-EDTA, and the remaining groups R'-R' 
are independently alkyl groups of 1 to 10 carbon atoms. 
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